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ABSTRACT 
Molecularly-Targeted Gold-Based Nanoparticles for Cancer Imaging and 
Near-Infrared Photothermal Therapy 
by 
Emily Shannon Day 
This thesis advances the use of nanopartic1es as multifunctional agents for 
molecularly-targeted cancer imaging and photothermal therapy. Cancer mortality has 
remained relatively unchanged for several decades, indicating a significant need for 
improvements in care. Researchers are evaluating strategies incorporating nanopartic1es 
as exogenous energy absorbers to deliver heat capable of inducing cell death selectively 
to tumors, sparing normal tissue. Molecular targeting of nanopartic1es is predicted to 
improve photothermal therapy by enhancing tumor retention. This hypothesis is 
evaluated with two types of nanopartic1es. 
The nanopartic1es utilized, silica-gold nanoshells and gold-gold sulfide 
nanopartic1es, can convert light energy into heat to damage cancerous cells. For in vivo 
applications nanopartic1es are usually coated with poly(ethylene glycol) (PEG) to 
increase blood circulation time. Here, heterobifunctional PEG links nanopartic1es to 
targeting agents (antibodies and growth factors) to provide cell-specific binding. This 
approach is evaluated through a series of experiments. 
In vitro, antibody-coated nanopartic1es can bind breast carcinoma cells expressing 
the targeted receptor and act as contrast agents for multiphoton microscopy prior to 
inducing cell death via photoablation. Furthermore, antibody-coated nanopartic1es can 
bind tissue ex vivo at levels corresponding to receptor expression, suggesting they should 
bind their target even in the complex biological milieu. This is evaluated by comparing 
the accumulation of antibody-coated and PEG-coated nanoparticles in subcutaneous 
glioma tumors in mice. Contrary to expectations, antibody targeting did not yield more 
nanoparticles within tumors. Nevertheless, these studies established the sensitivity of 
glioma to photothermal therapy; mice treated with PEG-coated nanoshells experienced 
57% complete tumor regression versus no regression in control mice. Subsequent 
experiments employed intracranial tumors to better mimic the clinical setting. These 
tumors are highly vascularized, so nanoparticles were addressed toward receptors 
abundantly expressed on tumor vessels using growth factors as a novel targeting strategy. 
Photothermal therapy with these vascular-targeted nanoparticles disrupted tumor vessels, 
leading to a 2.2-fold prolongation of median survival versus control mice. 
This work confirms that nanoparticle surface coating can affect biodistribution 
and therapeutic efficacy. With continued optimization of molecular targeting strategies, 
imaging and photothermal therapy mediated by nanoshells and gold-gold sulfide 
nanoparticles may offer an effective alternative to conventional cancer management. 
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Chapter 1: Introduction 
Despite tremendous gains in our knowledge of fundamental cancer biology over the past 
several decades, similar improvements in clinical practice and patient survival have not 
been achieved. Current front-line approaches to cancer therapy have been in use for 
more than 70 years: chemotherapy was introduced by Goodman and colleagues in the 
1940s to treat patients with lymphoma (Goodman et al. 1946); radiation therapy was used 
successfully in oncology as early as the 1890s (Kogelnik 1997); and, surgical resection of 
tumors can be traced to the writings of ancient Greeks and Egyptians (Pollock 2008). 
Although these medical techniques have been evolving and improving throughout 
history, there remains a significant need for advances in diagnosis and treatment. This 
need is evidenced by the fact that the lifetime risk of developing cancer for Americans 
born today is ~41 % and, maintaining current standards of care, one in four Americans is 
expected to die from cancer (National Cancer Institute 2010). Furthermore, cancer is not 
confined to the United States; rather, it is a global disease with projected worldwide 
incidence of 15.5 million cases in 2020 (Mathers and Loncar 2006). Therefore, new tools 
must be developed in order to reduce the burden of cancer. 
Working toward this goal of improved patient outcome, researchers have begun to 
develop nanoparticle-based platforms for detection and treatment of cancer. This thesis 
validates one form of therapy that incorporates nanoparticles as exogenous energy 
absorbers to provide high-resolution imaging of cancerous cells and to selectively deliver 
heat capable of inducing cell death to tumors. This technique offers several advantages 
over conventional therapeutic approaches, to be detailed later. In this chapter cancer 
biology and the challenges associated with diagnosis and treatment will be briefly 
described, recent developments in nanotechnology for cancer management will be 
discussed, and previous progress in the literature that provided a foundation for this 
research using nanoparticles for thermal cancer therapy will be reviewed. 
1.1 A Brief Introduction to Cancer Biology and Clinical Management 
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Cancer remains a clinical challenge today. To develop better tools for imaging and 
therapy, it is critical to understand the nature of the disease. Here, the hallmarks of cancer 
will be highlighted and current approaches to diagnosis and treatment will be discussed. 
1.1.1 Cancer Biology 
Tumorigenesis begins when a single cell acquires defects in the regulatory circuits that 
maintain homeostasis; this loss of balance between pro- and anti-growth signals confers 
growth advantages that lead to uncontrolled cell proliferation, resulting in formation of a 
tumor mass (Hanahan and Weinberg 2000). The process by which normal cells become 
malignant is marked by the accumulation of genetic alterations that induce either a gain-
of-function in proto-oncogenes that regulate cell growth and division or a loss-of-
function in tumor suppressor genes that ordinarily inhibit cell proliferation. Hanahan and 
Weinberg suggested that six alterations in cell physiology are characteristic of malignant 
cell behavior: self-sufficiency in growth signals, insensitivity to growth-inhibitory 
signals, evasion of apoptosis, limitless replicative potential, sustained angiogenesis, and 
the ability to invade tissue and metastasize (Hanahan and Weinberg 2000). More 
recently, Colotta et al. proposed that cancer-related inflammation is a seventh "hallmark 
of cancer" since inflammatory molecules can lead to genetic instability (Colotta et al. 
2009). Figure 1.1 depicts the seven hallmarks that contribute to cancer progression. 
Self-sufficiency in 
growth signals 
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Figure 1.1: The hallmarks of cancer. The seven acquired capabilities of cancer cells 
that lead to tumor progression. Image from Colotta et al. 2009. 
Because cancer cells require nutrients and oxygen to support continued growth of 
a tumor, vascularization is necessary for tumor growth beyond a diameter of 1-2 mm 
(Folkman 1971). To recruit development of new blood vessels, tumor cells excrete pro-
angiogenic factors such as VEGF (vascular endothelial growth factor), which encourage 
migration and survival of endothelial cells, and MMPs (matrix metalloproteinases) that 
degrade components of the extracellular matrix (Rundhaug 2003). Due to the imbalance 
of pro- and anti-angiogenic factors, vascular networks in and around tumors form rapidly 
and are characterized by architectural defects such as increased vessel diameter, 
tortuosity, endothelial fenestrations, and excessive branching (Carmeliet and Jain 2000). 
In addition, tumor vessels lack functional pericytes (Benjamin et al. 1999) and exhibit 
inter-endothelial cell openings as large as 2 Jlm (Hashizume et al. 2000), resulting in 
vascular "leakiness." Figure 1.2 emphasizes the architectural differences between 
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normal blood vessels and those found in and around tumors (Jain 2005). Later it will be 
discussed how these vascular differences between tumor and normal tissue are critical to 
successful use of nanoparticles in cancer management. 
Normal Abnormal 
Figure 1.2: Comparison of vessel architecture in normal and tumor tissue. Top row: 
Schematic representation of vessel structure showing that normal tissue vasculature is 
ordered and hierarchical while abnormal tumor vasculature is disorderly. Bottom row: 
Two-photon microscopy images of blood vessels in skeletal muscle (left) and colon 
carcinoma (right) showing that tumor vessels have increased diameter and chaotic 
architecture compared to normal vessels. Adapted from Jain 2005. 
Angiogenesis is an important factor not only for continued tumor growth but also 
for development of metastasis, the appearance of secondary tumors at sites distant from 
the original lesion (Fidler 1990). Most cancer-related deaths are caused by metastases 
that are resistant to conventional therapy. Treatment of metastases is increasingly 
complex because, as Fidler explained, when a tumor cell becomes metastatic it acquires 
several capabilities that allow it to escape its original site, survive circulation, and then 
flourish in a new environment (Fidler 1990). Not every cell that escapes the primary 
tumor will develop a secondary tumor, and research has shown that tumors metastasize 
preferentially to certain organs. Stephen Paget hypothesized in 1889 that this was 
because metastatic tumor cells have an affinity for the biological milieu of certain organs 
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(Paget 1889). This concept, known as the "seed and soil" hypothesis, suggests that 
metastases can form only when the tumor cell (the seed) and the organ microenvironment 
(the soil) are compatible. For this reason, successful elimination of metastases will 
require therapy targeted towards both cancerous cells and the factors present in tissue that 
enable their survival (Fidler 2003). In the next two sections, tools currently used to 
image and treat cancer will be discussed. 
1.1.2 Imaging Techniques Used to Diagnose and Monitor Cancer 
Medical imaging plays a crucial role in many aspects of cancer management throughout 
the entire duration of a patient's care. In addition to providing initial detection of disease, 
imaging techniques are used to guide biopsies, to assess the stage of disease, to formulate 
treatment plans, and to evaluate therapeutic response (Barentsz et al. 2006). The most 
common techniques used clinically today include X-ray radiography and computed 
tomography (CT), ultrasound (US), magnetic resonance imaging (MRI), and positron 
emission tomography (PET) (Barentsz et al. 2006; Frangioni 2008). 
X-ray radiography and CT rely on the principle of directing a beam of X-rays at a 
film or detector placed on the opposite side of the patient; the level of attenuation of the 
beam as it passes through the patient is determined by the density of the tissue 
encountered so that within the gray-scale images produced more dense tissues such as 
bone or calcifications appear white. With conventional X-ray, all structures are projected 
in one plane, but with CT the X-ray tube and detector rotate around the patient to produce 
axial images that can be reconstructed into three-dimensional images. By employing 
multiple detectors, several axial slices of the patient may be imaged simultaneously, 
allowing entire body scans to be completed within minutes. CT is at present the most 
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commonly used tool for assessment of cancer (Barentsz et al. 2006). One limitation of 
X-ray and CT is that good contrast is achieved only if the tumor attenuates X-rays much 
differently than the surrounding tissue. As a result, these methods are best suited for lung 
and bone cancer, although they are also used in breast mammography since there is good 
delineation between fat, tumor, and calcifications (Barentsz et al. 2006). Another 
drawback of using X-rays is that they are a type of ionizing radiation, which has been 
linked to increased risk of cancers later in life (Ron 2003; Smith-Bindman et al. 2009). 
Consequently, the necessity for employing these techniques should be carefully 
considered when other non-ionizing radiation imaging methods might be appropriate as 
well. 
Ultrasound is a less commonly used technique in which sound waves reflected by 
tissue provide information about the separation of tissue planes and their relative acoustic 
impedance. For example, fluid-filled structures do not return a signal and appear black, 
while calcium returns a clear signal and appears white. The advantages of US are that it 
provides good soft tissue contrast, is easily applied, and relays information in real time, 
enabling it to be used to guide biopsies. However, image quality is highly operator-
dependant and many parts of the body are inaccessible since the sound waves are highly 
scattered at bone and air interfaces (Frangioni 2008). Thus, its utility is mainly limited to 
gynecologic, liver, and kidney tumors. 
Magnetic resonance imaging is another non-ionizing radiation method of cancer 
imaging. In MR!, a patient is placed within a strong magnetic field that causes the 
hydrogen ions in their tissues to align. An applied radiofrequency pulse then causes 
some of the ions to change alignment by a variable angle; when the pulse is removed 
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these ions return to their original alignment. This change in magnetization induces a 
voltage that is detected by a receiver coil around the patient, and is then processed into an 
image. The relaxation behavior is different for each type of tissue, enabling high 
contrast. Images can also be weighted by either the Tl or T2 relaxation times, producing 
images that are either fat sensitive (Tl) or water sensitive (T2). MRI is critical for 
evaluation of brain and musculoskeletal tumors, but otherwise its use is limited because it 
is a lengthy and expensive procedure (Barentsz et al. 2006). 
PET is different from the other imaging modalities listed in that it provides 
functional rather than structural information. This is accomplished through the use of 
radiolabeled substances that emit positrons as they decay within the body. These 
positrons collide with nearby electrons, producing two 511 ke V annihilation photons 
traveling in opposite directions from each other that are then detected by a scintillator 
material in a scanner. The coincidence detection data is used to form a three-dimensional 
image (Kelloff et al. 2005). Contrast in PET is provided by differences in uptake of the 
radiolabeled substance between tissues. The main substance used in cancer imaging is 
fluorodeoxyglucose (FDG), a glucose analog that can pass through cell membranes via 
glucose transporters. The cellular uptake of FDG into tumors is increased over that of 
normal cells (which primarily utilize oxidative phosphorylation for energy) because 
cancer cells exhibit an increased rate of glycolysis, a phenomenon known as the Warburg 
effect (Kelloff et al. 2005). Recently, PET has been combined with CT in integrated 
PET -CT scanners that provide both functional and anatomic information, yielding a more 
powerful imaging technique (Barentsz et al. 2006). 
8 
Each of the above techniques has inherent strengths and weaknesses, and medical 
imaging will continue to improve with advances in technology. In the future it is likely 
that more imaging modalities that acquire both functional and anatomical information 
will emerge. Much excitement exists around new developments in molecular imaging, 
which has been broadly defined as the "visualization and characterization of biologic 
processes at the cellular and molecular level in vivo" (Abdullah 2006). This technique 
uses contrast agents capable of targeting cells based on their molecular characteristics, 
and later it will be discussed how nanoparticles could playa key role in the future of 
molecular imaging. It is predicted that molecular imaging will someday be used to detect 
cellular alterations early in disease progression, to evaluate and adjust treatment in real 
time, and to speed the drug development cycle (Weissleder 2006). Ultimately, having 
access to both structural and functional information about tumors should improve patient 
prognOSIS. 
1.1.3 Current Therapeutic Approaches to Cancer 
Conventional cancer treatment options include surgery, radiation, and chemotherapy and 
these may be used either alone or in combination. No matter which modality is used, the 
key to success lies in maximizing damage to tumor tissue while minimizing damage to 
healthy tissue. Here each will be described in brief. 
Surgery involves physical removal of the tumor mass, and it is the most effective 
treatment option for cases of localized disease when the entire tumor is capable of being 
resected. Often adjacent healthy tissue is removed to provide a surgical margin between 
the diseased and healthy tissue because any residual disease left behind increases the 
patient's risk of later recurrence or metastasis. Of course, surgical removal of tumors 
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carries all the same risks associated with any surgery: dangers of anesthesia, blood loss, 
and infection. The morbidity and risk of mortality associated with surgical resection is 
largely dependent on tumor location, the percentage of healthy tissue removed, and the 
amount of lost normal tissue that can be replaced by the body (McKinnell et al. 1998). 
For example, resection of a brain tumor is a higher-risk procedure than removal of a 
localized skin carcinoma due to the sensitivity of the organ involved. For this reason it is 
important to develop minimally invasive treatments for brain tumors, and this is one of 
the overall goals of this thesis. 
Radiation therapy exposes malignant cells to ionizing radiation from an external 
or implanted source to induce DNA damage, causing cells to die during mitosis 
(McKinnell et al. 1998). Radiation therapy is a regional therapy, meaning that the 
radiation is focused onto a specific predetermined treatment area and cells outside the 
irradiated area will remain unharmed. The cellular target for radiation is DNA, which is 
damaged either directly or indirectly by production of free radicals (Alison and Sarraf 
1997). The goal of treatment is to induce double-stranded DNA breaks. Since radiation 
exerts its effects on proliferating cells, it is capable of damaging not only cancer cells but 
also any rapidly dividing normal cell within the radiation field. Thus, the effect of 
radiation on normal tissues is a dose-limiting factor. 
Chemotherapy is the use of drugs to treat or control cancer. These compounds are 
typically administered systemically and can either target all proliferative cells or be cell 
cycle phase-specific. Chemotherapeutics are particularly useful when attempting to cure 
patients with multifocal or metastatic disease. On the other hand, allowing these very 
toxic chemicals to circulate throughout the body has a significant effect on tissues with 
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rapid renewal, which is why patients receiving chemotherapy often experience nausea, 
fatigue, hair loss, and thrombocytopenia. With the development of targeted therapeutics 
some of these symptoms have been alleviated, but there is still much to be accomplished. 
In summary, the three main treatment options for cancer include surgery, 
radiotherapy, and chemotherapy. Although these techniques have become the standard of 
care, they still cannot guarantee that every cancer patient will be cured. In addition they 
are limited by cost, invasiveness, morbidity, and toxicity. Therefore, it is imperative to 
develop therapeutics that will be both minimally invasive and highly effective. This is 
the goal of nanomedicine, and advances in nanotechnology for cancer management to 
date will be discussed in the next section. 
1.2 Nanotechnology in Cancer Management 
1.2.1 Advantages of Nanoparticles 
The past decade has seen explosive growth in the number of innovative technologies that 
use nanoparticles to image and treat cancer. The advantage of using nanoparticles in 
medical applications begins with their small size and large surface area-to-volume ratio. 
First, since research continues to reveal that changes at the molecular level are critical to 
tumor development, logic dictates that the disease should be combated at this scale. 
Furthermore, the small size ofnanoparticles (typically 10-200 nm) allows them to 
accumulate in tumors by exploiting the leaky vascular network. It was previously 
mentioned that tumors are characterized by poorly organized vasculature with large 
intercellular gaps; these gaps allow nanoparticles to extravasate into the tumor bed and 
once there, the nanoparticles are retained because the lymphatic drainage system of 
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tumors does not operate effectively. Matsumura and Maeda first described this ability of 
nanoparticles to enter and remain in tumor tissue and it became known as the "enhanced 
permeability and retention effect" (the EPR effect) (Matsumura and Maeda 1986). 
Nanoparticles are said to utilize passive targeting when they rely on their small 
dimensions and the EPR effect to achieve high intratumoral concentrations. 
The second advantage ofnanoparticles is their large surface area-to-volume ratio, 
which allows for labeling with a variety of moieties that can enhance image contrast, 
improve therapeutic payload, or promote tumor uptake. It has been suggested that the 
ideal "nanovector" will include multiple functionalities, allowing several tasks to be 
achieved with a single platform. As shown in Figure 1.3, ideal nanovectors consist of 
three parts: the core material, the therapeutic/imaging payload, and the biological surface 
modifiers (Ferrari 2005). The surface modifiers could include "stealth" molecules that 
hide nanoparticles from the body's scavenger systems or targeting moieties that promote 
nanoparticle accumulation within tumors. The most common stealthing agent is 
poly( ethylene glycol) (PEG), which provides a dynamic, hydrophilic cloud of chains that 
reduces opsonization by macrophages of the reticuloendothelial system (RES), thereby 
increasing nanoparticle circulation time (van Vlerken et al. 2007). As mentioned earlier, 
cancer is characterized by mutations in oncogenes; these mutations can lead to over-
expression of receptors on the tumor cell surface. The goal of adding targeting moieties 
to nanoparticles is to increase tumor retention time by facilitating binding with these 
receptors. Potential targeting moieties could include antibodies, peptides, and aptamers, 
and each of these will be discussed in more detail in Chapter 3. 
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Figure 1.3: The ideal multifunctional nanoparticle. A multifunctional nanoparticle 
should be able to deliver therapeutic agents, amplify imaging signal with contrast 
enhancers, avoid biobarriers with permeation enhancers, prevent elimination from the 
circulation with PEG, and enhance tumor accumulation with targeting moieties. Image 
modified from Ferrari 2005. 
Many nanoparticles are currently being studied for use in cancer imaging and 
therapy, and it would be impossible to provide a complete list here. However, in the next 
few sections some of the major advancements in cancer nanomedicine will be discussed. 
The use of nanoparticles as contrast agents will be introduced first, followed by the use of 
nanoparticles as drug delivery agents, and, lastly the use of nanoparticles as thermal 
therapeutics will be reviewed. 
1.2.2 Nanoparticles as Contrast Agents 
Nanoparticles' unique physicochemical properties, lack of overt toxicity, and ease of 
functionalization render them suitable as contrast agents. In addition, because they can 
be addressed to specific cellular targets, they offer potential for noninvasive molecular 
imaging and may be used to monitor changes in biological function such as enzyme 
activity, protein-protein interactions, or gene expression (Minchin and Martin 2010) in 
addition to providing anatomical tumor information. While a variety of nanoparticle 
contrast agents are being developed, only quantum dots, gold-based nanoparticles, and 
iron-oxide nanoparticles will be discussed here. 
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Quantum dots (QDs) are core/shell crystalline semiconductors typically <10 nm 
diameter used with optical imaging modalities; some excellent reviews of QDs have been 
published (Michalet et al. 2005; Rhyner et al. 2006). These particles exhibit size-
dependent emission that allows for tuning to the near-infrared region where imaging 
depth and signal-to-noise ratio are optimal. In addition, QDs exhibit molar extinction 
coefficients 10-50X that of organic dyes and they can be used in multiplexing. The most 
common quantum dot structure is a CdSe core with a ZnS shell, and it requires capping 
ligands to be soluble in aqueous solutions and appropriate for biological applications. 
Gao and colleagues recently developed QDs suitable for in vivo work by encapsulating 
them within a triblock copolymer and linking this amphiphilic polymer to tumor-
targeting ligands (2004). These functionalized QDs could be imaged in tumor-bearing 
mice following either intravenous or subcutaneous delivery (Gao et al. 2004). While this 
was an exciting development, QDs' transition to clinical use is still limited by potential 
toxicity concerns, as there is some evidence that the particles leach Cd2+ and Se2- ions 
(Michalet et al. 2005). 
Gold-based nanoparticles are suitable contrast agents for a variety of imaging 
modalities, allowing oncologists to choose the imaging technique most appropriate for 
the tumor location. For example, optical coherence tomography (Cang et al. 2005; Gobin 
et al. 2007), photoacoustic tomography (Wang et al. 2004; Li et al. 2009; Song et al. 
2009; Lu et al. 2010), and Raman spectroscopy (Zavaleta et al. ; Keren et al. 2008; Qian 
et al. 2008) have all been evaluated with gold-based nanoparticles as contrast agents. 
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Optical coherence tomography works similarly to ultrasound but utilizes reflections of 
light (rather than sound waves) through tissue to generate images. In photoacoustic 
tomography (PAT), tissue is irradiated with a short-pulsed laser and light absorption 
produces a rapid temperature rise and subsequent thermo-elastic expansion of the tissue. 
The pressure induced by this expansion prompts acoustic wave propagation, which is 
detected by an ultrasound transducer at the surface (Yuan and Jiang 2010). PAT is 
gaining popularity because it combines high contrast of optical imaging with high spatial 
resolution of ultrasound imaging. Finally, Raman spectroscopy is a technique that offers 
the potential to identify molecular species at the single-molecule level, and is dependent 
on the electromagnetic field enhancement that occurs with plasmonic nanostructures. 
Great strides have been made since the concept of surface enhanced Raman spectroscopy 
(SERS) first appeared (Jeanmaire and VanDuyne 1977), but technological advancements 
need to be made before this imaging modality will realize its full potential. 
Since MRI is one of the most powerful techniques in cancer management, efforts 
have been made to enhance contrast with superparamagnetic iron-oxide nanoparticles 
(lONPs). In a landmark study, dextran-coated IONPs outperformed gadolinium (a 
clinical contrast agent) with respect to permanence of imaging enhancement and total 
areas with improved contrast, rendering the IONPs more suitable for postoperative 
imaging (Neuwelt et aZ. 2004). IONPs have also been radiolabeled to provide dual 
imaging capability with MRI and PET (Lee et aZ. 2008). As mentioned previously, 
nanoparticle formulations with multimodality possibilities will likely be critical players in 
the future of cancer nanomedicine. For this reason, Moore and colleagues have endowed 
dextran-coated IONPs with both imaging and therapy capabilities by conjugating the 
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nanoparticles to silencing RNA for image-guided gene therapy (Medarova et al. 2007). 
This development highlights the potential of nanoparticles to act as delivery vehicles, and 
in the next section more nanoparticle-based drug delivery schemes will be discussed. 
1.2.3 N anoparticles as Drug Delivery Agents 
The goal of nanoparticle-mediated drug delivery is to reduce deleterious side effects and 
improve patient survival by increasing the relative proportion of drug delivered to the 
tumor versus the rest of the body. A variety of nanocarrlers have been developed, 
including liposomes, polymeric nanoparticles, micelles, dendrimers, and more (Peer et al. 
2007). Liposomes and polymer vesicles are the most commonly investigated agents, and 
they provide the benefit of allowing both covalent and non-covalent encapsulation of 
hydrophobic and hydrophilic drugs (Janib et al. 2010). The first clinically used 
nanoparticle was a PEGylated liposomal formulation of doxorubicin (DoxilTM) and it has 
been indicated for use in Kaposi's sarcoma, breast cancer, and refractory ovarian cancer 
(Ferrari 2005). Compared to the free drug, liposomal doxorubicin has prolonged 
circulation and decreased toxicity (Batist et al. 2001). Since the introduction of DoxilTM, 
two more non-PEGylated liposomal drugs (DaunoXome and Myoset) have been used 
clinically (Peer et al. 2007). 
While drugs encapsulated inside or bound to nanoparticles have shown much 
promise in improving chemotherapy, there is still little or no control over the release 
profile. The future of drug delivery for cancer and other diseases will likely utilize 
"smart" nanomaterials that can release their therapeutic payload at the desired site upon 
triggering from biological cues or on-demand (Couvreur and Vauthier 2006). For 
example, since the tumor microenvironment is often acidic, liposomes and polymer 
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vesicles that release drugs at acidic pH have been developed (Ding et al. 2010; Yang et 
al. 2010). Similarly, enzymatic degradation of drug-polymer conjugates and liposomal 
carriers has been proposed since enzymes such as matrix metalloproteases (MMPs) are 
present at high levels in tumor tissue (Chau et al. 2006; Hatakeyama et al. 2007). While 
these first two approaches utilize biological cues to prompt drug release, the use of local 
hyperthermia for on-demand tumor-specific drug delivery has been proposed since 1978 
(Yatvin et al. 1978). In vivo work showed that temperature-sensitive liposomes 
containing doxorubicin were significantly more effective at eliminating subcutaneous 
squamous cell carcinoma tumors in mice than free drug or non-temperature sensitive 
liposomes when release was initiated by the simple heating technique of placing the 
animal's leg in a warm water bath (Needham et al. 2000). More recently, nanoparticles 
capable of absorbing light and converting the energy into heat have been used as a more 
sophisticated source of heat generation. When modified with drugs and exposed to light, 
hollow-gold nanoshells (Braun et al. 2009; You et al. 2010), nanorods (Wei et al. 2008), 
and PLGA-gold half-shells (Park et al. 2009), have all demonstrated the ability to heat 
and subsequently release their therapeutic payloads. These systems offer the added 
benefit that hyperthermia has cytotoxic effects as well. In the next section, the use of 
nanoparticles for thermal therapy as a standalone treatment will be described. 
1.2.4 Nanoparticles as Thermal Therapeutics 
The benefits of hyperthermia in medicine have been known for some time: Hippocrates 
once stated, "Give me a fever, and I can cure any illness" (ca. 400BC). While 
hyperthermia has been used as adjuvant cancer treatment, it is not currently utilized as an 
independent treatment modality. Sources for heat generation, which induces cell death 
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through such mechanisms as protein denaturation and rupture of cellular membranes, 
include radiofrequency and microwaves, laser light, and ultrasound (Wust et al. 2002). 
Unfortunately, simple heating techniques fail to discern normal from diseased tissue, 
preventing the widespread use of this technology. To overcome this limitation, 
researchers are evaluating the use of nanoparticles as exogenous energy absorbers to 
provide specific delivery of heat selectively to tumors. Here, some of the successes 
achieved with nanoparticles will be highlighted. Parts of this section are derived from the 
co-authored review article: Day ES et al. "Nanoparticles for Thermal Cancer Therapy." 
Journal ofBiomechanical Engineering (2009); 131 (7): 07400l. 
The three sources most commonly used to activate nanoparticle heating are 
radiofrequency waves, magnetic fields, and near-infrared light. With radiofrequency 
ablation (RF A), an electrode inserted into a tumor applies a radiofrequency current that 
induces agitation of ions within the tissue, leading to frictional heating (Curley 2001). 
The conductivity properties of gold nanoparticles (Cardinal et al. 2008; Gannon et al. 
2008) and single-walled carbon nanotubes (Gannon et al. 2007) provide the possibility of 
more efficient heating, allowing RFA to be accomplished noninvasively, with reported 
penetration depths of 7 -17 cm. While RF A uses radio frequencies to produce an 
alternating electric field, magnetic fluid hyperthermia uses radiofrequencies to generate 
an alternating magnetic field. This offers the advantage that the irradiation can reach all 
tissues in the body. Heat generation of magnetic nanoparticles exposed to this field is a 
result of energy losses during the magnetization reversal process. The first attempt to 
heat tissue with magnetic materials was performed by Gilchrist et al. (1957), and since 
then the field has advanced greatly. Recently, the first clinical studies regarding 
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magnetic fluid hyperthermia were published, demonstrating the feasibility of this therapy 
for treatment of prostate cancer (Johannsen et al. 2005; Johannsen et al. 2007) and 
glioblastoma multiforme (Maier-Hauff et al. 2007; Maier-Hauff et al. 2010). These 
studies incorporated amino silane-coated iron-oxide nanoparticles. While iron-oxide is 
the most common choice of material for magnetic hyperthermia, a recent article 
suggested that carbon-coated iron could be an excellent alternative (Xu et al. 2010). 
The most extensively studied approach to thermal cancer therapy is excitation of 
nanoparticles with near-infrared light, and within this field plasmonic gold-based 
nanoparticles have received the most attention because they are biocompatible and their 
optical properties can be tuned by adjusting particle size, shape, and composition. When 
these nanoparticles are exposed to light at their resonance wavelength, the conduction-
band electrons begin to oscillate in unison, resulting in light absorption or scattering 
(Kennedy et al. 2010). Therapeutic applications take advantage of the fact that some of 
the absorbed light energy is converted into heat that induces damage of nearby cells; thus 
this approach to cancer treatment is known as photothermal therapy. Some of the 
nanoparticles investigated for photothermal therapy include gold nanorods (Dickerson et 
al. 2008), gold nanocages (Chen et al. 2007; Chen et al. 2010), hollow gold nanoshells 
(Lu et al. 2009), gold-gold sulfide nanoparticles (Gobin et al. 2010), and silica-gold 
nanoshells (Hirsch et al. 2003; Gobin et al. 2007). This thesis aims to further develop 
photothermal therapy with gold-gold sulfide nanoparticles and silica-gold nanoshells, so 
in Section 1.3 these particles will be described in more detail. Section 1.3 is partially 
adapted from the following co-authored book chapters: Bickford et al. (2010) and Morton 
et al. (2010). 
1.3 Introduction to Silica-Gold Nanoshells and Gold-Gold Sulfide 
N anoparticles 
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Gold-based nanoparticles are perhaps the most thoroughly studied among the numerous 
nanoparticles being explored as agents for cancer management, partially attributed to the 
well-documented uses of gold in human history. Starting from Faraday's investigation of 
colloidal gold in the middle 1800s, optical properties of metal nanoparticles have long 
been of interest in physical chemistry. This exploration led to a major breakthrough in 
the middle 1990s when core-shell structures were discovered to have highly tunable 
optical properties. In general, a nanoshell can be classified as any nanoparticle composed 
of a core coated with different materials. The first experimentally developed metal 
nanoshell consisted of an Au2S dielectric core surrounded by a gold shell (Zhou et al. 
1994), although it was later proposed that these nanoparticles actually consist of a gold 
aggregate structure (Norman et al. 2002). The ensuing debate about their composition 
remains ongoing today (Raschke et al. 2005; Zhang et al. 2005; Schwartzberg et al. 
2007), so within this thesis these nanoparticles will be referenced more generally as gold-
gold sulfide nanoparticles. More recently, a new nanoshell design consisting of a silica 
(Si02) core coated with a thin layer of gold was developed (Oldenburg et al. 1998). 
Since their inception, silica-based gold nanoshells have been studied as instruments for 
achieving superior diagnostic imaging applications, photothermal therapy, laser-tissue 
welding, controlled drug delivery, and for immunoassays (reviewed in Hirsch et al. 
(2006». The following sections will discuss the properties of these two types of 
nanoparticles and then describe their current use in cancer management. 
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1.3.1 Optical Properties 
The optical properties of gold-gold sulfide nanoparticles and silica-gold nanoshells, 
particularly the scattering and absorbing cross-sections, can be obtained using the Mie 
solution to Maxwell's equations, or Mie theory, for concentric spheres. Since the 
diameter (d) of both gold-gold sulfide nanoparticles and nanoshells is much less than the 
wavelength of the incident electromagnetic field (A.), that is d« A., Mie theory 
calculations can be performed using the quasi-static approach in which spatial variation is 
ignored but temporal dependence is preserved. To further simplify the calculations, the 
particles are approximated as perfect spheres and dipole-dipole interactions are neglected 
since the particle concentration in solution is low. The complete derivation of the optical 
properties of gold-gold sulfide nanoparticles using Mie theory has been published by 
Averitt et al., so only important results of the derivation will be discussed here (1999). 
Figure 1.4 displays the geometry used in performing Mie scattering simulations (Averitt 
et al. 1999). To solve the equations, the dielectric constants of the core (EI), shell (E2), and 
dispersive medium (E3) must be known, as well as the radius of the core (rl) and whole 
Figure 1.4: Nanoshell geometry used in Mie theory calculations. The core radius is rl 
and the total particle radius is r2. The dielectric constants EI, E2, and E3 are those of the 
core, shell, and dispersive medium, respectively. Image from Averitt et al. 1999. 
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To detennine the scattering and absorption cross-sections of the particles, some 
definitions must first be made. As shown in Equation 1, P is the ratio of shell volume to 
total particle volume and it is needed to define 8a and 8b, displayed in Equations 2 and 3. 
These are subsequently used to solve for the polarizability (a) in Equation 4, where 8 0 is 
the pennittivity of free space, 8.85 x 10-12 F/m. Polarizability describes the tendency of 
charge distribution to be distorted by an external electric field. 
Equation 1 
Equation 2 
Equation 3 
Equation 4 
Plasmon resonance of the electrons in the shell occurs at the point of maximum 
polarizability, which takes place when the denominator of Equation 4 approaches zero. 
Using the polarizability equation and the above definitions, the absorption (Equation 5) 
and scattering (Equation 6) cross sections can be obtained. Averitt et al. used these 
relationships to show that the wavelength of resonance depends on the ratio of the core 
radius to the total particle radius, seen in Equation 7 (1999). 
Equation 5 
Equation 6 
1 
3 
Equation 7 
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The relationship displayed in Equation 7 is important because it shows that the 
wavelength of plasmon resonance can be tuned based on particle geometry. For example, 
with a given shell thickness, a larger particle diameter shifts the peak plasmon resonance 
to longer wavelengths. Although these calculations were performed based on the values 
for gold-gold sulfide nanoshells, Oldenburg et al. showed that tunable optical resonances 
are also achievable with silica-gold nanoshells (1998). Figure 1.5 shows how nanoshells 
with a silica core can be tuned to have a peak plasmon resonance throughout the 
electromagnetic spectrum by altering the ratio of the core to total particle radius. 
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Figure 1.5: Optical resonances of nanoshells calculated with Mie theory. Nanoshells 
with a fixed 60 nm core radius display a shift in peak extinction of over 300 nm as the 
gold shell thickness decreases from 20 nm to 5 nm. Image from Day et al. 2010. 
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The optical "tunability" of nanoshells and gold-gold sulfide nanopartic1es renders 
them desirable for many biomedical applications, as will be discussed in the following 
section. In this thesis, nanoshells and gold-gold sulfide nanopartic1es will be compared 
for use in imaging and treatment of breast and brain tumors. 
1.3.2 Applications in Cancer 
The ability to synthesize nanoshells and gold-gold sulfide nanopartic1es (GGS-NPs) with 
peak extinction in the near infrared (NIR) region of the electromagnetic spectrum makes 
them particularly attractive for use as cancer diagnostic and therapeutic agents. This may 
be understood by considering interactions between light and tissue. There is a 
wavelength-dependent absorption of light by native chromophores in tissue, with the two 
main absorbers of visible and infrared light being water and hemoglobin. As seen in 
Figure 1.6, there is low absorbance by each of these tissue components in the "NIR 
window" from 650-900 nm (Weissleder 2001). Within this region light may penetrate 
deeply into tissue, allowing for noninvasive imaging and therapy of cancer when 
combined with nanopartic1es having their peak extinction at the same wavelength. By 
definition, extinction measures the amount of energy removed from incident light and is a 
combination of both absorption and scattering. Absorbed energy is mainly dissipated as 
Ohmic heating, which enables nanoshells and GGS-NPs to be used for photothermal 
applications, such as controlled drug delivery (Sershen et al. 2000; Bikram et al. 2007; 
Huang et al. 2008) and cancer hyperthermia (Hirsch et al. 2003; O'Neal et al. 2004; 
Gobin et al. 2010). Meanwhile, scattered light permits nanoshells to serve as contrast 
agents for several imaging applications, such as darkfield microscopy (Loo et al. 2005) 
and optical coherence tomography (OCT) (Gobin et al. 2007). The next few paragraphs 
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will overview some of the research accomplishments with gold-gold sulfide nanoparticles 
and nanoshells that provided a foundation for this thesis. 
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Figure 1.6: Absorption coefficient of major chromophores in tissue. Near infrared 
(NIR) wavelengths of light are best suited for biological applications due to minimal 
absorption by native tissue components. This region is thus dubbed the "NIR window." 
Image from Weissleder 2001. 
Cancer imaging and photothermal therapy mediated by gold-gold sulfide 
nanoparticles (GGS-NPs) or nanoshells (NS) can be summarized in a few steps. First, 
these nanoparticles must accumulate within the tumor, and this can be accomplished via 
intratumoral or intravenous delivery. When administered intravenously, nanoparticles 
utilize the EPR effect described earlier to accumulate within the tumor. Once a sufficient 
number of nanoparticles are within the tumor, imaging or therapy can be performed. For 
therapy, a NIR laser applied transdermally induces heating of the nanoparticles and 
subsequent necrosis of the tumor tissue. This process is depicted schematically in 
Figure 1.7. 
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Figure 1.7: The steps of nanoparticle-mediated photothermal therapy. First, 
nanoparticles delivered intravenously accumulate in the tumor by passing through inter-
endothelial cell openings. If desired, imaging may be performed to confirm nanoparticle 
presence. Second, a near-infrared laser is externally applied to the tumor region for a few 
minutes. This induces heating of the nanoparticles sufficient to induce cancerous cell 
death and necrosis of the tumor tissue. 
In 2003, Hirsch et al. were the first to demonstrate nanoparticle-mediated 
photothermal therapy using nanoshells to induce damage to SK -BR -3 human breast 
carcinoma cells in vitro (Hirsch et al. 2003). In the same report, they demonstrated the 
effects of this therapy in vivo. Transmissible venereal tumors grown subcutaneously in 
SCID mice were injected with PEG-passivated nanoshells or saline and then a NIR laser 
was applied (820 nm, 4 W/cm2, <6 min). Temperature measurements acquired during 
laser application demonstrated a mean temperature increase in the nanoshell group of 
almost 40°C, compared to only 10°C in the control group. Histology of excised tumors 
confirmed that tissue damage was confined to areas of nanoshelliocalization 
(Figure 1.8). This was the first time that local heat delivered by light-activated 
nanoshells was shown to damage tumor tissue in vivo. 
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Figure 1.8: Damage due to photothermal therapy is confined to regions within 
tumors that contain nanoshells. (a) Gross pathology of a tumor treated with nanoshells 
and NIR laser exposure. (b) Nanoshell location identified by silver staining. (c) Tissue 
damage in the region with nanoshells confirmed by H&E staining. (Hirsch et al. 2003) 
Following this study, the ability of intravenously administered PEG-coated 
nanoshells to thermally ablate tumors and thereby improve animal survival was verified 
with a subcutaneous murine tumor model (O'Neal et al. 2004). As shown in Figure 1.9, 
mice bearing CT26 colon carcinoma tumors that received nanoshell therapy displayed 
complete tumor regression and remained 100% tumor-free for the duration of the study. 
By comparison, the mean lifespan was 10.1 days for the non-treated group and 12.5 days 
for mice that received only laser exposure. This was the first demonstration that 
nanoshells delivered systemically could accumulate in tumors at levels sufficient for 
photothermal tumor destruction. Since these first two studies with breast and colon 
carcinoma tumors were published, in vitro studies have demonstrated that nanoshell-
mediated photothermal therapy is also effective against prostate (Stem et al. 2007; Gobin 
et al. 2008), brain (Bernardi et al. 2008), and liver cancers (Liu et al. 20 1 0). Currently, 
photothermal therapy with PEG-coated nanoshells is being investigated in a Phase I 
clinical trial for treatment of refractory head and neck cancer (ClinicaITrials.gov 2010). 
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Figure 1.9: Nanoshell-assisted photothermal therapy improves survival of tumor-
bearing mice. This plot depicts the differences in survival time for mice bearing CT26 
tumors that received no treatment, sham treatment (laser only), or nanoshell-assisted 
photothermal therapy (NAPT). (O'Neal et al. 2004) 
Although gold-gold sulfide nanoparticles were invented before silica-gold 
nanoshells, it wasn't until recently that their potential as mediators of photothermal 
therapy was tested. In a novel study, Gobin et al. used Mie theory to prove that GGS-
NPs have a larger ratio of absorption to scattering than nanoshells (2010). Then, using a 
subcutaneous murine tumor model, it was shown that these particles are equally effective 
at inducing tumor regression. Importantly, the GGS-NPs accumulated in the tumors used 
in this study over a longer timeframe than the silica-gold nanoshells; consequently 
therapy was more effective for GGS-NPs if the laser was applied 48 h post-intravenous 
injection (82% survival) rather than 24 h (71 % survival). For silica-gold nanoshells the 
maximum tumor accumulation occurred at 24 h, and following laser application at that 
time the mice experienced 82% survival (Gobin et al. 2010). This result emphasizes the 
importance of understanding nanoparticle distribution profiles so that the exciting energy 
source is applied at the proper time to maximize treatment effect. 
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F or future clinical success, it may be necessary to exploit the ability of nanoshells 
and gold-gold sulfide nanoparticles to act as contrast agents for a variety of imaging 
modalities; this could allow nanoparticle accumulation in the tumor to be monitored in 
real time, guiding decisions regarding when the laser should be applied. At present, 
nanoshells, but not GGS-NPs have been tested as in vivo contrast agents. Using optical 
coherence tomography, Gobin et al. successfully monitored nanoshell accumulation in 
subcutaneous tumors (Figure 1.10) and showed that these same nanoshells could also be 
used for photothermal therapy (2007). Similarly, two-photon microscopy has been used 
to monitor nanoshell accumulation in tumors and relate particle position to tumor vessels 
(Figure 1.11) (Park et al. 2008). One aim of this thesis is to prove that GGS-NPs are 
also suitable contrast agents for two-photon microscopy; this ability will be demonstrated 
in Chapter 4. 
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Figure 1.10: Optical coherence tomography (OCT) detects nanoshells in tumor 
tissue. The left and right panels show an OCT image from a tumor in a mouse that 
received saline or nanoshells, respectively. There is a significant increase in contrast 
intensity in the presence of the nanoshells. (Gobin et al. 2007) 
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Figure 1.11: Nanoshells can be visualized in tumors with two-photon microscopy. 
White light (a,c) and two-photon photoluminescence (b,d,e) images from mice injected 
with nanoshells (a,b,e) or saline (c,d). 3D visualization (e) of nanoshells (green) and 
blood vessels (red) demonstrates that the nanoshells are proximal to the tumor vessels. 
(Park et al. 2008) 
To provide the best possible imaging and therapy of cancer with nanoshells and 
gold-gold sulfide nanoparticles, their accumulation within tumors should be maximized. 
Some insight into the pharmacokinetics of these materials has been gained by studies 
investigating the biodistribution of PEG-coated nanoparticles in mice (James et al. 2007; 
Gobin et al. 2010). As previously mentioned, however, it is predicted that coating 
nanoparticles with targeting moieties should prolong the accumulation in the tumor and 
provide new opportunities for molecular-specific imaging and therapy . Working towards 
this goal, several groups have developed methods to functionalize nanoshells with 
antibodies or peptides, thereby enabling cell-specific binding (Loo et al. 2005; Gobin et 
al. 2008; Liu et al. 2010). For example, as shown in Figure 1.12, nanoshells coated with 
anti -IL 13 Ra2 antibodies bind U373 human high-grade glioma cells that over-express 
IL13Ra2 (interleukin 13 receptor alpha 2) to enable thermal therapy (Bernardi et al. 
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2008). In Chapter 4 it will be demonstrated that GGS-NPs can be molecularly addressed 
using the same chemistry described for silica-gold nanoshells. One flaw of all these 
preliminary targeting studies, however, is that they were performed in vitro, and it 
remained unknown if altering the surface coating on nanoshells and GGS-NPs would 
significantly alter their organ distribution and tumor accumulation profile in vivo. 
Therefore, one major goal of this thesis was to provide insight to this question. In 
Chapter 3 it will be shown that antibody -coated nanoshells can bind ovarian tumor tissue 
ex vivo at levels corresponding to the receptor expression, suggesting that targeting 
mechanisms should continue to work in the more complex in vivo environment. The 
biodistribution of targeted and PEG-coated nanoshells and GGS-NPs in tumor-bearing 
mice will be presented in Chapters 5 and 6. 
PEG-NS Anti-IL 13R-NS 
Figure 1.12: Antibody-coated silica-gold nanoshells bind targeted cells to mediate 
photothermal therapy. U373 cells that over-express the receptor IL13Ra2 were 
exposed to PEG-NS or Anti-IL13Ra2-NS prior to laser irradiation. Calcein AM and 
ethidium homodimer-l staining was performed to show live cells (green) and dead cells 
(red). Only antibody-coated nanoshells bound the targeted cells at levels sufficient to 
induce thermal damage upon laser irradiation. (Bernardi et at. 2008) 
1.4 Conclusions: Opportunities to Advance Cancer Therapy with 
Nanoshells and Gold-Gold Sulfide NanoparticIes 
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This thesis seeks to advance cancer therapy by further developing photothennal therapy 
mediated by nanoshells and gold-gold sulfide nanopartic1es. Photothennal therapy offers 
numerous benefits over conventional cancer therapy: compared to surgery, photothennal 
therapy is much less invasive; and, in contrast to radiation and chemotherapy, the 
mechanism of action is imparted only at desired locations when the laser is applied, 
creating a therapy that should have few side effects. Photothennal therapy is also 
advantageous compared to magnetically induced heating of nanopartic1es because much 
lower concentrations ofnanopartic1es are required (minimizing toxicity concerns) and 
because the procedures are faster and do not require expensive, specialized equipment. 
Silica-gold nanoshells and gold-gold sulfide nanopartic1es were chosen for 
investigation in this thesis from among the many nanopartic1es that could be used for 
near-infrared photothennal therapy for several reasons. First, these nanopartic1es are 
simple to fabricate and do not present toxicity concerns since the outer layer is comprised 
of metallic gold which has been shown to be relatively inert and thus biocompatible. 
Comparatively, nanorods require capping with cetyltrimethylammonium bromide 
(CTAB) during synthesis, which has known toxicities and must be replaced before in vivo 
application (Niidome et al. 2006). The compatibility of gold nanocages and hollow gold 
nanoshells remains to be validated in thorough studies, although it is anticipated that 
these nanopartic1es will be non-toxic. Second, the gold outer layer of nanoshells and 
GGS-NPs provides an added benefit as a surface readily available for bioconjugation. 
Finally, a third consideration in choosing a nanopartic1e platfonn is the photothennal 
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transduction efficiency, defined as the proportion of incident light being converted into 
photothermal power. Cole et al. found that for solutions ofnanoparticles at equal optical 
densities gold-gold sulfide nanoparticles and nanorods have similar photothermal 
transduction efficiencies that are higher than that of silica-gold nanoshells; though, when 
calculated on a per-particle basis, silica-gold nanoshells have the highest transduction 
cross section (Cole et al. 2009). Notably, all of these differed by less than a factor of3, 
suggesting that there is likely not a significant advantage of one nanoparticle versus 
another. Therefore, based on all these criteria, it was determined to include both gold-
gold sulfide nanoparticles and silica-gold nanoshells in these experiments. 
Previous research has indicated that PEG-coated nanoshells and gold-gold sulfide 
nanoparticles may be used in cancer management, and it has been predicted that the 
addition of targeting moieties to the nanoparticle surfaces will enhance cancer therapy by 
improving nanoparticle retention within tumors. This thesis aims to evaluate the benefits 
of molecular targeting through a series of experiments. To begin, Chapter 2 explains the 
methods used to synthesize nanoparticles for these experiments. In Chapter 3, the ability 
of antibody-coated nanoshells to specifically bind and treat cancerous cells in co-culture 
with non-targeted normal cells is demonstrated. In addition, the potential of antibody-
coated nanoshells to act as ex vivo diagnostic agents is shown. Using an in vitro model, 
Chapter 4 proves that antibody-coated gold-gold sulfide nanoparticles can be used as dual 
imaging and therapeutic agents. The second half of this thesis then focuses on in vivo 
validation of targeting schemes using high-grade glioma as a model tumor. Chapter 5 
describes the first attempt to compare the distribution of antibody-coated and PEG-coated 
nanoparticles in tumor-bearing mice. The sensitivity of glioma to nanoparticle-mediated 
photothermal therapy is also established. Finally, Chapter 6 demonstrates the ability to 
treat intracranial glioma tumors using vascular-targeted nanoparticles. To conclude this 
thesis, Chapter 7 summarizes the importance of the results, overviews the potential 
applications, and discusses the future directions for enhancing cancer imaging and 
photothermal therapy through targeted delivery of nanoparticles. 
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Chapter 2: Methods for Nanoparticie Synthesis, Stabilization, 
and Characterization 
2.1 Introduction 
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This chapter presents the methods used throughout this thesis to synthesize, stabilize, and 
characterize silica-gold nanoshells and gold-gold sulfide nanoparticles. 
2.2 Synthesis of Silica-Gold N anoshells 
A four-step process developed by Oldenburg et al. was used to fabricate nanoshells 
consisting of spherical silica cores and thin gold shells (Oldenburg et al. 1998). First, 
colloidal silica (120 nm diameter, synthesized or purchased from Precision Colloids, 
Cartersville, GA) was functionalized with 3-aminopropyl-triethoxysilane and decorated 
with small (~3 nm) gold colloidal particles. These gold colloid islands provided 
nucleation sites where additional gold could be reduced until a complete shell was 
formed. More thorough details of the production process are outlined below. 
2.2.1 Formation and Functionalization of Silica Nanoparticies 
Silica nanoparticles were formed following the StOber method (Stober et al. 1968). To 
produce ~120 nm diameter silica spheres 2.7-3.1 ml ammonium hydroxide (NHtOH, 
28%, Aldrich, S1. Louis, MO) was added to 45 ml 200 proof ethyl alcohol (EtOH) and, 
while stirring rapidly, 1.5 ml tetraethyl orthosilicate (TEOS, Aldrich) was added. After 
the mixture reacted overnight, the nanoparticle solutions were centrifuged twice (1750 g, 
30 min each) and re-suspended in EtOH. The silica nanoparticles were sized using 
scanning electron microscopy and only batches withpolydispersity less than 10% were 
used for subsequent steps. 
35 
To promote binding of negatively charged gold colloid to the silica nanoparticles, 
the silica surfaces were terminated with positively charged amine groups. This was 
accomplished by adding 5 J..l13-aminopropyltriethoxysilane (APTES, Aldrich) per 1 ml 
silica cores (at 4% by weight), and the reaction proceeded at room temperature for at least 
8 h. To encourage covalent bonding of silane groups to the surface, the spherical 
particles were then boiled for 1 h at 75°C while maintaining a constant volume in EtOH. 
This was followed by another two-step centrifugation (1750 g, 15 min) and re-suspension 
in fresh EtOH. 
2.2.2 Gold Colloid Formation and Seed Growth 
Gold colloid particles (~3 nm diameter) were prepared as described in the literature (Duff 
et al. 1993). A working dilution oftetrakis(hydroxylmethyl)phosphonium chloride 
(THPC) was made by addition of 400 J..lI THPC (Aldrich) to 33 ml Millipore water. 
Then, while stirring rapidly, 4 ml of the THPC dilution and 1.2 mIl M NaOH (Aldrich) 
were added to 180 ml Millipore water chilled to lOoC. After stirring 5 min, 6.75 ml of 
1 % chloroauric acid (HAuCI4, Aldrich) was quickly added, resulting in a light reddish-
brown suspension of colloid which was subsequently aged at 4°C for a minimum of 
2 weeks to allow the gold particles to reach the correct size. 
Seed particles are the precursors to silica-gold nanoshells are they are comprised 
of silica cores with evenly dispersed gold particles adsorbed to the surface. To make seed 
particles, 40 ml gold colloid was mixed with 300 J..lI amine-functionalized cores and 4 ml 
1 M NaCl. This reacted 2-3 days and the resulting seed was washed with Millipore water 
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through centrifugation (1650 g, 25 min, performed twice). Lastly, seed particles were 
diluted with Millipore water to an extinction of 0.1 units at 530 run wavelength. The seed 
formation process is illustrated in Figure 2.1 (a) and a transmission electron micrograph 
of a single seed particle is shown in Figure 2.1 (b). 
(b) 
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Figure 2.1: Production of "seed" nanoparticles. (a) Reacting gold colloid with amine-
functionalized silica nanoparticles yields "seed" nanoparticles composed of a 
discontinuous metal surface on a dielectric core. (b) Representative TEM of a seed 
particle. Scale 'bar = 20 run. 
2.2.3 Shell Growth 
The final step in formation of nanoshells is completion of the gold shell. First, a mixture 
of 12 ml of29.7 mM HAuC14 and 800 ml1.8 mM potassium carbonate was prepared and 
aged for a minimum of 24 h; this solution is referred to as KCarb-Gold. Optimization 
sweeps were performed in small quantities to determine volume ratios of seed solution to 
KCarb-Gold that produced nanoshells with the desired extinction characteristics; 
typically ratios ranged from 200-500 Jll seed per 1 ml KCarb-Gold. Once determined, the 
appropriate ratio was scaled up linearly to produce larger volumes of nanoshells. Seed 
was mixed with KCarb-Gold and, while rapidly mixing, formaldehyde was added at 10 Jll 
per 1 ml KCarb-Gold. This process reduces the gold and results in a contiguous gold 
shell over the surface of the silica particle. The characteristics of the nanoshells were 
determined by examining the spectral extinction profile in the range of 400-11 00 run with 
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a UV-Vis spectrophotometer (Cary Bio 50, Varian, Walnut Creek, CA). After analysis 
the nanoshells were washed for storage by centrifuging twice (750 g, 20 min) with re-
suspension in 1.8 mM potassium carbonate. Before use, nanoshells were re-suspended in 
DI water. Transmission electron micrographs of the process ofnanoshell formation have 
been published and are reproduced below (Figure 2.2) (Oldenburg et al. 1998). 
- 20nm 
Figure 2.2: The process of shell growth on a "seed" particle. This series of 
transmission electron micrographs displays the shell growth process. At left an initial 
"seed" nanopartic1e is shown. The three center images display gradual growth and 
coalescence of gold colloid on the silica nanopartic1e. At right is a completed nanoshell. 
Modified from Oldenburg et al. 1998. 
2.3 Synthesis of Gold-Gold Sulfide N anoparticles 
Gold-gold sulfide nanopartic1es (GGS-NPs) were synthesized using a variation of 
published literature techniques (Averitt et al. 1999; Schwartzberg et al. 2007). Solutions 
of2 mM HAuCl4 (Alfa Aesar, Ward Hill, MA) and 1 mM Na2S203 (Sigma, Saint Louis, 
MO) were prepared in Millipore water in amber glass vials, aged two days at room 
temperature, and mixed in small quantities at volumetric ratios ranging from 1: 1 to 1:2 
(HAuCI4:Na2S203). The ratio that produced nanopartic1es resonant near 800 nm as 
determined with a UV -visible spectrophotometer (Cary 50, Varian) was used to 
synthesize a large batch of nanopartic1es by linearly scaling the reaction volumes. 
An abundance of small gold spheres, rods, and flat triangular nanopartic1es 
existed in the initial reaction solutions as evidenced by electron microscopy and UV-
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visible spectrophotometry. It was important to enrich the fraction ofNIR-absorbing 
nanoparticles in the experimental solutions for several reasons: first, since the resonant 
wavelength of colloidal gold is not in the NIR, these nanoparticles do not offer diagnostic 
or therapeutic benefits with the approach under investigation in this thesis; second, 
eliminating these non-therapeutic nanoparticles allows the total nanoparticle dosage to be 
reduced, thereby minimizing concerns of organ toxicity; and third, elimination of these 
nanoparticles prevents their competitive binding to targets intended for the GGS-NPs. A 
multi-step centrifugation process was carried out to remove the by-product nanoparticles 
so that the final nanoparticle solutions used in experiments consisted of a majority of 
GGS-NPs. Changes in the fraction of contaminant nanoparticles and GGS-NPs were 
monitored by TEM and spectrophotometry, which indicated reduction in the peak near 
530 nm (indicative of colloidal gold) following purification (Figure 2.3). After 
purification, GGS-NPs were evaluated for in vitro and in vivo diagnostic and therapeutic 
capabilities in studies that will be detailed in later chapters of this thesis. 
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Figure 2.3: Purification of gold-gold sulfide nanoparticles. UV -visible spectroscopy 
shows reduction in the peak near 530 nm after centrifugation, indicating removal of small 
gold colloid. Transmission electron micrographs of a sample before (top right) and after 
(bottom right) centrifugation support this data. Scale bars = 35 nm. 
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2.4 Nanoparticle Stabilization with Poly(ethylene) Glycol 
The addition ofpoly(ethylene glycol) (PEG) to nanopartic1es produces a hydrophilic and 
flexible coating that provides steric stabilization and prevents opsonization, thereby 
reducing aggregate formation between nanopartic1es and increasing blood circulation 
half-life (Wang and Thanou 2010). For the studies in this thesis, PEG coatings were 
formed by adding mPEG-SH (5 kDa) to nanoshells or GGS-NPs suspended in Millipore 
water at an optical density of 1.5. For nanoshells, 1 part 25 flM mPEG-SH was added to 
9 parts nanoshells (~3 x 109 partic1es/ml), and for GGS-NPs 1 part 250 flM mPEG-SH 
was added to 9 parts GGS-NPs (4 x lOll partic1es/ml); these samples reacted overnight at 
4°C while rocking. mPEG-SH self-assembles on the nanopartic1es due to gold-sulfur 
interactions. PEGylated nanopartic1es were centrifuged or filtered to remove unbound 
molecules and suspended in the appropriate medium for the forthcoming application. 
2.5 Characterization Methods 
2.5.1 Electron Microscopy 
Scanning electron microscopy (SEM) and transmission electron microscopy (TEM) were 
used to visualize bare (non-PEGylated) nanopartic1es. Electron microscopy samples 
were prepared by drying 20 fll suspensions ofnanopartic1es on 300 mesh copper Gilder 
grids (Ted Pella, Inc., Redding, CA). SEM was performed on a FE! Quanta 400 field 
emission scanning electron microscope and TEM was performed on a JEOL 1230 high-
contrast transmission electron microscope or a JEOL 2010 transmission electron 
microscope. Typical SEM images of silica-gold nanoshells (left) and unpurified gold-
gold sulfide nanopartic1es (right) are displayed in Figure 2.4. 
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Figure 2.4: Scanning electron micrographs of nanoparticles. SEM images of 
nanoshells (left) and unpurified gold-gold sulfide nanoparticles (right) can be used to 
determine particle size and level of heterogeneity. Scale bars = 500 nm. 
2.5.2 UV -Visible Spectroscopy 
Nanoparticle extinction characteristics were determined by UV -visible spectroscopy with 
a Cary 50 Bio spectrophotometer (Varian). Red-shifts in plasmon resonance following 
conjugation indicated adequate PEG coverage. In addition, the quality of PEG coverage 
was gauged with spectroscopy by monitoring changes in extinction after mixing 900 J.lI 
nanoparticles and 100 J.lI 1 M N aCl. If nanoparticles were not properly stabilized, 
suspension in salt quickly resulted in lowered peak extinction due to formation of 
nanoparticle aggregates; nanoparticles were considered sufficiently stabilized if the peak 
extinction reduced by no more than 20% within 2 h of salt addition. Sample results from 
a salt stability test on nanoshells appear in Figure 2.5. Nanoshells coated with PEG 
remain in suspension after addition of salt so the optical density remains 91 % of the 
original value; non-coated nanoshells aggregate, causing the absorbance to drop to 22% 
of the original value. Control nanoshells incubated with water remain suspended, with 
98-99% of the initial absorbance maintained regardless of coating. 
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Figure 2.5: Stability of PEG-coated nanoshells in salt solution. Nanoshells coated 
with PEG remain stable in salt solution while bare nanoshells aggregate, leading to a drop 
in the absorbance over a period of 2 h. 
2.5.3 Dynamic Light Scattering and Zeta Potential Analysis 
Dynamic light scattering (DLS) and Zeta potential measurements were performed on a 
ZetaSizer NanoZS (Malvern Instruments, Worcestershire, UK) to confirm PEG coverage. 
DLS measures Brownian motion of nanoparticles in solution to estimate particle 
hydrodynamic diameter; larger nanoparticles display slower Brownian motion. 
Translational diffusion depends not only on particle size, but also on surface structure, so 
adding polymer coatings increases the hydrodynamic diameter. Hence, upon adequate 
PEG conjugation, nanoparticles should demonstrate increased hydrodynamic diameter. 
When a charged nanoparticle is placed in suspension, oppositely charged ions are 
attracted to the surface of the nanoparticle to form an electric double layer; ions closer to 
the nanoparticle are strongly bound while ions further from the surface are loosely bound. 
The edge of this loosely bound layer is known as the slipping plane, and ions within that 
boundary move with the particle as it moves in liquid. Zeta potential is the potential at 
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the slipping plane, and its magnitude indicates the stability of the colloidal system. As 
PEG is added to nanoparticles the zeta potential neutralizes since the polymer chains 
increase the distance of the slipping plane from the nanoparticle surface and reduce the 
nanoparticle mobility. Therefore, observing decreases in Zeta potential magnitude can be 
used as a quality control step to confirm sufficient coating. Sample DLS and Zeta 
potential measurements for nanoshells used in this thesis are demonstrated in Figure 2.6. 
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Figure 2.6: Hydrodynamic diameter and Zeta potential of bare and PEG-coated 
nanoshells. (Left) Hydrodynamic diameter of nanoshells increases by 30 nm upon 
addition of mPEG-SH. (Right) Zeta potential increases by 20 m V upon addition of 
mPEG-SH. 
2.6 Conclusions 
The methods in this chapter describe the synthesis and PEG passivation of nanoshells and 
gold-gold sulfide nanoparticles. The techniques used to characterize nanoparticles 
introduced here were used throughout the remainder of this thesis to ensure nanoparticle 
quality prior to use in experiments. 
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Chapter 3: Antibody-Coated Nanoshells for Enhanced Cancer 
Diagnosis and Therapy 
3.1 Introduction 
In the process of tumorigenesis, genetic alterations within cancer cells often induce up-
regulation of cell surface receptors. These over-expressed receptors are known as 
"molecular markers" that distinguish diseased tissue from normal tissue, and they provide 
a potential binding site for novel therapeutics. Molecularly-targeted therapeutics may 
improve cancer therapy by enhancing specificity, prolonging retention within tumors, and 
minimizing off-target effects. In this chapter, the addition of antibodies to nanoshell 
surfaces is evaluated as a means of providing tumor cell-specific targeting and enhanced 
photothermal therapy in vitro. In addition, the diagnostic potential of anti-HER2 
nanoshells is evaluated with ex vivo tumor samples. 
3.1.1 Passive versus Active Targeting of Tumors 
Nanoparticle accumulation within tumors can be accomplished through "passive" or 
"active" targeting. In passive targeting, nanoparticles' small size allows them to exploit 
tumors' leaky vasculature and poor lymphatic drainage, which promote increased 
extravasation and longer retention in the tumor interstitial space, respectively; this 
phenomenon is known as the enhanced permeability and retention (EPR) effect 
(Matsumura and Maeda 1986). While passive targeting can be effective, it is limited by 
the fact that the size and number of fenestrations within tumor vasculature varies widely; 
as a result, nanoparticles cannot be delivered to tumors with much precision. 
44 
The recent discovery of cancer cell biomarkers initiated a new thrust in the 
development of nanoparticle delivery mechanisms; scientists are now utilizing active 
targeting schemes that direct nanoparticles toward specific cell populations within a 
tumor by functionalizing the particles with moieties known to bind tumor cell antigens. 
For active targeting to be beneficial, it is imperative that the targeting ligand of choice is 
selective for antigens uniquely over-expressed by cancerous cells relative to normal cells. 
One advantage of active targeting is that when targeted nanoparticles bind cancer cells, it 
may prolong retention within the tumor compared to passive accumulation. In addition, 
active targeting may increase therapeutic efficacy by promoting cellular internalization of 
the nanoparticle and any drugs or imaging agents it may be ferrying. The differences 
between active and passive targeting are summarized visually in Figure 3.1 (Dong and 
Mumper 2010). 
Angiogenic tumor vessels 
are leaky and permeable 
Figure 3.1: Passive and active tumor targeting. Nanoparticles passively accumulate in 
tumors via the EPR effect since tumors exhibit leaky vasculature and poor lymphatic 
drainage. In active targeting, conjugated ligands facilitate nanoparticle binding to tumor 
cell antigens; this binding prolongs nanoparticle retention in the tumor and promotes 
receptor-mediated endocytosis. Modified from Dong and Mumper (2010). 
45 
One biomarker that has been extensively studied as a potential target is human 
epidermal growth factor receptor 2 (HER2), which was first identified as being amplified 
in up to 30% of breast cancer cases (Slamon et al. 1987). It is now known that HER2 is 
up-regulated in many human tumors, including medulloblastoma, ovarian, lung, gastric, 
and oral tumors, and that its over-expression correlates with a poorer clinical prognosis 
(Hung et al. 1995). HER2 has no known ligands, but it dimerizes with other HER family 
receptors to induce intracellular phosphorylation that provides binding sites for molecules 
that activate pro-tumorigenic signaling cascades, such as the MAPK proliferation 
pathway and the PI3K1Akt pro-survival pathway (Menard et al. 2003). In the next 
section, different methods of targeting receptors such as HER2 will be introduced. 
3.1.2 Targeting Schemes: Antibodies, Peptides, and Aptamers 
Several types of bioactive molecules are being investigated for active targeting, including 
antibodies, peptides, and aptamers. Each of these will be discussed here in brief, with 
focus on moieties specific for HER2; for a more thorough discussion, several excellent 
reviews exist in the literature (Peer et al. 2007; Huynh et al. 2010; Ruoslahti et al. 2010). 
Antibodies are the most commonly used targeting agents, with over 200 delivery 
systems based on antibodies and their fragments currently in development (Peer et al. 
2007). The first antibody therapy targeted towards HER2, Trastuzumab (Herceptin), was 
approved for treatment of breast cancer in 1998 (Albanell and Baselga 1999). More 
recently, anti-HER2 conjugated liposomes have demonstrated successful delivery of 
paclitaxel (Yang et al. 2007) and doxorubicin (Park et al. 2002; Kirpotin et al. 2006) in 
preclinical models. While some therapies utilize whole antibodies, others utilize 
antibody fragments. Whole monoclonal antibodies are advantageous because they offer 
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two binding sites per molecule, yielding higher binding affinity. However, the Fc portion 
on whole antibodies can bind Fc receptors on normal cells such as macrophages, leading 
to increased immunogenicity and clearance to the liver and spleen (Peer et al. 2007). To 
avoid this problem, antibody fragments that lack the Fc portion can be utilized, but these 
are less stable than their whole antibody counterparts. 
Some non-antibody targeting agents currently in development include growth 
factors (such as EGF or VEGF), vitamins (such as folic acid), and peptides (such as 
RGD, the ligand of the cell adhesion molecule av~3 that is up-regulated on tumor vessels, 
and Lyp-l, the ligand for the p32 receptor that is up-regulated on tumor cells undergoing 
stress) (Murphy et al. 2008; Park et al. 2010). Recently, a bi-functional peptide was 
developed that is capable of both neutralizing HER2 and delivering a toxin to disable 
mitochondrial function in HER2-positive tumors; this molecule is called BHAP, for bi-
functional HER2-blocking and apoptosis-inducing peptide (Fantin et al. 2005). 
The third class of targeting molecules to be discussed here are aptamers-short 
single-stranded DNA or RNA oligonucleotides that fold into well-defined structures that 
bind to their ligand by complimentary shape interactions (Blank and Blind 2005). These 
ligands are selected in vitro from large libraries of random sequences. A peptide aptamer 
against HER2 was recently developed and found to sensitize breast cancer cells to taxol 
(Kunz et al. 2006). While aptamers offer the benefits of having high affinity and no 
intrinsic toxicity or immunogenicity (Blank and Blind 2005), they are expensive to 
produce which minimizes their current utility. 
This chapter evaluated antibody coatings as a means of enhancing tumor cell 
targeting of nanoshells since antibodies are the most widely accepted targeting technique 
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and have already achieved FDA approval. Nanoshells were coated with antibodies 
against HER2 and binding affinity was evaluated both in vitro and ex vivo. Anti-HER2 
nanoshells selectively targeted HER2-positive cancerous cells and facilitated thermal 
ablation in vitro in both monoculture and co-culture experiments. The targeting ability of 
anti-HER2 nanoshells was further demonstrated through ex vivo binding to ovarian tumor 
tissue specimens; the degree of nanoshell binding correlated with HER2 expression. 
Together, these results imply that anti-HER2 nanoshells could be used clinically in the 
future to ascertain from biopsy specimens whether a patient might benefit from anti-
HER2 targeted photothermal therapy; however, in vivo distribution and efficacy of anti-
HER2 coated nanoshells remain to be evaluated in future studies. 
3.2 Materials and Methods 
3.2.1 Preparation of PEG-Antibody Conjugates 
Heterobifunctional poly( ethylene glycol) (PEG) was employed as a linker to coat 
nanoshells with antibodies. Specifically, the linker was 2 kDa orthopyridyl-disulfide-
poly(ethylene glycol)-N-hydroxysuccinimide (OPSS-PEG-NHS, Nektar, San Carlos, 
CA); this molecule has known biocompatibility and improves antibody mobility on the 
particle surface. OPSS-PEG-NHS was conjugated to anti-HER2 antibodies 
(NeoMarkers, Fremont, CA) by mixing 1 part 81 J.lM OPSS-PEG-NHS with 9 parts 
1 mg/ml anti-HER2 at 4°C overnight. As shown schematically in Figure 3.2 the NHS 
terminus is cleaved during this reaction and a stable amide bond is produced between 
primary amines on the antibody and carboxyl groups on the PEG chain. 
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Figure 3.2: Preparation of PEG-antibody conjugates. This representation shows an 
antibody (R) with an available primary amine binding to OPSS-PEG-NHS in a basic 
solution. First the NHS group is cleaved in water and then an amide bond forms at the 
carboxy lie terminus. At the end of the reaction the antibody is covalently attached to the 
PEG molecule. 
3.2.2 Attachment of Targeting Agents to N anoshells and Quantification of 
Antibody Coverage with the Enzyme-Linked Immunosorbent Assay 
Nanoshells suspended in milli-Q water at an optical density (OD) of 1.5 were exposed to 
OPSS-PEG-anti-HER2 for 1 h at 4°C at a 1500:1 molar ratio. Next, samples reacted in 
5 J.1M mPEG-SH (5 kDa, Laysan Bio, Inc. , Arab, AL) overnight at 4°C to passivate any 
exposed gold surface area. Nanoshells coated with mPEG-SH only (no antibody) were 
also synthesized for use as a negative control. Following antibody and/or PEG 
modification, nanoshells were centrifuged to remove unbound molecules, aspirated, and 
suspended in the appropriate medium for the prospective application. 
To quantify the number of antibodies on the nanoshells, a modified enzyme-
linked immunosorbent assay (ELISA) was utilized. Targeted (coated with PEG-anti-
HER2 and mPEG-SH) and control (only mPEG-SH coated) nanoshells incubated with 
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10 J.lg/ml horseradish peroxidase (HRP)-labeled goat anti-mouse IgG (Sigma). 
Nonspecific reaction sites were blocked with 3% bovine serum albumin (BSA, Sigma) in 
PBS. To remove unbound HRP-Iabeled antibodies, nanoshells were centrifuged twice at 
500 g for 5 min and suspended in 3% BSA. Bound HRP was developed with 3,3',5,5'-
tetramethylbenzidine dihydrochloride (TMB, Sigma) for 15 min and the reaction stopped 
by addition of 2 M sulfuric acid. Developed HRP was compared to a standard curve of 
the appropriate HRP-Iabeled anti-IgG by measuring the absorbance at 450 nm. The 
number of antibodies per nanoparticle was calculated by dividing the number of 
peroxidase-labeled anti-IgG moieties by the number ofnanoshells in solution. 
3.2.3 In Vitro Binding of Anti-HER2-Coated Nanoshells to Targeted Breast 
Carcinoma Cells and Subsequent Photothermal Therapy 
To demonstrate that antibody targeting yields enhanced nanoshell binding to cell surface 
receptors, anti-HER2 nanoshells and PEG nanoshells were incubated with SK-BR-3 
breast carcinoma cells, which over-express the HER2 receptor (Kraus et al. 1987). SK-
BR-3 cells were cultured in McCoy's 5A Medium (Sigma) containing 10% fetal bovine 
serum and 1 % penicillin-streptomycin at 37°C in a 5% C02 environment and incubated 
for 1 hour with 5 x 109 anti-HER2 nanoshells or PEG nanoshells (both suspended in 
McCoy's 5A). Rinsing with PBS removed unbound particles and treatment with 2.5% 
gluteraldehyde fixed the cells. Staining with Amersham Silver Enhancer, which deposits 
silver onto the gold surface, allowed visualization ofnanoshells via light microscopy. 
Following the binding assay, a second experiment tested whether the degree of 
anti-HER2 nanoshell binding to cells was sufficient for photothermal ablation. SK-BR-3 
cells were again cultured and exposed to anti-HER2 nanoshells or PEG nanoshells for 1 h 
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prior to rinsing thrice with PBS. Samples were covered with McCoy's 5A Medium and 
irradiated with an 808 nm laser (Coherent, Inc., Santa Clara, CA) at 88 W/cmz for 7 min. 
After incubating 2 h at 37°C, cell viability was assessed by labeling with ca1cein AM 
(1 ~M, Molecular Probes, Eugene, OR), a live cell stain, and ethidium homodimer-l 
(4 ~M, Molecular Probes), a dead cell stain. Fluorescence microscopy was performed 
with an inverted Zeiss Axiovert 135 microscope (Carl Zeiss) to determine viability. 
3.2.4 In Vitro Destruction of Targeted Breast Carcinoma Cells in Co-Culture 
with Non-Targeted Endothelial Cells 
To prove specificity of antibody targeting, photothermal therapy of cancerous cells that 
over-express HER2 placed side-by-side with healthy cells exhibiting normal HER2 
expression was attempted. SK-BR-3 (HER2+) and Human Umbilical Vein Endothelial 
Cells (HUVECs) were cultured separately on cover slips coated with 1 % gelatin and 
placed adjacently in a I-well culture slide with no gap between the slips. The samples 
were incubated with anti-HER2 nanoshells or with PEG nanoshells for 1 h prior to 
rinsing and laser treatment at the interface of the coverslips (88 W/cmz, 7 min). Samples 
incubated at 37°C overnight prior to examination of viability with a fluorescent live/dead 
stain as described above. 
Differences in receptor expression between the two cell types were confirmed 
with immunohistochemistry. Cultured SK-BR-3 cells and HUVECs were fixed in 10% 
formalin for 10 min, rinsed with PBS, and endogenous peroxidase activity was blocked 
with 5 min treatment in 3% HzOz in PBS. To block nonspecific sites, cells incubated 
with 3% BSA in PBS for 90 min; next, 300 ~l mouse anti-human HER2 antibody 
(5 ~g/ml, Lab Vision) was added to the wells. After 1 h, cells were rinsed 3 times with 
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PBS. The HRP-conjugated secondary antibody (2 J..lg/ml, Sigma) was then added to each 
well for 40 min. After three changes of PBS, samples were developed with AEC (3-
amino-9-ethy1carbazole) to produce a red stain indicative ofHER2 presence. 
3.2.5 Ex Vivo Binding of Immunonanoshells to Ovarian Tumor Tissue with 
Varying Target Receptor Expression 
Lastly, to prove that anti -HER2 nanoshells could be utilized in a diagnostic setting to 
guide treatment decisions, ovarian tumor tissue with varying HER2 expression was 
exposed to anti-HER2 nanoshells and PEG nanoshells ex vivo. Frozen sections (30 J..lm 
thickness) of tumors grown in mice were received from Dr. Anil Sood's lab at MD 
Anderson Cancer Center. The three ovarian tumor types studied were SKOV3ipl, 
Hey A8, and A2780-PAR, listed in order of decreasing HER2 expression according to 
literature review (Marth et al. 1992; Lewis et al. 1993; Peles et al. 1993; Yu et al. 1993). 
Sections were brought to room temperature and a hydrophobic barrier was drawn around 
the tissue. Samples incubated in PBS for 5 min and were blocked with 3% BSA in PBS 
for 2 h prior to incubation with anti-HER2 nanoshells or PEG nanoshells for 1 h at room 
temperature. After rinsing three times with PBS, samples were mounted and imaged via 
darkfield microscopy using a CytoViva adaptor coupled to an Axiovert 135 microscope 
(Carl Zeiss). With this technique, images are produced from light scattered by the 
samples and nanoshells are easily detected since they have superior scattering compared 
to tissue components (Loo et al. 2005; Loo et al. 2005; Gobin et al. 2008). 
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3.3 Results and Discussion 
3.3.1 Quantification of Antibodies on Nanoshells 
Antibody quantification with the modified ELISA confirmed that anti-HER2-coated 
nanoshells bound significantly more HRP-antibodies than PEG-coated nanoshells 
(p=0.01 , student' s t-test). The ELISA indicated ---300 antibodies per anti-HER2-coated 
nanoshell, while control PEG-coated nanoshells remained free of antibody (25 ± 29 
antibodies/nanoparticle ). 
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Figure 3.3: Quantification of anti-HER2 antibody coverage on nanoshells. Number 
of anti-HER2 antibodies bound per nanoshell determined by the modified ELISA. 
Antibody-free controls show minimal background signal. 
3.3.2 Antibody-Coated N anoshells Bind to Targeted Cancer Cells and 
Facilitate Thermal Ablation 
Silver enhancement confirmed that anti-HER2 nanoshells were able to bind the HER2-
expressing SK-BR-3 cells (Figure 3.4). By comparison, PEG nanoshells showed 
minimal staining, demonstrating the ability of PEG to prevent non-specific adsorption. 
Cells that did not receive nanoshells also showed minimal staining. 
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Figure 3.4: Anti-HER2 nanoshells bind HER2-positive cells. A high degree of silver 
staining provided evidence that anti-HER2 nanoshells bound to HER2-positive SK-BR-3 
cells, while minimal staining was observed on cells that incubated with PEG nanoshells 
or saline. Scale bar = 100 J.lm. 
Figure 3.5 shows the results of the viability assay performed after laser 
irradiation on SK-BR-3 cells grown in mono culture and exposed to different nanopartic1e 
solutions. Cells receiving laser irradiation after incubation with saline or PEG-coated 
nanoshells remain viable, as demonstrated by the green calcein AM fluorescence. In 
contrast, cells that were exposed to anti-HER2 nanoshells display a circular region of 
death (red, EthD-l) where the laser was applied. In these targeted samples, a sufficient 
number of nanoshells bound to the cells in order to produce heat capable of inducing 
irreversible membrane damage. 
No NS PEG NS Anti-HER2 NS 
Figure 3.5: Targeted nanoshells mediate photothermal ablation of cancer cells. 
Ca1cein AM staining indicated that cancerous cells remained viable (evidenced by green 
fluorescent signal) when exposed to saline or PEG nanoshells prior to laser irradiation. 
When SK-BR-3 cells were incubated with anti-HER2 nanoshells and exposed to the 
laser, a red fluorescent EthD-l signal indicative of cell membrane damage was observed 
in the region where the laser was applied. Scale bar = 500 J.lm. 
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3.3.3 Antibody-Coated N anoshells Enable Specific Targeted Ablation of 
Cancerous Cells in Co-Culture with Endothelial Cells 
Attempting photothermal therapy of cancerous cells that over-express HER2 placed side-
by-side with healthy cells exhibiting lower HER2 expression proved specificity of 
antibody targeting. Expression ofHER2 on SK-BR-3 cells but not HUVECs was 
confirmed with immunohistochemistry (Figure 3.6). HUVECs and SK-BR-3 cells 
grown on coverglass and placed adjacently were exposed to the same particles and laser 
parameters, and then a viability assay was performed. In Figure 3.7, when HUVECs (top 
half of each image) and SK-BR-3 cells (bottom half of each image) were exposed to PEG 
nanoshells, which do not bind cells, both cell types remained alive post-laser treatment 
(evidenced by green calcein AM fluorescence) . When these cells were exposed to anti-
HER2 nanoshells, only the targeted SK-BR-3 cells within the laser spot were destroyed 
while the proximal HUVECs remained unharmed. Cells of each type outside the laser 
path remained viable, proving that photothermal therapy requires a balanced dose of 
nanoparticles and laser energy. 
SK-BR-3 HUVEC 
Figure 3.6: HER2 expression status in two cell lines. Immunohistochemistry revealed 
that SK-BR-3 cells over-express HER2, shown by red HRP/AEC staining, while 
HUVECs do not. Thus, these cell lines are useful for determining the specificity of anti-
HER2 coated nanoshells. Scale bar = 200 Jlm. 
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Figure 3.7: Targeted nanoshells provide cell type-specific photothermal therapy. 
HUVECs and SK-BR-3 cells grown on coverslips and placed adjacently were exposed to 
either PEG nanoshells (top image) or anti-HER2 nanoshells (bottom image) prior to laser 
irradiation at the interface of the slips. (Top): Since PEG nanoshells do not bind cells, 
both cell types remained viable after laser exposure, indicated by green calcein AM 
fluorescence. (Bottom): Anti-HER2 nanoshells bound the HER2-expressing SK-BR-3 
cells but not the HUVECs, so only SK-BR-3 cells experienced loss in viability after laser 
treatment, shown by red ethidium homodimer-l fluorescence. Scale bar = 500 Jlm. 
3.3.4 Anti-HER2 Nanoshells Bind Tumor Tissue Ex Vivo to Indicate Relative 
Target Receptor Expression 
While the above in vitro studies confirmed the ability of anti -HER2 nanoshells to bind 
HER2-positive cells grown in culture, it remained unknown whether this ability would be 
maintained when the nanopartic1es were exposed to complex tissue architectures. To 
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answer this question, anti -HER2 and PEG-coated nanoshells were incubated with ovarian 
tumor tissue specimens having varied receptor expression, and samples were imaged with 
darkfield microscopy. As shown in Figure 3.8, the anti -HER2 nanoshells bound tumor 
tissue at levels corresponding to the HER2 expression, while the PEG nanoshells showed 
minimal binding to each tumor type. Thus, there is good correlation between the ability 
of targeted nanoshells to bind receptors both in vitro and ex vivo. 
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Figure 3.8: Darkfield microscopy of nanoshell binding to ovarian tumor tissue ex 
vivo. N ano shell s appear golden red against the bluish tissue background and the degree 
of anti-HER2 nanoshell binding correlates with tissue HER2 expression. PEG nanoshells 
do not bind the tumor tissue. Scale bar = 50 f..!m. 
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3.3.5 Discussion 
Molecular targeting has emerged as a promising new tool in the fight against cancer and 
this chapter aimed to demonstrate enhancement of photothermal cancer therapy through 
targeted delivery of nanoshells. Previous in vivo studies have relied on the EPR effect to 
deliver nanoshells to tumors (O'Neal et al. 2004); it is predicted that antibody targeting 
may enhance the accumulation of nanoshells in tumors, allowing the use of lower 
nanoshell or laser dosages. 
As demonstrated by the modified ELISA, the OPSS-PEG-NHS linker was able to 
bind a significant number of antibodies to the nanoshell surface. The density of ~300 
anti-HER2 antibodies per nanoshell greatly exceeded the reported density of 30-50 
antibodies on liposomes of similar size (Park et al. 2002), so nanoshells should 
demonstrate greater binding affinity. Silver staining confirmed that antibody-coated 
nanoshells bound HER2-positive SK-BR-3 breast carcinoma cells at high levels and a 
viability assay proved that these targeted nanoshells enabled thermal ablation upon 
exposure to a near-infrared laser. PEG nanoshells, which do not bind cell surface 
receptors, were rinsed away during washing thus preventing cell death after NIR 
irradiation. 
The specificity of antibody targeting was demonstrated in a co-culture experiment 
in which HER2-negative HUVECs and HER2-positive SK-BR-3 cells were placed side-
by-side prior to incubation with the nanoshells and subsequent laser treatment. The anti-
HER2 nanoshells bound only the SK -BR -3 cells, so only these targeted cells died when 
the laser was applied. When co-cultured cells were incubated with PEG nanoshells, 
neither cell type lost viability following therapy. In a similar experiment, anti-HER2 
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nanoshells' specificity was confirmed by treating SK-BR-3 in co-culture with human 
dermal fibroblasts (HDFs); these data were recently published (Lowery et al. 2006). 
These in vitro results demonstrate the ability ofnanoshell-mediated photothermal therapy 
to provide extremely localized and specific cancer therapy, which should minimize side 
effects when translated in vivo. 
Lastly, the ability of anti-HER2 nanoshells to bind targeted receptors in a more 
complex tissue environment was demonstrated. Anti-HER2-coated nanoshells exposed 
to ovarian tumor tissue with relatively high or low levels of HER2 expression bound to 
the specimens at corresponding frequencies, while PEG-coated nanoshells did not bind 
the tumor specimens. This agrees with the results of Bickford et al., who demonstrated 
that anti-HER2 nanoshells could bind to HER2-positive human breast tumor specimens 
ex vivo but not to HER2-negative tumor specimens or to healthy tissue (Bickford et al. 
2010). In the future, biopsy specimens could be exposed to anti-HER2 nanoshells to 
determine a patient's receptor level status and guide decisions regarding treatment. By 
evaluating receptor status ex vivo, it could be possible to predict whether a patient would 
benefit from anti-HER2 targeted photothermal therapy. 
3.4 Conclusions 
In conclusion, these results support the hypothesis that antibody targeting may provide a 
means of enhancing nanoshell-mediated photothermal therapy. Targeted nanoshells 
specifically bind cancerous cells that over-express the desired receptor, even when in 
close proximity to cells with normal HER2 expression. The ability of antibody-coated 
nanoshells to bind a variety of tumor cell types has now been demonstrated in vitro; this 
includes breast (Loo et al. 2005; Lowery et al. 2006), medulloblastoma (Bernardi et al. 
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2008), and glioma cell lines (Bernardi et al. 2008). Recently, some exciting new data has 
established that photothermal therapy with anti-HER2 nanoshells is effective even against 
Trastuzumab-resistant breast cancer cells in vitro (Carpin et al. 2011); thus, anti-HER2 
nanoshell photothermal therapy may be an appropriate alternative for patients whose 
tumors have failed to respond to prior immunotherapy. 
While the results of in vitro targeting studies are positive, antibody targeting of 
these nanopartic1es remains to be validated in vivo; this will be a major focus of the 
second half of this thesis. In Chapter 4, it will be shown that the same conjugation 
chemistry used to functionalize nanoshells may also be used to functionalize gold-gold 
sulfide nanopartic1es. Then, in Chapter 5, the ability of antibody-targeted nanoshells and 
gold-gold sulfide nanopartic1es to reach subcutaneous glioma tumors in the complex 
biological milieu will be examined and compared to the distribution and tumor uptake of 
PEG-coated nanopartic1es. Ultimately, it will be important to test multiple tumor types 
and targeting schemes in vivo to determine the best molecular markers and nanopartic1e 
formulations for effective photothermal therapy. 
Chapter 4: Gold-Gold Sulfide Nanoparticles as 
Multifunctional Agents for Imaging and Therapy of Cancer 
4.1 Introduction 
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Researchers have recently begun to engineer nanoparticles with properties suitable for 
integrated imaging and therapy of cancer in an effort to better manage the disease (Ferrari 
2005). The advantage of these technologies lies in the possibility to "see and treat" 
tumors in a single setting, which is anticipated to reduce the cost of patient care and to 
improve personalized medicine. This chapter introduces gold-gold sulfide nanoparticles 
(GGS-NPs) as multifunctional agents for targeted imaging and therapy of cancer via 
multiphoton microscopy followed by higher intensity photoablation. This "theranostic" 
approach would be ideal for pinpointing precise treatment sites following initial tumor 
detection with wide-field imaging modalities. Much of this work was published in: Day 
ES et al. "Antibody-conjugated gold-gold sulfide nanoparticles as multifunctional agents 
for imaging and therapy of breast cancer." Int J Nanomedicine (2010); 5: 445-454. 
4.1.1 Nanoparticle Theranostics 
Theranostic nanoparticles are defined by the ability to simultaneously deliver imaging 
and therapeutic functions (Xie et at. 2010). Two main classes ofnanoparticle 
theranostics exist: the first uses imaging to track therapeutic delivery, while the second 
uses imaging to guide subsequent on-demand, site-specific therapy. Here, a few 
examples from each class will be discussed to demonstrate the advantages of nanoparticle 
theranostics and to indicate where improvements can be made. 
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Image-guided drug delivery (IGDD) is an important concept in medical oncology 
because it may help clinicians optimize local delivery of therapeutics or gather feedback 
of treatment response. One IGDD method encapsulates contrast agents and drugs within 
polymeric or liposomal nanoparticles and has been shown not only to enable in vivo 
monitoring but also to improve therapeutic efficacy. For instance, Murphy et al. 
visualized real-time delivery of doxorubicin to tumor vessels with intravital microscopy 
by co-encapulating the cytotoxic drug in small unilamellar vesicles (SUVs) with the 
fluorophore BODIPY; these SUVs reduced tumor growth and inhibited metastasis of two 
orthotopic tumor models with 15 times less doxorubicin than required for free drug 
delivery (Murphy et at. 2008). This improvement was significant given that 
chemotherapy is often dose-limited due to systemic toxicity. Unfortunately, one 
drawback of this technique is that fluorophores are susceptible to photobleaching. To 
circumvent this limitation the fluorophore could be replaced with small nanoparticle 
contrast agents. For example, iron-oxidepanoparticles (IONPs) have been placed within 
larger polyacrylamide nanoparticles (Reddy et al. 2006) or micelles (Nasongkla et al. 
2006) to provide contrast for magnetic resonance imaging (MRI), one of the most 
common diagnostic techniques employed in cancer. 
A second approach to IGDD involves covalent attachment of therapeutic agents to 
a nanoparticle contrast agent. This approach was elegantly demonstrated using IONPs 
for gene therapy: researchers predicted that conjugating silencing RNA (siRNA) to 
IONPs wouldfeduce the rate of degradation by RNases in vivo, a major barrier to clinical 
translation (Medarova et al. 2007). In a landmark study, Moore and colleagues 
demonstrated that dextran-coated IONPs coupled to siRNA against BircS (an anti-
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apoptotic gene encoding the protein survivin) dramatically reduced survivin expression in 
human colon adenocarcinoma xenografts (Medarova et af. 2007). Additionally, the 
IONPs were linked to the NIR dye Cy5.5, allowing distribution to be monitored with both 
optical microscopy and MR!. More recently, a peptide targeting the tumor antigen 
uMUC-l has been added to the conjugate in an attempt to improve tumor accumulation 
and enable image-guided delivery of siRNA to breast adenocarcinoma xenografts (Kumar 
et af. 2010). This approach exemplifies the potential oftheranostic nanoparticles to 
provide multiple functionalities (imaging, therapy, targeting) and to improve therapeutic 
efficacy compared to free delivery. 
Although several groups have employed nanoparticles as cargo-carriers with 
some success, controlled release of cargo has yet to be gained, so risk remains for non-
specific delivery. To eliminate this risk of burst drug release at undesired locations, 
researchers are developing a second class of theranostic nanoparticles that can provide 
on-demand therapy without incorporating potentially toxic drugs; these nanoparticles 
have intrinsic properties suitable for imaging and therapy. One recently developed and 
interesting technique uses a laser pulse to generate intracellular plasmonic nanobubbles 
(PNBs) around excited gold nanoparticle clusters (Lukianova-Hleb et aZ. 2010; 
Lukianova-Hleb et af. 2010). The laser energy determines the size and lifetime of the 
bubble created, allowing precise control over imaging and therapy: nanometer-sized 
PNBs act as diagnostic agents by scattering light from a probe laser, while larger 
micrometer-sized PNBs rapidly expand and collapse to induce mechanical damage to cell 
membranes. While this new theranostic platform is exciting in that it offers cell-specific 
imaging and therapy, it requires additional development. Currently the pump and probe 
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lasers operate at 532 nm and 690 nm, respectively, which are outside the tissue water 
window (650-900 nm), so it is likely that application in large organisms will be limited 
by light penetration. Furthermore, the technique relies on nanoparticle cluster formation 
through receptor-mediated endocytosis and since this process cannot be controlled, it is 
uncertain whether PNB generation will work in large tumors where individual cell-uptake 
of nanoparticles may be heterogeneous throughout the tumor volume. 
While plasmonic nanobubbles offer an interesting approach to combined cancer 
imaging and therapy, they are still in the early stages of development; a more established 
theranostic approach is to use iron oxide or gold-based plasmonic nanoparticles for 
cancer hyperthermia and simultaneous imaging. One advantage of these nanoparticles is 
that because they have already demonstrated therapeutic efficacy against a variety of 
tumor types in vivo, clinical translation of theranostic approaches that incorporate these 
nanoparticles may be more rapid. Furthermore, these nanoparticles are appropriate 
imaging agents without modification. Maier-Hauff et al. recently reported results of a 
clinical trial of magnetic fluid hyperthermia (MFH) in which the density of amino silane-
coated iron-oxide magnetite nanoparticles was mapped in glioblastoma tumors using 
computed tomography (CT) to guide subsequent thermotherapy (Maier-Hauff et al. 
2010). They observed a significant increase in patient survival compared to a reference 
population, a remarkable feat given the aggressive nature of this type of tumor. Even so, 
MFH also exhibits limitations, one being the high iron concentration (~30 mg/cm3 tumor) 
required for heating; it will be critical to monitor long-term effects of this high 
nanoparticle exposure. Perhaps a more noteworthy limitation is that MRI cannot be used 
to track tumor progression after nanoparticle infusion due to imaging artifacts caused by 
their presence. Given that MRI is a very common diagnostic method, it will be 
undesirable to exclude its use. 
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As an alternative to IONPs, gold-based nanoparticles for cancer hyperthermia 
(such as nanorods, nanoshells, and nanocages) are an acceptable theranostic platform 
whose use has not been shown to interfere with the performance ofMRI and CT. These 
nanoparticles also achieve effective heating at much lower concentrations than IONPs, 
reducing the risk of nanoparticle-induced toxicity in clearance organs such as the liver, 
spleen, and kidney. Gold-based, NIR-resonant nanoparticles are suitable contrast agents 
for a variety of optical imaging modalities, allowing oncologists to choose the imaging 
technique most appropriate for the tumor location. Moreover, optical imaging is rapid 
and simple, allowing quick tumor visualization prior to subsequent laser application for 
thermal therapy. Thus far, optical coherence tomography (Cang et al. 2005; Gobin et al. 
2007) and photoacoustic tomography (Wang et al. 2004; Li et al. 2009; Song et al. 2009; 
Lu et al. 2010) have been evaluated with gold-based NIR-resonant nanoparticles as 
contrast agents, but these techniques are limited to wide field-of-view applications. In 
the next section, multiphoton microscopy will be introduced as a more promising 
imaging modality that offers high resolution at the microscopic level, with the ability to 
obtain both functional and morphological information. 
4.1.2 Multiphoton Microscopy 
Multiphoton microscopy has historically been used to evaluate fluorescent signals in cell 
and animal model studies (Zipfel et al. 2003). Similar to confocal microscopy, 
multiphoton microscopy excites fluorophores by delivering photons with a focused laser 
beam. With confocal microscopy a continuous wave, visible wavelength laser delivers 
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single photons of energy sufficient for fluorophore excitation; however, because the 
excitation is not limited to the focal plane, a pinhole must be added to the optical 
configuration to eliminate out-of-focus light and improve image resolution. Instead, 
multiphoton microscopy incorporates an ultrafast, pulsed laser to simultaneously deliver 
two near-infrared photons of half the required excitation energy. As a result, acquired 
images have superior resolution since NIR light interferes minimally with tissue and only 
fluorophores at the focal plane of the laser become excited since this is where the 
probability of two photon events is maximal. The differences in fluorophore excitation 
between confocal microscopy and multiphoton microscopy are represented in Figure 4.1 . 
Although fluorophores are the traditional contrast agents for two-photon microscopy, 
recent work has demonstrated that nanoparticles with strong surface plasmon resonance 
in the near-infrared regime can be employed as well. The next section will expand on use 
of nanoparticles as multi photon contrast agents reported in recent literature. 
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Figure 4.1: Comparison of one- and two-photon fluorophore excitation. A) Jablonski 
diagrams of the excitation, relaxation, and fluorescence emission processes. B) 
Excitation occurs throughout a fluorescein solution with single-photon illumination but 
only at the focal volume using two-photon excitation. (Soeller and Cannell 1999). 
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4.1.3 Multiphoton Microscopy with Near-Infrared Absorbing Nanoparticles 
Advances in the use of nanopartic1es as contrast agents for multiphoton microscopy came 
following the discovery by Boyd et al. that roughened metal surfaces exhibit two-photon 
induced photoluminescence (TPL), a phenomenon attributed to coupling of light with 
localized plasmon resonances (Boyd et al. 1986). Similarly, NIR-resonant nanoparticles 
excited with a pulsed laser luminesce when electrons in the sp-band recombine with holes 
in the d-band created following near-simultaneous absorption of single photons (Imura et 
al. 2005). Recent studies of two-photon induced photoluminescence of silica-gold 
nanoshells and gold nanorods have indicated that these nanopartic1es display enhanced 
properties for multi photon microscopy compared to traditional fluorophores, including 
brighter signals and increased resistance to photobleaching (Wang et al. 2005; Park et al. 
2008). Specifically, the TPL signal of a single nanorod is nearly 60 times brighter than a 
single rhodamine 6G molecule (Wang et al. 2005), and nanoshells are approximately 140 
times brighter than fluorescent beads and display brightness on the same order of 
magnitude as nanorods (Park et al. 2008). Furthermore, the signal intensity of both 
nanoshells (Bickford et al. 2008) and nanorods (DUff et al. 2007) is much greater than 
cell autofluorescence in this spectral region, enabling superior contrast with this imaging 
modality. The enhanced luminescent signal reported for gold-based nanopartic1es 
compared to traditional fluorophores and the ease of conjugation ofbiomolecules to gold 
surfaces renders these materials ideal contrast agents for multiphoton microscopy. 
In this thesis, gold-gold sulfide nanopartic1es (GGS-NPs) were tested as a 
theranostic alternative to nanoshells and nanorods for combined multi photon microscopy 
and thermal cancer therapy. Although GGS-NPs have been utilized as drug-delivery 
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vehicles (Huang et al. 2008; Ren et al. 2008; Tan et al. 2009), mediators of hyperthermia 
(Gobin et al. 2010), and as single nanoparticle molecular sensors (Raschke et al. 2004) 
their application as simultaneous imaging and therapy probes has not been previously 
explored; in this chapter, the multifunctional capacity ofGGS-NPs will be demonstrated. 
Considering that GGS-NPs display stronger absorption efficiency than nanoshells and do 
not possess the toxicity concerns associated with the capping surfactants of nanorods, 
these nanoparticles appear ideally suited as theranostic agents. In the following 
experiments, the optical properties and gold surface chemistry of GGS-NPs were 
exploited to provide targeted contrast and therapy of cancerous cells in vitro. Using the 
same chemistry described in Chapter 3 for silica-gold nanoshells, GGS-NPs were 
functionalized with anti-HER2 antibodies to specifically target SK-BR-3 breast 
carcinoma cells that over-express the HER2 receptor (Kraus et al. 1987). This receptor is 
amplified in approximately 30% of breast cancer cases, thereby making it an excellent 
target for novel therapeutics (Slamon et al. 1987). Upon exposure to a pulsed NIR laser, 
GGS-NPs demonstrated TPL and could therefore be used to visualize targeted SK-BR-3 
cells in vitro via multiphoton microscopy with low incident laser powers. By then 
increasing the power output ofthe excitation laser, thermal damage could be induced to 
targeted cells and not to non-targeted cells. The ability to image GGS-NPs during their 
concurrent use as photothermal agents renders them highly attractive for use in cancer 
management, particularly since most procedures necessitate specific heat delivery to 
maintain integrity of nearby vital tissue. 
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4.2 Materials and Methods 
4.2.1 Nanoparticle Preparation 
Gold-gold sulfide nanoparticles were synthesized as described in Chapter 2 following 
literature techniques (Averitt et al. 1999; Schwartzberg et al. 2007). GGS-NPs were 
visualized with transmission electron microscopy (TEM); the diameter of at least 50 
nanoparticles per sample was measured with ImageJ software (NIH, Bethesda, MD). 
Calculation of the mean diameter revealed a slight batch-to-batch variability in average 
particle size, which ranged from 26 nm to 37 nm. Dynamic light scattering was also 
incorporated to assess nanoparticle size, and analysis of multiple batches with a ZetaSizer 
NanoZS (Malvern Instruments, Worcestershire, UK) revealed an average hydrodynamic 
diameter of 42.2 nm, in good agreement with the TEM results. 
GGS-NPs were conjugated to either anti-HER2 (NeoMarkers, Fremont, CA) or 
nonspecific anti-IgG (Sigma) antibodies using 2 kDa orthopyridyl-disulfide-
poly(ethylene glycol)-N-hydroxysuccinimide (OPSS-PEG-NHS, Creative PEGWorks, 
Winston Salem, NC) as a linker. PEG-antibody conjugates were prepared by reacting 
one part 125 J.lM OPSS-PEG-NHS with 9 parts 1 mg/ml antibody at 4°C overnight. This 
reaction produces a stable amide bond between primary amines on the antibody and 
carboxyl groups on the PEG chain that are exposed when the NHS terminus is cleaved in 
water. Particles suspended in milli-Q water at an optical density of 1.5 were exposed to 
PEG-antibody conjugates for 1 h at 4°C at a 100:1 volumetric ratio. Following antibody 
coupling, GGS-NPs reacted with a solution ofmPEG-SH (5 mM, 5 kDa, Laysan Bio, 
Inc., Arab, AL) for a minimum of 4 h at 4°C (l :200 volumetric ratio) to passivate any 
exposed gold surface area. GGS-NPs coated with mPEG-SH only (no antibody) were 
also synthesized for use as a negative control. Self-assembly of PEG-antibody and 
mPEG-SH onto the nanoparticle surface is possible due to dative interactions between 
sulfur and gold. Following antibody and/or PEG modification, GGS-NPs were 
centrifuged to remove unbound molecules, aspirated, and suspended in phosphate 
buffered saline (PBS) at an optical density of2.0 (~4.2 x lOll particles/ml) unless 
otherwise noted. 
4.2.2 Quantification of Antibody Bound to Nanoparticies 
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To verify that antibody and mPEG-SH successfully bound the GGS-NP surface, changes 
in hydrodynamic diameter were monitored. Using a Malvern ZetaSizer NanoZS, four 
nanoparticle formulations were studied: (1) Bare GGS-NPs, (2) GGS-NPs coated with 
mPEG-SH, (3) GGS-NPs coated with mPEG-SH and anti-IgG antibodies, and (4) GGS-
NPs coated with mPEG-SH and anti-HER2 antibodies. The mean hydrodynamic 
diameter was averaged from three sets of nanopartic1es, with individual sets also tested in 
triplicate. 
Antibodies present on GGS-NPs were quantified using the modified enzyme-
linked immunosorbent assay (ELISA) introduced in Chapter 3. Targeted (coated with 
mPEG-SH and antibody) and control (only mPEG-SH coated) nanoparticles were 
incubated with 10 J..lg/ml horseradish peroxidase (HRP)-labeled goat anti-mouse IgG (for 
quantification of mouse anti-human HER2) or HRP-Iabeled rabbit anti-goat IgG (for 
quantification of goat anti-mouse IgG) (both HRP antibodies from Sigma). Nonspecific 
reaction sites were blocked with a 3% solution of bovine serum albumin (BSA, Sigma) in 
PBS. To remove unbound HRP-Iabe1ed antibodies, the nanoparticles were centrifuged 
twice at 1500 g for 8 min and suspended in 3% BSA. The HRP bound to GGS-NPs was 
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developed with 3,3' ,5,5'-tetramethylbenzidine dihydrochloride (Sigma) for 15 min and 
the reaction stopped by addition of 2 M sulfuric acid. Developed HRP was compared to 
a standard curve of the appropriate HRP-Iabeled anti-IgG by measuring the absorbance at 
450 nm with a spectrophotometer. The number of peroxidase-labeled anti-IgG moieties 
was divided by the number of GGS-NPs in solution to calculate the number of antibodies 
per nanopartic1e. The number of nanopartic1es was derived from the Beer-Lambert law 
with the extinction coefficient ofGGS-NPs obtained from Mie theory as described in the 
literature (Averitt et al. 1999). 
4.2.3 Instrumentation 
A Zeiss Laser Scanning Microscope (LSM) 510 Meta (Carl Zeiss, Inc., Thornwood, NJ) 
equipped with a femtosecond-pulsed Ti:sapphire laser source (Chameleon, Coherent, 
Inc., Santa Clara, CA) was used to perform multiphoton microscopy and photothermal 
therapy experiments. The wavelength of the output laser beam was tuned to match the 
peak extinction of the GGS-NPs and operated with a pulse width of 140 fs and repetition 
rate of90 MHz. A short-pass dichroic mirror reflected incident NIR light onto the 
sample through a 20X objective (numerical aperture (NA) = 0.75) or a 63X objective 
(NA = 1.4) and passed photoluminescence. An infrared-blocking filter reduced 
background signal and the META detector collected TPL from the GGS-NPs between 
451-644 nm. A schematic of the microscope configuration is provided in Figure 4.2. 
For these studies, average excitation power was measured with a power meter placed at 
the focal plane of the objective. 
META Detector 
IR-Blocking Filter 
Plate 
Di chroi c Mirror 
Objective 
Sample 
Figure 4.2: Muitiphoton system configuration. 
4.2.4 Verification of Two-Photon Induced Photoluminescence 
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The ability ofGGS-NPs to produce two-photon induced photoluminescence (TPL) was 
probed by imaging particles in aqueous solution with the multi photon microscope 
excitation power ranging from I-10m W. The average emission intensity determined 
with ImageJ software was plotted versus excitation power to observe any correlation. To 
aid comparison of the signal from GGS-NPs with luminescence reported in the literature 
for other nanoparticles, silica-gold nanoshells (149 nm diameter) were also synthesized 
and imaged. For comparative analysis, 500 ~l nanoshells and GGS-NPs in aqueous 
solution at equal optical density (OD = 10) at 800 nm were loaded in separate chambers 
on coverglass and imaged with 1 m W and 10m W excitation. The mean intensity per 
particle was determined using ImageJ software (NIH) to calculate the ratio of signal 
intensity between the two particle types. 
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4.2.5 Cell Culture 
For in vitro imaging and therapy analysis, SK-BR-3 breast carcinoma cells (American 
Type Culture Collection, Manassas, V A), which over-express the HER2 receptor, were 
cultured in McCoy's 5A growth medium (Sigma) containing 10% fetal bovine serum and 
1 % penicillin-streptomycin at 37°C in a 5% C02 environment. Cells transferred to 15 ml 
conical tubes (6 x 105 cells/tube) were centrifuged (115 g, 3 min) to form pellets that 
were subsequently suspended in 1 ml of one of the four following solutions: (1) GGS-
NPs coated with anti-HER2 and mPEG-SH, (2) GGS-NPs coated with anti-IgG and 
mPEG-SH, (3) GGS-NPs coated with only mPEG-SH, or (4) PBS. Cells incubated in 
these solutions for 30 min at 37°C in a hybridization chamber (VWR International, West 
Chester, PA) with constant 7 rpm rotation. Following incubation, the samples were 
centrifuged (115 g, 3 min), aspirated, and diluted in PBS to remove any particles not 
bound to the cells. This rinsing procedure was repeated three times followed by 
suspension in 1 ml growth media. Interestingly, the pellets of cells exposed to anti-HER2 
conjugated GGS-NPs appeared dark to the eye while those of cells exposed to control 
nanoparticles or PBS appeared white, indicating the affinity of these nanoparticles for 
their targeted cell surface antigens. Cells were cultured on chambered coverglass 
overnight before experiments were performed. 
One advantage of two-photon microscopy in biomedical applications is that high-
resolution 3D images can be constructed due to the exceptional optical sectioning. To 
mimic tissue and determine the imaging depth of multiphoton microscopy with GGS-NP 
contrast agents, collagen phantom gels were prepared. First, SK-BR-3 cells were 
exposed to anti-HER2 functionalized GGS-NPs or PBS as described above. Then a gel 
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precursor was made and aliquoted into chambered coverglass in 5 ~l droplets; the 
precursor consisted of 167 ~l cell suspension (1 x 106 cells/ml), 83 ~l 0.1 N NaOH, 83 ~l 
lOX sterile PBS, and 667 ~l collagen. The droplets cured in a 37°C oven to promote gel 
formation, and cell culture media (500 ~l) was added prior to imaging the samples with 
the multiphoton microscopy system. 
4.2.6 Multiphoton Microscopy and Photothermal Ablation 
For imaging nanoparticles bound to cells in 2D, incident laser power was 1 m W with a 
pixel dwell time of 12.8 ~sec, and the laser beam was raster-scanned across a 
450 ~ x 450 ~m area through a 20X objective. Calculating laser intensity by dividing 
power by the area of the Airy disc, this power corresponds to a fluence of 0.96 J/cm2• 
For multiphoton microscopy in 3D gels, the power was increased to 2 mW while 
reducing pixel dwell time to 6.4 ~sec, thus maintaining the fluence used in 2D 
experiments. In these experiments, different focal planes were imaged throughout the 
entire gel by adjusting the focal height by 5 ~m between scans. 
The ability ofGGS-NPs to act as both imaging and therapy agents was assessed 
using the 2D system by first imaging SK-BR-3 cells with the laser power of 1 mW. To 
perform photothermal ablation the samples were repositioned and the laser power was 
increased to 50 mW with a 12.8 ~sec dwell time (thus yielding 48.1 J/cm2 fluence). 
Samples were treated with a single pass of the laser for both imaging and therapy. One 
hour later, cells were labeled with calcein AM (1 ~M, Molecular Probes, Eugene, OR), a 
live cell stain, and ethidium homodimer-1 (4 ~M, Molecular Probes), a dead cell stain. 
Fluorescence microscopy was performed with an inverted Zeiss Axiovert 135 phase 
contrast microscope (Carl Zeiss) to determine viability. 
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4.2.7 Determining Effects of Therapy on Cell Membrane Structure 
Loss of membrane integrity is one mechanism of cell death induced by localized 
nanoparticle heating. Therefore, to monitor any changes in membrane structure, another 
set of2D experiments was performed in which SK-BR-3 cells were labeled with the 
lipophilic membrane stain Dil (5 ~M, Molecular Probes, Eugene, OR) for 10 min at 37°C 
prior to incubation with the anti-HER2 nanopartic1es or PBS as described in Section 
4.2.5. Dil-labeled cells were exposed to 50 mW laser power and imaged with high-
resolution (63X, NA = 1.4) time-lapse photography to monitor changes in membrane 
morphology. For this laser power, pixel dwell time, and numerical aperture, the fluence 
was calculated to be ~30 J/cm2• A 543 nm laser excited Dil while GGS-NPs were 
simultaneously excited with the pulsed 810 nm Ti:Sapphire laser. 
4.3 Results and Discussion 
4.3.1 Nanoparticle Characterization 
A representative TEM and extinction spectrum for the GGS-NPs are displayed in Figure 
4.3. Successful conjugation of targeting moieties to the GGS-NPs was confirmed by 
monitoring increases in hydrodynamic diameter and by quantifying the attachment with a 
solution-based ELISA. Bare GGS-NPs possessed a mean hydrodynamic diameter of 
42.2 nm that increased to 58.0 nm upon addition ofmPEG-SH. Further increase occurred 
when either antibody formulation was included, with diameter of 69.8 nm for anti-IgG 
coated nanoparticles and 63.4 nm for anti-HER2 coated nanoparticles. These results 
suggested that the antibody and mPEG-SH were able to self-assemble on the nanoparticle 
surface using the disulfide or thiol therminus, respectively. 
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Figure 4.3: Characterization of GGS-NPs. (a) TEM of GGS-NPs. Scale bar = 40 run. 
(b) Extinction spectrum ofGGS-NPs with peak resonance at 800 run. 
Antibody quantification confirmed that both anti -HER2 and anti -IgG coated 
GGS-NPs bound significantly more HRP-antibodies than PEG-coated GGS-NPs (p<0.01 
for both using a student's t-test). The ELISA on anti-HER2 GGS-NPs indicated 
55.0 ± 4.0 antibodies per nanoparticle, while control GGS-NPs remained free of antibody 
(-1.3 ± 2.6 antibodies/nanoparticle). Similar antibody densities were obtained for anti-
IgG GGS-NPs compared to control GGS-NPs, with targeted nanoparticles bearing 
32.6 ± 3.2 antibodies/nanoparticle and control GGS-NPs showing negligible background 
(-1.1 ± 1. 5 antibodies/nanoparticle). 
4.3.2 Gold-Gold Sulfide Nanoparticles Exhibit Two-Photon Induced 
Photoluminescence 
The ability ofGGS-NPs to produce TPL was probed by imaging nanoparticles in aqueous 
solution with the multiphoton microscope excitation power ranging from 1-10 mW. A 
quadratic dependence of nanoparticle emission intensity as a function of incident laser 
power was observed, with the slope of the fit linear curve being 2.06 ± 0.03 , indicating a 
two-photon absorption process (Figure 4.4) (Wang et al. 2005; Durr et al. 2007 ; 
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Bickford et al. 2008; Park et al. 2008). When the mean luminescence intensity of several 
hundred GGS-NPs and silica-gold nanoshells was compared, analysis revealed that at 
1 m W excitation the brightness ratio of GGS-NPs to nanoshells was 1: 1.03, proving that 
GGS-NPs are on the same order of magnitude brightness as silica-gold nanoshells, which 
have already demonstrated success as in vivo multiphoton contrast agents (Park et al. 
2008). When excitation power was increased to 10m W, the brightness ratio of GGS-NPs 
to nanoshells increased to 2.57: 1. The damage threshold for silica-gold nanoshells has 
been reported as 4.5 m W, and therefore it is possible that the reduced nanoshell 
luminescence resulted from particle melting (Park et al. 2008). The GGS-NPs appear to 
have a higher damage threshold than nanoshells have, indicating that GGS-NPs may 
convert more incident multiphoton energy to luminescence than to heat, thereby making 
them more suitable as combined diagnostic and therapeutic agents. However, it should 
be noted that this explanation is speculative as experiments confirming/refuting damage 
were not included in this study . 
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Figure 4.4: GGS-NPs exhibit two-photon induced photoluminescence. GGS-NPs 
display a quadratic dependence of luminescence intensity on excitation power when 
exposed to an 800 nm pulsed laser. 
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4.3.3 Antibody-Conjugated Gold-Gold Sulfide Nanoparticles Enable Imaging 
and Thermal Ablation of Targeted Breast Cancer Cells 
The application of GGS-NPs as dual agents for cancer imaging and treatment was 
investigated by utilizing low laser powers (1 mW) to image cancerous cells tagged with 
anti-HER2 targeted nanopartic1es and high laser powers (50 m W) to induce cell death via 
nanopartic1e heating. Results of two-photon microscopy performed with 1 m W 
excitation are displayed in Figure 4.5, where Figure 4.5(a) displays the TPL signal 
(observed only for anti-HER2 GGS-NPs attached to SK-BR-3 cells), Figure 4.5(b) is a 
brightfield (BF) image of the same field of view, and Figure 4.5(c) is an overlay of the 
TPL and BF images. Successful targeting of SK-BR-3 cells with anti-HER2 GGS-NPs 
was demonstrated by the increased TPL signal versus controls as shown in Figure 4.5(a). 
At this laser power, SK-BR-3 cells alone (samples incubated with PBS) did not exhibit a 
luminescent signal; thus any luminescence observed can be attributed to the presence of 
GGS-NPs. Cells incubated with nanopartic1es functionalized with nonspecific antibodies 
or with only mPEG-SH could not be discerned, thereby verifying that these non-targeted 
nanopartic1es were removed during the rinsing process and proving the specific targeting 
of anti-HER2 functionalized GGS-NPs to SK-BR-3 cells. 
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Anti-HER2 Anti-lgG PEG PBS 
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Figure 4.5: Anti-HERl GGS-NPs provide enhanced contrast of cancer cells. 
(a) Two-photon photoluminescence images of SK-BR-3 cells exposed to the pulsed laser 
operating at 1 m W. (b) Brightfield images in the same field-of-view as the luminescence 
images. ( c) Overlay of images (a) and (b), showing that luminescence is confmed to cells 
targeted with anti-HER2 GGS-NPs. Scale bars = 100 J.lm. 
In collagen gels containing SK-BR-3 cells previously exposed to anti-HER2 
GGS-NPs, nanoparticle luminescence was observed throughout the entire thickness 
(~200 J.lm). Figure 4.6 shows a 3D reconstruction of the TPL signal rendered in ImageJ; 
additionally, merged brightfield/TPL images from various depths within the gel verify 
that the signal co-localized with cells. No luminescence was observed in gels containing 
cells previously exposed to PBS. The observed imaging depth of 200 J.lm using GGS-
NPs improves upon reported imaging depths of75 J.lm for gold nanorods in tissue 
phantoms (Durr et al. 2007) and 130 J.lm for nanoshells in tumors (Park et al. 2008) . 
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Furthermore, it is possible that using GGS-NPs as contrast agents may allow even deeper 
imaging because the depth of field of the objective used in these experiments prevented 
imaging further into the samples. 
OJ..lm 70 J..llTI 150 J..lffi 
Figure 4.6: Two-photon microscopy of cells in collagen gels. Photoluminescence from 
anti-HER2 GGS-NPs enabled visualization of cells throughout a 200 J.!m thick collagen 
gel (top; scale bar = 200 J.!m). The bottom row displays a merged TPL and brightfield 
image from three depths within the gel, verifying that the nanoparticle signal co-localized 
with cells and was confined to a thin optical section (scale bars = 100 J.!m). 
For nanoparticle-assisted laser therapy, the samples were repositioned and the 
laser power increased to 50 m W. Figure 4.7 displays results of the viability/cytotoxicity 
assay performed after exposing cells to the nanoparticles and laser. No loss in cell 
viability was observed in regions exposed to 1 m W laser power (0.96 J/cm2) indicating 
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that this energy is insufficient to induce localized heating of the GGS-NPs in this time 
frame and can be safely implemented to image nanoparticle-targeted cells. Using 50 mW 
laser power (48.1 J/cm2) samples previously exposed to PBS or control nanoparticles 
remained viable, while cell death was induced by thermal damage in cells exposed to 
anti-HER2 GGS-NPs, indicated by the red EthD-1 fluorescence in the square-shaped 
region where the laser beam was raster-scanned across the sample (Figure 4.7). Cells 
outside the laser path remained viable, implying that anti-HER2 GGS-NPs alone were not 
toxic. This observation is in keeping with the results of prior studies that have examined 
and established the biocompatibility of GGS-NPs (Huang et al. 2008; Ren et al. 2008). 
Anti-HER2 Anti-lgG PEG PBS 
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Figure 4.7: GGS-NPs yield targeted cell death with sufficient incident laser power. 
Cancerous cells remained viable (evidenced by green ca1cein AM fluorescence) when 
exposed to 1 m W laser power, regardless of nanoparticle presence. At 50 m W laser 
power a red fluorescent ethidium homodimer-1 signal indicative of membrane damage 
was observed in cells exposed to anti-HER2 GGS-NPs only where the laser was applied. 
Laser exposure alone was harmless to cells, as was laser exposure combined with 
nonspecifically targeted nanoparticles. Scale bars = 250 Jlm. 
4.3.4 Photothermal Therapy Compromises Cell Membrane Integrity to 
Induce Cell Death 
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The results of the calcein AM/ethidium homodimer-1Iive/dead stain following sufficient 
laser exposure suggested that one mechanism of cell death was loss of membrane 
integrity caused by localized nanoparticle heating. EthD-1 is excluded from cells with an 
intact membrane; thus, the EthD-l signal observed in targeted SK-BR-3 cells exposed to 
the 50 m W laser suggested that structural damage took place during photothermal 
therapy. To observe these changes, SK-BR-3 cells were labeled with DiI (a lipophilic 
membrane stain) prior to incubation with anti-HER2 GGS and exposure to the NIR laser. 
During therapy, changes in membrane morphology were observed using time-lapse 
photography. 
As seen in Figure 4.8, membrane morphology of cells exposed to anti-HER2-
GGS-NPs appeared normal before the 50 mW laser was applied (t = 0 seconds), initial 
signs of membrane damage appeared within 10 seconds, and extensive damage due to 
hyperthermia occurred within 30 seconds. Control cells exposed to only the 50 mW laser 
did not display signs of membrane injury. During this study it was noted that constant 
excitation with the 50 m W pulsed laser caused the observed GGS-NP TPL signal to 
diminish over time, a finding which is consistent with reports of decreased TPL signals 
for nanorods after prolonged exposure to a continuous wave laser operating between 7.5 
and 60 m W (Huff et al. 2007) or a pulsed laser above 10m W (Black et al. 2008). This 
loss in signal is likely due to restructuring/melting of the nanoparticles, although further 
studies need to be performed to confirm this hypothesis. 
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T=Osec T = 10 sec T=30sec 
Figure 4.8: Time-lapse photography of cells exposed to anti-HER2 GGS-NPs and 
50 m W laser power. The fluorescent red DiI membrane stain indicates regions of 
membrane blebbing generated by localized hyperthermia, with examples indicated by 
white arrows. Scale bar = 20 f.lm. 
4.3.5 Discussion 
Theranostic nanoparticles have potential to fulfill the need for novel methods to detect 
and treat neoplasia that thoroughly eliminate disease and improve survival while 
minimizing side effects since the thermal insult is confined to a small spatial region. The 
objective of these studies was to demonstrate that GGS-NPs can be used simultaneously 
as contrast and therapeutic agents using conventional multi photon microscopy. In the 
foreseeable future, this technology will be limited to applications where the tumor is 
easily accessible due to the restricted penetration depth (several hundred microns) of 
pulsed near-infrared laser light; therefore breast carcinoma was used as a model system. 
Because epidermal growth factor receptor 2 (HER2) is amplified in approximately 30% 
of breast cancer cases and is associated with a poor prognosis clinically, it is an excellent 
target for novel anti-cancer agents (Slamon et al. 1987). GGS-NPs can be specifically 
targeted towards SK-BR -3 breast carcinoma cells that express this receptor in vitro by 
functionalizing the gold surface with anti-HER2 antibodies, and these targeted cells can 
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be visualized using the two-photon induced luminescence of GGS-NPs under excitation 
with a low-intensity pulsed NIR laser. Using a higher intensity of the laser caused 
nanoparticle heating that induced membrane blebbing and yielded photothermal ablation 
of targeted cancer cells. This study provided a proof-of-concept that GGS-NPs used in 
conjunction with multiphoton microscopy can provide the ability to "see and treat" 
tumors in a single setting. 
GGS-NPs offer several advantages that render them attractive among the growing 
list of gold-based nanoparticle regimens for cancer management. As previously 
mentioned, GGS-NPs are smaller than silica-gold nanoshells and nanorods, two of the 
most thoroughly studied gold-based nanotherapeutics; this smaller size may correlate 
with improved stability and enhanced tumor delivery in vivo (Zhang et aZ. 2009; Gobin et 
aZ. 2010). GGS-NPs also do not require capping with surfactants; removing this 
requirement eliminates toxicity concerns associated with surfactants such as the cetyl-
trimethylammonium bromide (CTAB) surfactant used to prepare nanorods (Niidome et 
aZ. 2006) and it leaves the gold surface available for conjugation to biomolecules. This 
thesis provided the first demonstration that antibodies can be tethered to GGS-NPs by 
utilizing the available gold and exploiting the same chemistry used for coating silica-gold 
nanoshells (see, for example: (Lowery et aZ. 2006) and (Gobin et aZ. 2008)). 
Another advantage of GGS-NPs is that they absorb light more efficiently than 
nanoshells, and this enhanced absorption should yield improved imaging and therapy. 
Though GGS-NPs have been studied for many years, their application in photothermal 
cancer therapy has only recently been explored (Gobin et aZ. 2010). In that work, a 
continuous wave laser was used to excite the GGS-NPs, while in this work a pulsed laser 
was employed. Use of a pulsed laser not only provides a new imaging capability by 
producing TPL from the nanopartic1es; it also enables simultaneous therapy and this is 
the first demonstration that the nanopartic1es may be used as a theranostic device. It 
should be noted that use of a high intensity pulsed laser also allows therapy to be 
achieved more rapidly and with lower total energy dosages than required for continuous 
lasers, and using lower laser total energies should cause significantly less heating and 
damage to surrounding tissue in vivo. 
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The main advantage of two-photon microscopy in medical imaging is the ability 
to provide sub-cellular resolution at depths of up to several hundred microns in tissue 
(Zipfel et al. 2003). Advancement of this technology to the clinical setting is currently 
hindered by the cost and size of commercially available multiphoton microscopes; 
however, the price of femtosecond pulsed lasers should decrease as they become more 
commonly used, and research to miniaturize two-photon microscopes and reduce their 
complexity is ongoing. Recent successes in development of two-photon endoscopes were 
achieved by incorporating microelectromechanical systems (MEMS) scanning mirrors 
into the microscope design (Hoy et al. 2008; Jung et al. 2008). Specifically, 
Piyawattanametha et al. have fabricated a lightweight (2.9 g), MEMS-based two-photon 
microscope and demonstrated its ability to track individual red blood cells flowing in 
neocortical microvasculature of adult mice, establishing the future potential for two-
photon imaging in vivo (Piyawattanametha et al. 2009). With further development, 
multiphoton microscopy combined with dual imaging and therapy GGS-NPs could 
provide an effective method to pinpoint and treat specific sites following initial tumor 
detection with wide-field imaging modalities. In one potential application, TPL of 
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targeted nanopartic1es could indicate tumor margin status and any suspicious cells could 
be eliminated with higher intensity photoablation, removing the need for biopsies and 
additional surgery. This ability to "see and treat" would be particularly beneficial when 
preservation of normal tissue surrounding neoplastic regions is critical. 
4.4 Conclusions 
The data presented confirms that NIR-absorbing GGS-NPs have properties that render 
them suitable as a multifunctional agent for cancer management using multiphoton 
microscopy. Nanopartic1es functionalized with anti-HER2 antibodies bound effectively 
to SK-BR-3 breast carcinoma cells, while those coated with anti-IgG or mPEG-SH did 
not attach to cancer cells. Luminescence emitted by GGS-NPs upon excitation with a 
pulsed laser resulted from a two-photon absorption process and was as bright as 
luminescence emitted from silica-gold nanoshells. At 1 mW laser excitation, SK-BR-3 
cells labeled with anti-HER2 GGS-NPs were safely visualized and upon increasing 
excitation to 50 mW, cell death was induced following membrane blebbing. 
Nanopartic1e heating and subsequent cell death was confined to the area where the laser 
beam was raster-scanned across the sample. Irradiation alone at either power did not 
generate changes in cell morphology or cause loss of viability. 
These results indicate that GGS-NPs are an appropriate choice of the ran os tic 
agent for use with multiphoton microscopy. GGS-NPs decorated with antibodies can 
provide enhanced contrast of targeted cancer cells versus non-targeted healthy cells at 
low incident powers; if imaging results suggest that a region is highly malignant, a higher 
power can then be applied to induce localized nanopartic1e heating and subsequent 
hyperthermic damage to the suspicious lesion. Having the ability to visualize and treat 
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tumor cells with high precision will improve cancer management by minimizing damage 
to normal tissue surrounding neoplastic regions. In addition, removing the waiting period 
between time of detection and time of treatment will prevent increases in tumor burden 
that cause eradication of the disease to become more difficult. 
Chapter 5: Evaluation of Nanoparticle-Mediated Thermal 
Therapy Using a Subcutaneous Brain Tumor Model 
5.1 Introduction 
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Primary brain tumors represent one of the most challenging forms of neoplasia to treat. 
High-grade glioma is the most aggressive type of primary brain tumor and despite 
medical intervention the median survival is only 12-15 months and 5-year survival is less 
than 5% (Daumas-Duport et al. 1988; Stupp et al. 2005; Wen and Kesari 2008; Gladson 
et al. 2010). Surgery is an acceptable treatment option if the tumor location is amenable 
to removal, but often the infiltrative nature of high-grade glioma prevents complete 
resection. Radiation therapy and chemotherapy are also viable treatment options but they 
are plagued by side effects that range from minor reactions (e.g. nausea, hair loss) to 
extreme complications such as personality changes, loss of physical ability, or cognitive 
dysfunction (Butler et al. 2006; Ricard et at. 2009). Therefore, there is a significant need 
for advances in care not only to improve survival but also to improve quality of life post 
treatment. This chapter evaluates the ability of nanoparticle-mediated photothermal 
therapy to meet this need using an in vivo subcutaneous tumor model. 
5.1.1 Transport of Nanoparticles to Brain Tumors for Drug Delivery and 
Hyperthermia 
A major obstacle to successful management of brain tumors is the precise delivery of 
therapeutic agents, a problem compounded by the blood-brain barrier (BBB). The BBB 
is a physical barrier, composed of tightly connected brain capillary endothelial cells, that 
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inhibits transport of molecules into the brain, preventing delivery of potentially useful 
therapeutic agents. The BBB is often disrupted in high-grade glioma but it remains intact 
in early stage brain tumors; consequently, researchers have recently begun to investigate 
nanoparticles as chemotherapeutic delivery vehicles or as exogenous energy absorbers for 
hyperthermia treatment of glioma. These approaches have found moderate success and 
the potential of nanobiotechnology in management of glioma has recently been 
highlighted in an excellent review article (Jain 2010). In cases where the BBB is 
disrupted, nanoparticle-drug complexes may be delivered to the tumor systemically; 
however, ifthe BBB remains intact other delivery methods must be employed. In this 
section, four methods to enhance nanoparticle accumulation in brain tumors with an 
intact BBB will be introduced. 
One strategy to enhance drug delivery to brain tumors is convection enhanced 
delivery (CED), a technique that establishes fluid convection in the brain by maintaining 
a positive pressure gradient during interstitial infusion. In a recent paper, Hadjipanayis et 
al. demonstrated that antiEGFRvIII antibody could be conjugated to 10 nm diameter iron 
oxide nanoparticles (lONP) and delivered to brain tumors using CED (Hadjipanayis et al. 
2010). The IONPs served two purposes in this study: (1) to act as a therapeutic agent and 
(2) to act as a magnetic resonance imaging (MRI) contrast agent, allowing delivery to the 
tumor to be monitored in real time. In vitro the antiEGFRvIII-IONP conjugates induced 
apoptosis ofEGFRvIII-expressing glioblastoma cells but not normal astrocytes. In a 
subsequent experiment mice bearing malignant glioma tumors in the right striatum were 
exposed to either serum, IONPs only, antiEGFRvIII only, or antiEGFRvIII-IONP 
conjugates and all the treatment groups had a significant improvement in survival time 
versus the serum control group when data was analyzed with a log-rank test. Median 
survival was 11 days, 16 days, 17 days, and 19 days, respectively. These results 
demonstrate the promise of using nanoparticles and CED to enhance drug delivery to 
brain tumors. 
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A second technique to improve brain tumor drug delivery involves physically 
disrupting the blood-brain barrier for a short period of time. Liu et al. introduced a two-
pronged approach to enhance delivery of the anticancer drug epirubicin to brain tumors 
using iron oxide nanoparticles as the carrier platform (Liu et al. 2010). In this method the 
permeability of the BBB was increased locally using focused ultrasound (FUS) and then 
an external magnetic force was applied to attract the magnetic IONPs coated with 
epirubicin and enhance their deposition at the target site. When tested in mice bearing 
intracranial tumors, T1-weighted MRI confirmed that FUS disrupted the BBB and T2-
weighted MRI showed that magnetic targeting (MT) provided an increase in local 
accumulation ofIONPs. Interestingly, the amount ofnanoparticles in the tumor 
increased with magnetic field strength and correlated with the relaxivity of the 
nanoparticles. Most importantly, the level of epirubicin delivered to the tumor with 
combined FUSIMT was sufficient to slow tumor growth (106% volume increase with 
treatment after 8 days compared with 313% growth for control) and increase survival 
(18.3 days for control, 20.5 days for epirubicin-IONPs with FUSIMT). To further 
validate this method a study should be performed that compares tumor response 
following delivery of free epirubicin with delivery using IONPs and combined FUSIMT. 
The modalities described above utilized iron oxide nanoparticles as drug delivery 
vehicles that simultaneously enable distribution to be monitored in real time, and are just 
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two examples of a variety of strategies being developed to evade the BBB and enhance 
delivery of chemotherapeutics to brain tumors. Another way to evade the BBB is to 
deliver nanoparticles or drugs directly into the tumor, although this increases the 
invasiveness of therapy and thus is generally undesirable. German researchers 
demonstrated this approach in a recent Phase II trial of magnetic fluid hyperthermia 
(Maier-Hauff et aZ. 2010). In that work, IONP solutions were administered into the 
tumor and treatment consisted of six semi-weekly thermotherapy sessions with adjunct 
stereotactic beam radiotherapy performed immediately before or after each session. As 
mentioned in Chapter 4, this paper reported an improvement in survival compared to a 
historical reference population (Maier-Hauff et aZ. 2010). However, Weller and Wick 
recently contested these results by identifying several flaws in the study design, including 
that: (1) comparison to historical populations is an inappropriate method to determine 
efficacy, (2) efficacy could not be demonstrated since an experimental treatment was 
combined with an established treatment, and (3) the authors did not collect data on 
subsequent treatments taken by the patients, making it impossible to estimate the impact 
of treatment (Weller and Wick 2010). Despite the current controversy surrounding the 
results, the study does establish the future potential of nanoparticle-mediated thermal 
therapy for elimination of brain tumors. 
Lastly, a fourth approach to enhance nanoparticle deposition within brain tumors 
possessing an intact BBB is macrophage-mediated delivery. Macrophages have a natural 
ability to traverse the BBB, so Hirschberg and colleagues investigated whether nanoshell-
loaded macrophages could penetrate tumor spheroids composed of human grade IV 
glioma cells (Baek et al. 2011). They found that macrophages containing silica-gold 
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nanoshells penetrated deeply into the spheroids and upon laser irradiation these spheroids 
displayed significant growth reduction compared to spheroids that received empty 
macrophages. This delivery method remains to be validated in future in vivo 
experiments. 
A variety of components in the systems described above can be altered to 
optimize treatment efficacy, including the choice of nanoparticle and drug, the surface 
chemistry utilized, and the delivery mechanism employed. With further development it is 
possible that nanoparticle delivery to brain tumors for drug release and hyperthermia may 
improve the prognosis for patients with primary brain tumors. While the delivery 
methods discussed in this section focused on evading the blood-brain barrier, it has been 
demonstrated that the BBB is not fully functional in all brain tumors; in these cases 
cancer cells may be directly targeted. In the next section, targeting brain tumors via cell 
surface receptor expression will be discussed. 
5.1.2 Targeting Brain Tumors via Anti-IL13Ra2 
The blood-brain barrier is preserved in low-grade brain tumors, but most highly 
malignant gliomas have disrupted BBBs at clinical presentation. Investigations have 
shown there is an opening of interendothelial tight junctions in human gliomas (Long 
1970) that is accompanied by loss or down-regulation of the tight junction molecules 
claudin-l, claudin-5, and occludin (Liebner et al. 2000). In addition, glioma cells secrete 
factors that actively degrade the intact BBB, but the nature of these factors remains 
unknown (Schneider et at. 2004). As a result of these molecular and morphological 
changes, the capillaries of highly malignant tumors are more leaky than those in normal 
brain tissue, thus providing a route for enhanced nanoparticle or drug accumulation in 
these tumors. This difference may be further exploited by targeting therapies toward 
surface receptors expressed on tumor cells, such as interleukin-13 receptor alpha 2. 
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Interleukin-13 receptor alpha 2 (lLI3Ra2) is highly expressed in many adult and 
pediatric gliomas, while expression in the normal brain is practically non-existent (Joshi 
et al. 2000; Kawakami et al. 2004). This receptor, which binds the T-cell derived 
cytokine interleukin-13, has subsequently emerged as a promising target for novel 
therapeutics. For example, Madhankumar et al. demonstrated that IL13-coated 
liposomes carrying doxorubicin could specifically bind glioblastoma multiforme tissue 
specimens but not normal cortex (Madhankumar et al. 2006). Furthermore, the IL13-
conjugated liposomes demonstrated enhanced therapeutic efficacy compared to non-
targeted liposomes in vivo using a subcutaneous glioma tumor mouse model. Other 
IL13Ra2-targeted therapies in development include cytotoxins (Debinski et al. 1999), 
viruses (Zhou and Roizman 2006), and immunotherapies (Eguchi et al. 2006). 
Similarly, silica-gold nanoshells coated with anti-IL13Ra2 antibodies have been 
shown to bind and mediate photothermal ablation of glioma cells in vitro (Bernardi et al. 
2008). The first aim of this chapter was to expand upon this in vitro success and to 
evaluate the benefit of this molecular targeting strategy by comparing the distribution of 
anti-IL13Ra2-coated and PEG-coated nanoshells and gold-gold sulfide nanoparticles in 
mice bearing subcutaneous U373 glioma tumors. While it was anticipated that antibody 
targeting would provide increased nanoparticle accumulation in subcutaneous tumors, the 
results did not indicate such an advantage. Therefore, in the second aim of this chapter, 
the ability of nanoparticle-mediated photothermal therapy to eradicate high-grade glioma 
in vivo was examined with only PEG-coated nanoparticles. By commencing in vivo 
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experiments of nanoparticle-mediated photothermal therapy with subcutaneous tumors, it 
was possible to establish the sensitivity of these tumors to hyperthermia before moving 
forward to the more complicated intracranial tumor model to be discussed in Chapter 6. 
5.2 Materials and Methods 
5.2.1 Nanoparticle Preparation and Characterization 
Nanoshells (NS) and GGS-NPs were prepared using the methods of Chapter 2. PEG-
antibody (PEG-Ab) conjugates made by reacting one part 125 J..lM OPSS-PEG-NHS 
(Creative PEGWorks) with 9 parts 1 mg/ml mouse anti-human IL13Ra.2 (Cell Sciences, 
Canton, MA) at 4°C overnight were mixed with particles suspended in milli-Q water at 
an optical density of 1.5 for 1 h. GGS-NPs received 125 PEG-Ab per nanoparticle and 
NS received 1000 PEG-Ab per nanoparticle. Following antibody coupling, particles 
incubated with mPEG-SH (5 mM for GGS-NPs/l mM for NS, 5 kDa, Nektar, Huntsville, 
AL) overnight at 4°C to passivate any exposed gold surface area. Nanoparticles of each 
type were also prepared with only mPEG-SH (no antibody). Following antibody and/or 
PEG modification, nanoparticles were centrifuged to remove unbound molecules, 
aspirated, and suspended in sterile phosphate buffered saline (PBS) at an optical density 
of 60. This corresponds to ~ 1. 7 x lOll particles/ml for NS and ~ 1.1 x 1013 particles/ml 
for GGS-NPs. The number of antibodies present on the nanoparticles' surfaces was 
quantified using the ELISA method introduced in Chapter 3. 
5.2.2 Cell Preparation 
U373 human high-grade glioma cells (ATCC, Manassas, VA) were engineered to 
constitutively express the firefly luciferase gene to enable imaging of tumor growth in 
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vivo. An MSCV (murine stem cell virus) retroviral vector with a gene encoding the 
fusion protein eGFP-Firefly Luciferase (eGFP.FFLuc) was used to generate firefly 
luciferase expressing cells (Ahmed et al. 2007). Cells were seeded at low density in a 6-
well plate in a high-titer retroviral supernatant derived from a producer cell line stably 
transfected to shed these viral particles. Polybrene facilitated viral entry into the U373 
cells. This procedure was repeated 2-3 times after which cells were harvested and sorted 
for eGFP positivity. The intensity oflight was tested routinely in a luminometer after 
addition of 150 mg/kg D-luciferin (Xenogen, Alameda, CA) prior to conducting the 
animal experiments to ensure the uniformity of light emission from the tumor cells. 
5.2.3 Tumor Implantation and Bioluminescent Imaging 
Firefly luciferase-expressing U373 cells were maintained in RPMI 1640 medium 
(Invitrogen Corp., Carlsbad, CA) supplemented with 1 % glutamine and 10% fetal bovine 
serum and cultured at 37°C in a 5% C02 environment. Cells were detached from culture 
flasks with trypsin-EDT A and diluted in culture media for inoculation into mice. All 
animals were used under an approved protocol of the Institutional Animal Care and Use 
Committee of Baylor College of Medicine. To induce tumor growth, 106 U373 cells 
were injected subcutaneously in the right hind flank of male IcrTac:ICR-PrkdcscID mice 
(Taconic Farms, Hudson, NY). Tumor development was monitored by measurement 
with calipers and with bioluminescent imaging. When tumor diameter reached 3-5 mm, 
the mice received intravenous injections of 100 III PEG-coated or anti-IL13Ra.2-coated 
nanoshells (1.7 x 1011 particles/mI), GGS-NPs (1.1 x 1013 particles/ml), or saline. These 
concentrations correlate to equal optical densities (OD = 60) of the nanoparticle types. 
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Isoflurane anesthetized animals were imaged using the Xenogen IVIS 100 system 
(Caliper Life Sciences, Alameda, CA) 10 min after receiving intraperitoneal injections of 
150 mg/kg D-Iuciferin (Xenogen), which emits light when oxidized in the presence of 
luciferase and A TP. The photons emitted from luciferase-expressing U373 cells within 
the animal body and transmitted through the tissue were quantified using "Living Image," 
a software program provided by the same manufacturer. A pseudo-color image 
representing light intensity (blue least intense and red most intense) was generated and 
superimposed over the grayscale reference image. Mice were imaged daily following 
cell implantation to monitor tumor development. 
5.2.4 Assessment of Nanoparticle Distribution and Verification of Target 
Expression 
A biodistribution study determined the time of maximum nanoparticle accumulation in 
tumors following intravenous delivery (and thus the optimal time for laser application). 
Three mice per group were euthanized at 6, 24, and 48 h post-tail vein injection of 
nanoparticles and the blood, brain, tumor, spleen, liver, and muscle were collected for 
assessment of gold content. Each tissue specimen was divided into three pieces--one for 
qualitative analysis of nanoshell accumulation by histology and two for quantitative 
analysis with neutron activation analysis (NAA) and inductively coupled plasma-mass 
spectrometry (lCP-MS). Blood was only tested by NAA and ICP-MS. 
Sample Preparation/or Neutron Activation Analysis and Inductively Coupled 
Plasma-Mass Spectrometry 
Samples for NAA were lyophilized, weighed, and shipped to Texas A&M 
University for analysis as described previously (James et al. 2007). Blanks and samples 
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were irradiated with calibration standards in the Texas A&M University's Nuclear 
Science Center 1 MW TRIGA research reactor for 4-14 h based on the anticipated gold 
content. The irradiation position used has an average neutron flux of -lxl 013 n/( cm2s). 
High purity germanium detectors with nominal resolutions of 1.74 keY or better and 
efficiencies of 25-47% by industry standard measurement quantified the 412 ke V 
gamma-line from 198 Au. Gold concentrations were acquired and computed with Canberra 
Industries' Open VMS alpha processor-based Genie-ESP software. 
ICP-MS samples were lyophilized, weighed, and digested with 0.5 ml aqua regia 
for 48 h. Trace grade nitric acid and hydrochloric acid were purchased from Sigma-
Aldrich (St. Louis, MO) and VWR (West Chester, PA), respectively. Digested samples 
were further diluted with 1 % aqua regia and filtered through a 0.45 J.lm filter. Standard 
solutions of known gold concentrations were prepared in 1 % aqua regia using certified 
reference material Gold Standard for ICP (Sigma-Aldrich). The standards and samples 
were analyzed for 197 Au with germanium as an internal standard using the ELAN 9000 
ICP-MS from Perkin-Elmer (Waltham, MA). 
Preparation of Histological Specimens 
Histological specimens were formalin-fixed, paraffin-embedded, and cut into 
6 J.lm sections. To verify expression of the target receptor, tumor sections were stained 
and compared to muscle and brain. Deparaffinized and hydrated sections incubated with 
10 J.lg/ml proteinase K for 15 min at 37°C to recover antigen. Slides were rinsed with 
water and PBS containing 0.05% Tween20 (PBST) and blocked with 5% BSA in PBST 
for 1 h prior to overnight incubation (4°C) with goat anti-human IL13Ra2 (15 J.lg/ml, 
R&D Systems). After three rinses with PBST, endogenous peroxidase activity was 
quenched by 15 min treatment with 3% H202 in methanol. Following PBS rinsing, 
samples were exposed to HRP-conjugated rabbit anti-goat IgG (10 Jlg/ml, Abcam) for 
1 h, rinsed with PBS and developed with AEC substrate for 10 min. Sections were 
counterstained with hematoxylin (Dako, Carpinteria, CA) for 1 min and blue stained 
nuclei were developed with 37 mM N~OH. Slides were mounted with Faramount 
media (Dako) and imaged with a Zeiss Axiovert 135 microscope. 
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To confirm nanoparticle presence, unstained specimens were examined by 
darkfield microscopy. Darkfield imaging was performed with the Axiovert 135 inverted 
microscope coupled to a Cyto Viva high-resolution adaptor (Cyto Viva, Auburn, AL). 
With this technique, indirect sample illumination enables image production from light 
scattered by the samples and nanoparticles are easily detected since they have enhanced 
scattering properties compared to tissue components (Loo et al. 2005; Loo et al. 2005; 
Gobin et al. 2008). 
Some tumor samples for darkfield microscopy were also stained with FITC-
conjugated anti-CD31 and DAPI to show nanoparticle proximity to blood vessels. To 
retrieve antigen, deparaffinized samples incubated with 10 Jlg/ml proteinase K for 15 min 
at room temperature. After blocking non-specific binding sites with 10% goat serum in 
PBS for 45 min, slides received rat anti-mouse CD31 (5 Jlg/ml) overnight. Three rinses 
(5 min each) were performed and then the slides received FITC-conjugated goat anti-rat 
IgG (20 /lg/ml) for 1 h before a final rinsing procedure. A drop ofVectashie1d mounting 
medium containing DAPI was placed on each slide and the samples were sealed with 
coverglass prior to darkfield and fluorescence microscopy. 
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5.2.5 Assessment of Therapeutic Efficacy 
After the biodistribution study confirmed that PEGylated nanoparticles delivered via the 
tail vein accumulated in subcutaneous U373 tumors, a survival study was carried out to 
evaluate the effectiveness of nanoparticle-mediated photothermal therapy in vivo. 
Tumor-bearing mice received intravenous injections of 100,....1 PEG-coated NS 
(1.7 x lOll particles/ml, n = 7 mice), PEG-coated GGS-NPs (1.1 x 1013 particles/ml, n = 7 
mice), or saline (n = 8 mice) when tumor diameter reached 3-5 mm. Following a 24 h 
circulation period, mice were anesthetized with sodium pentobarbital (50 mglkg, 
intraperitoneal injections) and tumors were swabbed with glycerol as an index matching 
agent prior to transdermal irradiation for 3 min with an 800 nm diode laser (Coherent, 
Inc., Santa Clara, CA) set to an intensity of 4 W/cm2 (spot diameter = 9 mm). Tumor 
length and width were measured with digital calipers daily following treatment to track 
growth or regression. Tumor development was also monitored with bioluminescent 
imaging. Since photon flux from the tumor is proportional to the number of light 
emitting cells, the signal intensity indicates response to treatment. Mice were monitored 
for 90 days or until tumors reached 10 mm in largest diameter, at which point they were 
euthanized by carbon dioxide asphyxiation. 
5.2.6 Statistical Analysis 
Survival results were expressed as a Kaplan-Meier curve and survival between treatment 
and control groups was compared using a log-rank test with calculations performed in 
MedCalc Software (Mariakerke, Belgium). Differences in survival were considered 
significant for p<0.05. 
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5.3 Results and Discussion 
5.3.1 Nanoparticle Characterization 
Nanoparticles had peak plasmon resonance near 800 nm. Figure 5.1 displays results of 
the ELISA, which indicated 171.5 antibodieslNS and 22.4 antibodies/GGS-NP; this result 
correlates to even surface coverage between the particle types when expressed as moles 
per surface area. 
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Figure 5.1: Surface coverage of anti-IL13Ra2 on nanoparticles. The antibody groups 
are significantly different from their PEG counterparts (*p<0.05, student's t-test). 
5.3.2 Verification of Antigen Expression In Vivo 
Immunohistochemistry confirmed presence of the target receptor (lL 13Ra2) in the tumor 
tissue with pink staining (Figure 5.2). The muscle and normal brain show minimal 
staining, which is important since successful targeted therapy must be able to distinguish 
tumors from normal proximal tissue. Thus, the U373 tumor model is valid for studying 
targeted nanoparticle delivery in vivo. 
100 
Tumor Muscle Brain 
Figure 5.2: Immunohistochemistry verified IL13Ra2 expression in tumors. IL13Ra2 
is stained pink (HRP/AEC) and nuclei are stained blue (hematoxylin). The receptor is 
not expressed in muscle adjacent to tumors or in the brain. Scale bars = 1 00 ~m. 
5.3.3. Quantitative and Qualitative Analysis of N anoparticle Biodistribution 
in Tumor-Bearing Mice 
No adverse effects ofnanoparticle injections were observed at the delivery site or 
systemically in these experiments. Uptake in tumor and other organs was assessed 
through both quantitative and qualitative techniques and the results were in good 
agreement. 
Analysis of Gold Content Demonstrated Nanoparticle Accumulation in Tumors 
Neutron activation analysis (NAA) (James et al. 2007) and inductively coupled 
plasma-mass spectrometry (lCP-MS) (Niidome et al. 2006; De Jong et al. 2008; 
Sonavane et al. 2008) have been demonstrated as effective methods for determining gold 
content in tissue specimens. In this study the mean and standard deviation of gold 
content in each organ were calculated from three mice per nanoparticle group after 
circulating for 6, 24, and 48 h (lCP-MS results shown in Figure 5.3). Generally, the 
distribution trends observed with NAA and ICP-MS were in good agreement; however, it 
should be noted that NAA consistently reported higher gold content than ICP-MS. There 
are two possible explanations for this difference: (1) nanoparticles may be 
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heterogeneously distributed throughout the tissues; (2) the filtration step necessary to 
remove biological material from samples before entry into the Iep-MS may remove some 
gold from the solution. Nevertheless, both techniques are useful to determine trends of 
accumulation and the best time for laser irradiation. Results of Iep-MS are shown in 
Figure 5.3 and a table with complete results of Iep-MS and NAA for all particle types is 
provided in Table 5.1. 
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Figure 5.3: Distribution of PEG-coated and anti-IL13Ra2-coated nanoparticles. 
Gold present in six different organs at 6, 24, and 48 h post tail-vein delivery of antibody-
targeted nanoshells (A), PEGylated nanoshells (B), antibody-coated GGS-NPs (e), or 
PEGylated GGS-NPs (D) determined by Iep-MS. Data depicts mean ± standard error for 
n=3 samples for all sets except GGS-NPs at 24 h, for which n= 1. 
For all nanoparticle formulations, as the level of gold decreased in the blood there 
was a subsequent increase in the spleen and liver, two organs associated with the 
reticuloendothelial system. N ano shell s cleared preferentially through the spleen, while 
GGS-NPs cleared mainly via the liver, indicating that nanoparticle size does influence in 
vivo behavior. There was minimal uptake in the muscle and brain at all times. PEG-
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nanoshell clearance from the blood followed an exponential decay with a calculated 
circulation half-life of 4.8 h, comparable to the 4.1 h half-life ofnanoshells determined 
by Xie et al. (2007). The circulation half-life ofPEGylated GGS-NPs was 12.4 h. For 
nanoshells, the addition of antibody induced much more rapid removal from the blood, 
while GGS-NPs maintained a similar circulation half-life. In general, for PEG-NS the 
gold content measured in each organ followed the trends observed by James et al., who 
used neutron activation analysis to assess biodistribution of 130 nm diameter nanoshells 
in healthy and tumor-bearing mice (James et al. 2007). 
Although the original hypothesis was that molecular targeting via antibodies 
would yield enhanced tumor uptake, ICP-MS and NAA revealed that the maximum 
tumor uptake occurred with PEGylated nanoshells. The intratumoral PEG-NS 
concentration increased for the first 24 h following tail vein delivery and stabilized at 
~50 ppm (~g gold/g dry tissue) thereafter; by comparison, the intratumoral gold content 
was less than 10 ppm for PEG-GGS, Ab-NS, and Ab-GGS (Table 5.1). The amount of 
PEG-NS in the tumor 24 h post-injection was 35 times higher than the concentration in 
muscle adjacent to the tumor, so collateral damage to normal tissue regions surrounding 
the tumor was anticipated to be minimal during photothermal therapy. One explanation 
for why antibody targeting did not promote tumor accumulation is that the Fc portion of 
the antibody may have accelerated opsonization (coating with blood proteins), marking 
the particles for more rapid clearance by the immune system. This is supported by the 
high level of gold observed in the liver for all antibody-conjugated particles at the 6 h 
timepoint when compared to the PEGylated formulations (Table 5.1). 
Gold Content Detennlned by 
Gold Content Detennil1ed by NAA for NanosheUs 
Gold Content Oetermlned by HM for Gold-Gold Sulfide Nanoparticle.s 
Mean t Standard Deviation (JIg gold/g dry tissue) 
Table 5.1: Gold concentration in dry tissue measured by ICP-MS and NAA. Data are the mean and standard 
deviation of gold in each organ determined from samples of three mice; groups without standard deviations reported 
had less than 3 samoles. 
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Darkfield Microscopy Corroborated ICP-MS and NAA Results 
Darkfield microscopy provided a visual confirmation of the ICP-MS and NAA 
findings. Figure 5.4 displays sample images from tissue procured 24 h post-nanoparticle 
injections (except for GGS-Ab Tumor, which is from 48 h because the 24 h tumor was 
too small to divide between NAA, ICPMS, and histology). Nanoshells and GGS-NPs 
appear red against the blue-gray tissue background by darkfield microscopy due to their 
enhanced ability to scatter light, and were present in the spleen, liver, and tumor 
(Figure 5.4). Nanoparticles were not readily observed in the brain and muscle by 
darkfield microscopy; this was expected given that quantitative analysis indicated gold 
content in these tissues was minimal. 
Spleen Liver Tumor Muscle Brain 
NS-PEG 
NS-Ab 
GGS-PEG 
GGS-Ab 
Figure 5.4: Darkfield microscopy visually confirmed nanoparticle biodistribution 
trends. Nanoparticles are visible in the spleen, liver, and tumor. Scale bars = 50 J.!m. 
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Since the PEGylated nanoshells displayed maximum tumor uptake, tumor 
sections from mice that received these particles were stained with FITC-antiCD31 and 
DAPI. Analysis with fluorescence and darkfield microscopy revealed that these 
nanoparticles remained in close proximity to the tumor vessels and can be observed 
traveling towards the center of the tumor from the highly vascularized periphery by 
flowing through the vessels (Figure 5.5). This supports the results of Perrault et aI. , who 
recently demonstrated that nanoparticles with diameter greater than 100 nm have 
decreased diffusive transport and therefore do not extravasate beyond several cell lengths 
from tumor vessels (Perrault et al. 2009). 
Figure 5.5: PEG-coated nanoshells remain proximal to tumor vessels. Darkfield and 
fluorescence microscopy show PEGylated nanoshells (pseudo colored red) traveling 
towards the center of the tumor from the periphery by flowing through the vessels (FITC-
antiCD31 , green). Nuclei are fluorescently labeled blue (DAPI). Scale bar = 50 ~m. 
5.3.4 Animal Survival Time Lengthens Following Nanoparticle-Mediated 
Photothermal Therapy 
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Based on the conclusions of the biodistribution study, laser exposure was performed 24 h 
post-tail vein delivery ofPEGylated NS or GGS-NPs to give the nanoparticles sufficient 
time to accumulate in subcutaneous U373 tumors. Following laser irradiation mice were 
monitored daily to track tumor growth and regression using bioluminescent imaging and 
caliper measurements to indicate cellular development and changes in size. When the 
tumor reached 10 mm in largest diameter, the mice were euthanized. Nanoshell-mediated 
photothermal therapy induced tumor regression and led to improved survival versus 
control animals, while mice receiving GGS-NPs experienced only a partial response. 
Bioluminescent Imaging Indicated Nanoshell-Mediated Photothermal Therapy Induced 
Tumor Regression 
Bioluminescent imaging of tumors following laser irradiation helped distinguish 
each animal's response to therapy, with some mice experiencing complete response to 
treatment while others exhibited partial or non-response (Figure 5.6). The mouse shown 
in the first row of Figure 5.6 received nanoshell-assisted laser therapy and displayed 
complete tumor regression without signs of re-growth for the entire period of study. This 
mouse had a visible scab and loss of luminescence in the location of the tumor within just 
three days of treatment. The presence of a scab is indicative of the intense local heat 
generated by nanoshells within the tumor during laser irradiation; similar blemishes were 
not seen on mice that received laser irradiation only. The mouse in the second row also 
received nanoshell-mediated photothermal therapy and is an example of a partial 
responder, evidenced by initial loss in signal intensity during the first week following 
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laser irradiation and subsequent reappearance of tumor cell luminescence by day 20 post-
irradiation. The third row shows the mouse from the GGS-NP group that experienced the 
best treatment response (i.e. longest survival time of 24 days) and was a partial 
responder, and the fourth row shows a mouse from the control group; for mice in the 
control group the signal intensity and tumor burden increased continually following laser 
irradiation. 
Nanoshell-Mediated Photothermal Therapy Improved Survival 
Survival probability was another metric used to evaluate the effectiveness of 
therapy. Figure 5.7 is a Kaplan-Meier diagram showing the percentage of mice still alive 
versus time following laser irradiation for the PEG-NS treatment, PEG-GGS-NP 
treatment, and laser only control groups. While the mice that received PEG-GGS-NPs 
did not display improved survival versus the control, the mice that received PEG-NS 
responded well to treatment. Analysis with a log-rank test revealed that the survival 
curves for the PEG-NS and laser control groups differed significantly (p = 0.0155) and it 
can be concluded that nanoshell-mediated photothermal therapy significantly improves 
survival time. Tumors progressed rapidly in the control group and none of the eight mice 
survived beyond 24 days (mean survival = 13.3 days); similarly, mean survival in the 
PEG-GGS-NP group was 14.1 days. By comparison, four of seven mice in the nanoshell 
therapy group survived for the entire 90 day period of study (overall survival = 57%) and 
each of these mice was completely tumor free without sign of recurrence at that time. 
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Figure 5.6: Bioluminescent imaging of tumors following laser irradiation. The 
mouse in the first row displayed loss of luminescence within 3 days of nanoshell therapy 
and remained tumor-free for the rest of the study. The mice in the second and third rows 
experienced partial response to therapy with nanoshells or GGS-NPs, respectively, 
evidenced by initial loss in signal intensity but the tumors later recurred. The fourth row 
shows a mouse from the control group in which signal intensity and tumor burden 
increased continually following laser irradiation. 
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Figure 5.7: Kaplan-Meier survival analysis. Survival versus time for the nanoshell 
therapy group (red line, n=7), the GGS-NP therapy group (green line, n=7), and the laser 
control group (blue line, n=8) for the 90 day period of study. None of the mice in the 
control or GGS-NP group survived beyond 24 days. By comparison, four of seven mice 
(57%) in the NS treatment group were still alive and tumor-free at day 90 post-laser 
irradiation. Analysis with a log-rank test revealed a significant improvement in survival 
with nanoshell-mediated photothermal therapy (p=O. 0155). 
5.3.5 Discussion 
The prognosis for patients with high-grade glioma remains dismal with conventional 
multi-modality treatment techniques indicating an urgent need for novel therapeutic 
advances (DeAngelis 2001). Hyperthermia is an attractive therapeutic approach; 
however, currently available simple heating techniques cannot distinguish normal from 
diseased tissue. To circumvent this problem, exogenous tumor-targeted heating agents 
(such as nanoshells, GGS-NPs, nanorods, magnetic nanoparticles, and carbon nanotubes) 
have been employed to provide specific heating of diseased regions while minimizing 
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thermal insult to normal tissue. Nanoshell-assisted photothermal therapy has 
demonstrated effectiveness against a variety of tumors in preclinical studies, with 80-
100% survival in murine models of colon carcinoma (O'Neal et al. 2004; Gobin et al. 
2007) and in vitro successes against breast (Lowery et al. 2006), prostate (Gobin et al. 
2008), and brain (Bernardi et al. 2008) tumor cell lines. The ability to heat nanoshell-
laden tumors but not white matter in a canine brain metastasis model has also been 
reported (Schwartz et al. 2009). Gold-gold sulfide nanoparticles have also seen recent in 
vitro (Day et al. 2010) and in vivo (Gobin et al. 2010) success as hyperthermia mediators 
for breast and prostate tumor lines. The aim of this work was to expand upon previous 
research by testing these gold-based nanoparticles as a tool for photothermal management 
of glioma, a highly infiltrative primary brain tumor. The ideal treatment strategy for 
malignant gliomas is one that produces minimal collateral damage to the surrounding 
central nervous system structures. 
The results shown here suggest that nanoshell-mediated photothermal therapy is 
an effective method for destruction of glioma in vivo. Nanoshell-mediated photothermal 
therapy resulted in a statistically significant increase in survival, an exciting result given 
the exceedingly invasive nature ofthis type of tumor. In addition, it is highly 
encouraging that more than half of the mice in the nanoshell treatment group displayed 
complete tumor regression following only one laser treatment, and it is possible that 
mUltiple exposures could further increase the therapeutic benefit. Although the GGS-NP 
group did not display improved overall survival, the IVIS data indicated a partial 
response so it is likely that optimization of particle dosage and laser parameters could 
provide a therapeutic benefit with these nanoparticles. 
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The only side effect to treatment observed in either group was presence of a scab 
that healed naturally over time, which indicated the extreme heat-producing capability of 
these nanoparticles. Similar skin changes have been reported during thermal therapy 
with carbon nanotubes (Moon et al. 2009), but this is a relatively minor side effect 
compared to those from conventional therapy, which can range from chemotherapy-
induced nausea to extreme changes in personality or cognitive capacity induced by 
surgery or radionecrosis. Nevertheless, in the clinical setting it will be necessary to 
monitor temperature changes during the course of nanoparticle-mediated photothermal 
therapy in order to prevent unwanted damage to normal brain tissue. This can be 
accomplished using magnetic resonance thermal imaging, as previously described by 
Schwartz et al. (Schwartz et al. 2009). With temperature carefully monitored, magnetic 
fluid hyperthermia was well-tolerated in a feasibility study reported by Maier-Hauff et al. 
with only minor side effects observed (Maier-Hauff et al. 2010), so it is expected that 
thermal therapy mediated by nanoshells or GGS-NPs would elicit similar responses with 
minimal side effects. 
One advantage of nanoparticles activated by a magnetic field is the ability to treat 
deeply embedded brain tumors without the need for invasive procedures, as the strength 
of the applied magnetic field is not attenuated by passage through the body. By 
comparison, NIR light cannot penetrate the human skull so treatment of human brain 
tumors with nanoshell-mediated photothermal therapy will likely require use of fiber 
optic laser probes to deliver the light energy. Very large tumors might require multiple 
procedures or application of the laser from several directions to ensure damage 
throughout the tumor volume. While this will increase the invasiveness of the procedure, 
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it does offer the benefit that laser irradiation (and thus thermal therapy) can be delivered 
to very specific locations, thereby minimizing off-target effects. Schwartz et al. have 
previously demonstrated the feasibility of using fiber optic probes for nanoshell-mediated 
thermal therapy of a canine brain tumor model (Schwartz et al. 2009). Based on this 
research, the use of fiber optic probes could feasibly be translated to treatment of glioma. 
Interstitial light delivery is currently being investigated in an ongoing Phase I clinical 
trial for treatment of head and neck cancer, and this study will help determine the 
applicability of this approach (ClinicalTrials.gov 2010). It should be noted that the 
combined use of directed laser energy and accurate temperature monitoring (such as with 
magnetic resonance thermal imaging) would help circumvent one of the limitations of 
hyperthermia, which is lack of control over the vascular environment of the tumor. For 
example, although increased vessel density would provide enhanced nanoshell 
deposition, it may also induce more rapid cooling due to blood flow; since effective 
therapy requires a precise balance of nanoshell dosage and applied laser energy, 
temperature monitoring during therapy could help guide decisions regarding these 
parameters to ensure even heat distribution throughout the tumor. 
Histology and ICP-MSINAA revealed that nanoparticles delivered intravenously 
were selectively located in tumors and not adjacent muscle, which is highly desirable for 
the minimization of thermal damage to adjacent healthy tissue. Low nanoparticle 
concentrations were also found in normal brain, which is advantageous since heating of 
vital areas in this organ should be avoided. Since most highly malignant central nervous 
system (CNS) tumors have disrupted blood-brain barriers (BBBs) at presentation, 
nanoparticle penetration into the tumor should be adequate as previously demonstrated by 
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successful intravenous delivery of PEG-coated nanoshells to intracranial tumors in a 
canine model (Schwartz et al. 2009). In cases where PEG-coated nanoparticies do not 
extravasate across the BBB at levels sufficient for effective heating, methods to enhance 
tumor accumulation or to target tumor vasculature will need to be employed. 
One goal of these studies was to determine the ability of antibody -coated 
nanoparticies to target high-grade glioma tumors in vivo, since previous in vitro work 
demonstrated that anti-ILl3Ra2 coated nanoshells could successfully bind glioma cells 
and facilitate thermal ablation (Bernardi et al. 2008). Contrary to expectations, antibody 
targeting yielded less nanoparticie accumulation within the tumors than the traditional 
"stealth" PEG coating. In the future, it would be worthwhile to study whether targeting 
with antibody fragments without the immunogenic portion would improve these results. 
The conclusions drawn from this study agree with other recent reports that antibody 
targeting does not increase nanoparticie concentration within tumors, but it does 
influence intratumorallocalization and cellular internalization of nanoparticies (Kirpotin 
et al. 2006; Choi et al. 2010; Huang et al. 2010). 
A second counter-intuitive result from these studies was that larger silica-gold 
nanoshells had more tumor accumulation (~50 ppm) than smaller gold-gold sulfide 
nanoparticies «10 ppm) (note: for equivalent accumulation, GGS-NPs needed to 
demonstrate ~35 ppm in the tumor since at equal optical densities a solution ofGGS-NPs 
has ~ 75% the mass of gold in a solution ofNS). However, this result is consistent with a 
recent paper from Warren Chan's group in which the tumor uptake of gold nanoparticies 
in the 20-100 nm size regime was elegantly and exhaustively investigated (Perrault et al. 
2009). They demonstrated that tumor accumulation of 40-1 00 nm diameter nanoparticles 
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is exclusively dependent on blood half-life, while for smaller nanoparticles the tumor 
uptake depends on both half-life and size. Smaller nanoparticles permeate the tumor 
interstitial space at a higher rate, causing more rapid clearance into surrounding tissue 
and leading to a lower degree of overall accumulation (Perrault et al. 2009). Since the 
GGS-NPs used in these experiments were roughly 25-35 nm, it is likely that the reduced 
tumor uptake observed compared to nanoshells is a result of this phenomenon. 
No adverse response to nanoshell or GGS-NP presence in the body was observed 
in the timeframe examined, though the effects of prolonged or repeated exposure remain 
to be investigated. A few studies have briefly examined safety but the timeframe remains 
on the order of months. For example, James et al. found that nanoshells persist in the 
body up to 28 days post injection without toxicity (James et al. 2007), and O'neal et al. 
reported that mice remain healthy greater than 90 days post therapy (O'Neal et al. 2004), 
consistent with this work. There is currently no evidence that nanoshells or GGS-NPs are 
degraded by the body and the laser energies used in treatment are much lower than the 
energy required to break the particles down to their component parts, so it is anticipated 
that these nanoparticles' long-term compatibility will be largely determined by the 
surface characteristics and gold has been used clinically for many decades. An initial 
assessment of nanoshell safety in humans will be gained from the ongoing Phase I 
clinical trial of nanoshell-mediated photothermal therapy for treatment of head and neck 
cancer (ClinicalTrials.gov 2010). Given the dismal prognosis and life expectancy for 
children and adults with high-grade glioma, innovative treatment approaches must be 
explored and the risklbenefit ratio carefully assessed. 
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5.4 Conclusions 
In summary, the effectiveness of nanoshell-mediated photothermal therapy has 
been demonstrated against high-grade glioma in vivo using a subcutaneous murine tumor 
model. PEGylated nanoshells delivered intravenously accumulated in subcutaneous 
tumors at levels sufficient to induce destructive heating of cancerous cells upon 
transdermal irradiation with a near infrared laser. Treatment led to subsequent tumor 
regression and improved overall survival versus control mice that received laser 
irradiation alone. These results warrant further investigation of nanoshell-mediated 
photothermal therapy for treatment of primary brain tumors and studies using orthotopic 
tumor models will be discussed in Chapter 6. Since anti-IL13Ra2 targeting proved 
ineffective using a subcutaneous tumor model, in Chapter 6 the ability of nanoshells to 
treat intracranial tumors by targeting and disrupting tumor vasculature is investigated. 
These orthotopic models are critical for validation of the technique not only because of 
need to verify nanoshell accumulation in intracranial tumors, but also because 
microenvironment plays a critical role in tumor cell behavior and may influence response 
to treatment. In addition, these studies help elucidate whether adjustments need to be 
made to particle concentration or laser parameters to accommodate for attenuation of 
light as it passes through the normal brain prior to reaching the tumor. In the future, this 
novel approach to cancer therapy could yield a promising alternative to conventional 
treatment modalities. 
Chapter 6: Treatment of Intracranial Tumors with Vascular-
Targeted N anoparticles 
6.1 Introduction 
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Angiogenesis plays a critical role in tumor development, and high-grade gliomas are 
among the most densely vascularized tumors. Consequently, there has been a surge in 
the development of anti-angiogenic therapies for treatment of malignant glioma. Several 
excellent reviews of vascular-targeted therapy have been published (see (Chamberlain 
2008) and (Tuettenberg et al. 2006) for discussions of anti-angiogenic glioma therapy, or 
(Ruoslahti et al. 2010) for information about vascular-targeted nanopartic1es). While this 
relatively new approach to treating malignant brain tumors has been greeted with much 
enthusiasm, a thorough review of the literature shows that anti-angiogenic strategies 
currently used clinically suffer two major drawbacks. First, most therapies are cytostatic, 
requiring long-term continuous treatment. Second, as will be discussed in more detail 
later, many treatments suffer from development of cellular resistance. In this chapter, the 
ability to disrupt glioma tumor vasculature with nanopartic1e-mediated photothermal 
therapy is investigated as a means to build upon the successes and overcome the 
limitations of other anti-angiogenic therapies. 
The vascular endothelial growth factor (VEGF) signaling pathway has been 
identified as a key regulator of angiogenesis and VEGF receptor-2 (VEGFR-2) is highly 
expressed in glioma endothelium (Plate et al. 1994). Therefore, in this thesis, nanoshells 
and gold-gold sulfide nanoparticles were coated with VEGF to facilitate binding with 
VEGFR-2. In vitro experiments confirmed the ability ofVEGF-coated nanoparticles to 
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bind VEGFR-2 expressing endothelial cells and facilitate thermal ablation of these cells. 
Subsequent in vivo studies performed with a clinically relevant intracranial tumor model 
verified that systemically delivered vascular-targeted nanoparticles accumulate in 
orthotopic glioma tumors at levels sufficient to disrupt tumor vasculature upon near-
infrared laser irradiation. 
6.1.1 Advantages of Targeting Brain Tumor Vasculature 
The idea that tumors are angiogenesis-dependent was proposed forty years ago (Folkman 
1971), and since then a variety of therapies targeted towards tumor vasculature have been 
developed. The rationale in support of anti-angiogenic therapy is multi-fold. First, areas 
of increased vascular permeability are spatially non-uniform in tumors, leading to 
irregular blood flow, edema, and high interstitial pressures. These factors hinder the 
delivery of therapeutic agents to the tumor interstitial space via the enhanced 
permeability and retention effect. Targeting markers selective for tumor vessels avoids 
delivery difficulties since luminal endothelial cells are readily accessible to compounds in 
circulation and tissue penetration is not required for the therapeutic agent to reach its 
target (Chamberlain 2008; Ruoslahti et al. 2010). This accessibility is particularly 
important for treatment of brain tumors since difficulty crossing the blood-brain barrier 
has limited the efficacy of many drugs. A second benefit of targeting tumor vessels is 
that the genetic and molecular changes that occur in tumor-associated endothelial cells 
are consistent across multiple tumor lineages, and therefore a single agent may be 
effective against several different diseases. The final rationale in support of anti-
angiogenic therapy is that endothelial cells are relatively genetically stable and therefore 
less likely to develop resistance than tumor cells; however, recent evidence suggests that 
if only one angiogenic pathway is inhibited, cells may compensate by signaling through 
an alternative pathway or by invading farther into the normal brain (Tuettenberg et al. 
2006; Keunen et al. 2011). Thus, new therapeutics must be carefully evaluated to 
confirm complete disruption of targeted cells. 
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Most anti -angiogenic therapies aim to disrupt tumor vasculature so that 
subsequent reduction in nutrient and oxygen transport will result in tumor necrosis. 
Another therapeutic approach is vascular "normalization", which aims to correct the 
structure and function oftumor vessels (Jain 2005). Normalization is predicted to 
improve chemotherapy by reducing interstitial pressure, thereby increasing overall drug 
content within the tumor and equalizing drug distribution throughout the tumor. 
Normalization should also heighten tumor oxygenation, sensitizing cells to both 
chemotherapy and radiation therapy. However, a recent study investigating the effect of 
Bevacizumab, an antibody against vascular endothelial growth factor (VEGF) approved 
by the Food and Drug Administration for second-line treatment of glioblastomas, on 
intracranial tumors in rats found that "a 'morphological' normalization of the vascular 
bed is not necessarily accompanied by a 'functional' normalization of the vascular 
supply" (Keunen et al. 2011). In fact, contrary to the hypothesis of normalization, it was 
observed that Bevacizumab treatment resulted in a more hypoxic tumor environment. 
Furthermore, this hypoxia promoted a metabolic change in tumor cells toward glycolysis 
that led to increased tumor cell invasion into the normal brain (Keunen et al. 2011). 
From the results of this study, it is apparent that vascular normalization needs to be more 
carefully assessed to determine its utility in treatment of brain tumors. 
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There are several potential targets for vascular-focused therapies, including Uv 
integrins and angiogenic growth factor receptors and their ligands (Choudhury et at. 
2010). In preliminary studies in tumor-bearing mice, conjugating doxorubicin to peptides 
with integrin-binding motifs, such as RGD, increased efficacy and decreased toxicity 
versus mice treated with non-targeted doxorubicin (Arap et ai. 1998). In a separate study 
reported by the Cheresh group, when doxorubicin was encapsulated in liposomes coated 
with cyclic RGD peptides there was a marked reduction in tumor metastasis (Murphy et 
at. 2008). Additional targets for anti-angiogenic therapy include the growth factor 
receptors EGFR (epidermal growth factor receptor), PDGFR (platelet-derived growth 
factor receptor), and VEGFR (vascular endothelial growth factor receptor), and these 
have been targeted primarily with antibodies or small molecule inhibitors (Choudhury et 
at. 2010). In the next section, utilizing VEGF and VEGFR as a targeting strategy will be 
discussed in detail since this ligand/receptor pair is the most important for glioma 
angiogenesis and has thus received the most focus amongst developing therapeutics 
(Reardon et al. 2008; Miletic et al. 2009). 
6.1.2 Vascular Endothelial Growth Factor as a Targeting Strategy 
Vascular endothelial growth factor (VEGF) and its receptors are key regulators in the 
development and progression of glioma. VEGF is a tumor-secreted cytokine that exerts 
its effect by interacting with the transmembrane tyrosine kinase receptors VEGF 
receptor-l (VEGFR-I; also known as Fit-I) and VEGFR-2 (also known as Flk-I or 
KDR), expressed on vascular endothelial cells, and the neuropilin receptor expressed on 
vascular endothelium and neurons. When VEGF binds the extracellular domain of 
VEGFR-2, the main receptor involved in tumor angiogenesis, it leads to receptor 
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dimerization and intracellular receptor autophosphory lation that promotes downstream 
signaling in favor of endothelial cell proliferation, migration, and survival (Figure 6.1) 
(Rini and Small 2005). For a more thorough discussion of the biology ofVEGF and its 
receptors, the following review articles are recommended: (Dvorak 2002; Cross et al. 
2003 ; Ferrara et al. 2003). 
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Figure 6.1: A simplified schematic of the VEGF signaling cascade. Binding of VEGF 
to VEGFR-2 results in dimerization and autophosphorylation of the intracellular receptor 
tyrosine kinases. This activates several pathways that promote endothelial cell survival, 
proliferation, and migration, resulting in increased angiogenesis. Figure from Rini and 
Small 2005. 
VEGF' s paracrine effects between a brain tumor mass and its vasculature have 
been known for some time, but recently an additional autocrine effect of VEGF has been 
reported (Knizetova et al. 2008). In their paper, Knizetova et al. used RT-PCR to 
demonstrate that VEGF and its receptors are co-expressed in a variety of human brain 
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tumor cell lines (2008). Then, through a series of experiments it was shown that this co-
expression yields autocrine signaling that enhances tumor cell growth and viability; 
furthermore, inhibition ofVEGFR-2 with a small molecule led to the conclusion that 
VEGFR-2 is the major mediator of these effects (Knizetova et al. 2008). Thus, novel 
therapeutics could aim to disrupt both paracrine and autocrine signaling pathways. 
Currently, monoclonal antibodies are the main form ofanti-VEGFNEGFR 
therapy. While some groups have attempted immunotherapy of glioma with only a single 
antibody targeting VEGFR-2 (Kunkel et al. 2001) or VEGF (Keunen et al. 2011), most 
have focused on using antibodies against multiple targets in combination. These include 
antibodies against VEGFR-2 and EGFR (Yi et al. 2010); against VEGF and VEGFR-1 
(Stefanik et al. 2001); and against VEGFR-2, EGFR, and cadherin (Lamszus et al. 2005). 
The advantage of using multiple targets, as mentioned above, is that it minimizes 
potential for cells to compensate through alternative angiogenic pathways. 
This chapter introduces a novel approach to anti-angiogenic cancer therapy with 
vascular-targeted nanoparticles. Here, nanoparticle-mediated photothermal therapy is 
used to disrupt tumor vasculature; this physical disruption should be less susceptible to 
the cellular escape mechanisms that have troubled other anti-angiogenic therapies. 
Nanoshells and gold-gold sulfide nanoparticles were coated with VEGF 165, the most 
common isoform ofVEGF, and in vitro studies demonstrated these nanoparticles can 
bind to VEGFR-2 positive endothelial cells. Then, distribution and survival studies were 
performed using intracerebral U373 tumors. It was critical to assess therapeutic efficacy 
using an intracerebral tumor model for a number of reasons. First, microenvironment 
influences cancer cell behavior, so studying the effect of therapy on tumors in their 
122 
natural setting is more clinically relevant than the subcutaneous model used in Chapter 5. 
Second, the intracranial model allows effects of therapy on the normal brain to be 
assessed; any new treatment for brain tumors must minimize damage to the normal brain 
to ensure the best possible quality of life for patients following therapy. 
The ability of VEGF -coated and PEG-coated nanoparticles to be systemically 
delivered to intracranial U373 tumors was confirmed with ICP-MS. Interestingly, this 
cell line is one of the glioma types found by Knizetova et at. to express VEGFR-2 
(Knizetova et at. 2008), so VEGF -coated nanoparticles could potentially bind both 
tumor-associated endothelial cells and the tumor cells themselves. Although this dual-
targeting ability was not directly evaluated in this thesis it does provide potential for 
multimodal therapy in which the photothermal effect could be exerted on both the tumor 
mass and on the tumor vasculature simultaneously. 
Based on the distribution data, photothermal therapy experiments were performed 
using nanoshells but not gold-gold sulfide nanoparticles. For these experiments, tumor 
implantation was performed using the method of Gaber et at. in which a cranial window 
was placed over the tumor (2004). This glass window served two purposes: (1) it 
allowed laser light to be delivered to the tumor, and (2) it allowed changes in tumor 
vasculature following therapy to be monitored with intravital microscopy. Analysis of 
intravital microscopy images taken just prior to laser exposure and again three days later 
revealed that vessel density decreased over time in mice treated with VEGF -coated 
nanoshells but increased in mice treated with saline. Additionally, histology of mice 
sacrificed immediately following laser exposure showed regions of vascular damage in 
the tumor but not in the normal brain of mice that received VEGF-coated nanoshells. 
Ultimately, vascular-targeted therapy led to a slight improvement in animal survival. 
6.2 Materials and Methods 
6.2.1 Nanoparticle Preparation and Characterization 
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Nanoshells and gold-gold sulfide nanoparticles prepared by the methods introduced in 
Chapter 2 were coated with mPEG-SH +/- OPSS-PEG-VEGF. OPSS-PEG-VEGF was 
synthesized via the same chemistry for antibody-PEG coupling shown in Figure 3.2, 
where "R" is now VEGF with available primary amines. OPSS-PEG-NHS (Creative 
PEGWorks, Winston Salem, NC) reacted at a 10:1 molar ratio with murine VEGF l65 
(PeproTech, Rocky Hill, NJ) at 4°C overnight. Conjugation was confirmed via silver 
staining on proteins separated by polyacrylamide gel electrophoresis (SDS-PAGE; 4-15% 
Tris-HCI precast gels and silver stain from Bio-Rad, Hercules, CA). 
VEGF-coated nanoparticles were prepared by reacting nanoparticles suspended in 
milli-Q water (OD=1.5) with OPSS-PEG-VEGF for 1 h at 4°C. GGS-NPs received 100 
OPSS-PEG-VEGF per nanoparticle and NS received 1500 OPSS-PEG-VEGF per 
nanoparticle. Following coupling, nanoparticles incubated with mPEG-SH (5 kDa, 
Laysan Bio, Arab, AL) overnight at 4°C; GGS-NPs received 1 part 250!-lM mPEG-SH to 
9 parts nanoparticles and NS received 1 part 25 !-lM mPEG-SH to 9 parts nanoparticles. 
Control nanoparticles were also prepared with only mPEG-SH (no VEGF). Following 
VEGF and/or PEG modification, nanoparticles were purified and concentrated with cross 
flow filtration using 11 cm2 polysulfone filters with 0.05 !-lm MWCO (MicroKros 
Modules, Spectrum Laboratories, Inc., Rancho Dominguez, CA). Following 
concentration, samples were suspended in sterile phosphate buffered saline (PBS). 
To confirm and quantify the presence the VEGF on nanoparticles, dynamic light 
scattering, Zeta potential measurements, and the modified ELISA were performed as 
described in earlier sections of this thesis. For the ELISA, nanoparticles were first 
incubated with 100 ~g/ml rabbit anti-murine VEGF (PeproTech), then with 200 ~g/ml 
HRP-conjugated anti-rabbit IgG (Sigma). All other aspects of the analysis remain the 
same as described in Chapters 3, 4, and 5. Salt stability tests were also performed to 
confirm adequate PEG-SH coverage. 
6.2.2 In Vitro Assessment of Vascular-Targeted Photothermal Therapy 
Initial in vitro experiments were performed to confirm that VEGF -coated nanoparticles 
could bind VEGFR-2 positive cells and facilitate thermal therapy of these targeted cells. 
MS1 (Mile Sven 1) murine endothelial cells, which express VEGFR-2, were obtained 
from ATCC and cultured in Dulbeco's Minimum Essential Medium (DMEM) 
supplemented with 10% fetal bovine serum and 1 % GPS (L-glutamine, penicillin, and 
streptomycin). Cells grown in chambered coverglass were exposed to 1 ml saline, 1 ml 
PEG-coated nanoparticles (OD=4), or 1 ml VEGF-coated nanoparticles (OD=4). After 
rinsing three times to remove unbound particles, an 808 nm laser was applied at 
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60 W/cm2 for 3 min. Following a 1 h incubation period, samples were stained with 1 ~M 
calcein AM and 4 ~M ethidium homodimer-1 (Live/Dead staining kit, Molecular Probes) 
and fluorescence microscopy was performed with an inverted Zeiss Axiovert 135 phase 
contrast microscope to investigate cell viability. Samples were also imaged with 
darkfie1d microscopy using a Cytoviva adaptor on the same microscope to assess 
nanoparticle binding to the cells. 
6.2.3 Tumor Inoculation and Cranial Window Placement 
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Following the in vitro assessment of vascular-targeted photothermal therapy, in vivo 
models were used to study nanoparticle accumulation in intracranial tumors and to 
evaluate the ability of these nanoparticles to facilitate disruption of tumor vasculature 
with photothermal therapy. All animals were used under an approved protocol of the 
Institutional Animal Care and Use Committee of Baylor College of Medicine. These in 
vivo experiments used the same U373 human high-grade glioma cell line discussed in 
Chapter 5. The cells were engineered to constitutively express both the firefly luciferase 
gene (FFLuc) and green fluorescent protein (GFP) as previously described (Ahmed et al. 
2007). This dual expression enabled tumor growth to be monitored in vivo with intravital 
microscopy to observe the GFP signal or with the Xenogen IVIS 100 bioluminescence 
imaging system (Caliper Life Sciences) to observe the luciferase activity. 
U373 cells were maintained in RPMI 1640 medium (Invitrogen Corp., Carlsbad, 
CA) supplemented with 1% glutamine and 10% fetal bovine serum and cultured at 37°C 
in a 5% C02 environment. Cells were detached from culture flasks with trypsin-EDTA 
and diluted in culture media to 5 x 107 cells/ml for inoculation into mice. For the 
nanoparticle distribution study, mice were anesthetized with 50 mg/kg Nembutal (sodium 
pentobarbital) solution delivered intraperitoneally. The fur over the scalp was removed 
with a razor and the surgical area cleaned with alcohol. An incision was cut in the skin 
1 mm lateral right to the middle sagittal suture and 2 mm anterior of the lambdoid suture, 
then a microsurgical drill was used to create an 0.8 mm diameter Burr hole in the skull. 
Using a Hamilton syringe, 2 Jl1 cell suspension was injected 3 mm deep into the right 
cerebrum of male IcrTac:ICR-PrkdcscID mice (Taconic Farms, Hudson, NY) for a total 
injection of 105 U373 cells. The wound was closed with surgical glue and tumor 
development was monitored daily with bioluminescent imaging. 
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F or treatment studies, tumors were implanted using the cranial window procedure 
described by Gaber et al. (2004). The day before surgery, the fur over the scalp was 
removed with hair removal cream. For surgery, each mouse was anesthetized with 
sodium pentobarbital (50 mg/kg, i.p. delivery), the animal's head placed in a sterotaxic 
frame and its body placed on a heating mat to maintain body temperature throughout the 
procedure. The surgical area was cleaned with alcohol and Betadine, and eye ointment 
was applied to the eyes with a sterile cotton swab. Using fine scissors, the scalp over the 
parietal cortex was removed to reveal the sagittal and lambdoid sutures and the fascia was 
removed from the skull with forceps to leave a dry surface for drilling. With a 
microsurgical drill, a rectangular cranial window (approximately 4-5 mm width and 
length) was made; final breakthrough of the skull was accomplished with fine forceps. 
Once the brain was exposed, artificial cerebral spinal fluid (aCSF) was applied 
frequently. The aCSF is composed of 0.22 g KCI, 0.305 g MgCh-6H20, 0.264 g CaCh, 
7.71 g NaCI, 0.402 g urea, 0.665 g dextrose, and 2.066 g NaHC03 in one liter of 
Millipore H20. Using a Hamilton syringe, 2 JlI cell suspension (l05 cells total) was 
slowly injected 3 mm deep into the right cerebrum, 1 mm lateral ofthe middle sagittal 
suture and 2 mm anterior of the lambdoid suture. Then, a glass cranial window was 
placed over the exposed cerebral cortex and fixed to the surrounding skull with 
cyanoacrylate glue. The tumor implantation site (red dot) and cranial window are 
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depicted schematically in Figure 6.2. After surgery, mice received intraperitoneal 
injections of 0.2 mg/kg buprenorphine (Buprenex) every 12 hours for 2 days to minimize 
pain. In addition, the mice were given antibiotics in their water for 5 days following 
surgery to prevent onset of infection (1.7 ml Baytril 100 (enrofloxacin, 100 mg/ml stock 
solution) per 400 ml H20). 
suture 
Figure 6.2: Tumor inoculation and cranial window placement. Tumor cells are 
implanted 3 mm below the surface of the brain at the position 2 mm anterior to the 
lambdoid suture and 1 mm lateral to the middle sagittal suture, as indicated by the red 
circle. Then a glass cranial window (depicted as a black and white box) is sealed over the 
opening. Image modifed from Gaber 2004. 
6.2.4 Analysis of Nanoparticle Accumulation in Intracranial Tumors 
It was necessary to determine whether intravenously administered nanoparticles could 
accumulate in orthotopic tumors. As discussed in Chapter 5, tumor size correlates with 
bioluminescence signal intensity and preliminary studies demonstrated that tumor 
diameter was 3-5 mm when tumor signal was above 106 units for 3 days. Based on these 
criteria, when tumor diameter reached 3-5 mm, mice received intravenous injections of 
100 Jll PEG-coated or VEGF-coated nanoshells (1.7 x lOll particles/ml) or GGS-NPs 
(1.1 x 1013 particles/ml). These concentrations correlate to equal optical densities 
(OD=60) of the nanoparticle formulations. After waiting 6, 24, or 48 h the mice were 
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euthanized and tissue was collected for analysis of gold content by ICP-MS. Tissue 
studied included spleen, liver, blood, kidney, heart, tumor, and normal brain. Three mice 
were used per group per timepoint, for a total of 36 mice. 
6.2.5 Verification ofVEGF Receptor Expression in Orthotopic Tumors 
VEGFR-2 expression in tumor tissue was confirmed with immunofluorescent staining. 
Paraffin-embedded tissue cut into 6 ~m sections incubated in xylene twice for 10 min 
before hydrating through a series of alcohol (100%, 90%, 70%, 50%) and water. Slides 
incubated in proteinase K (10 ~g/ml, 37°C, 15 min) and were cooled with running water 
for 3 min. After rinsing with PBS containing 0.05% Tween20 (PBST), non-specific 
binding sites were blocked with 10% donkey serum in PBS for 45 min. Samples then 
reacted with rat anti-mouse VEGFR-2 (15 ~g/ml, R&D Systems) and goat anti-mouse 
CD31 (15 ~g/ml, R&D Systems) overnight at 4°C. Three rinses with PBST were 
performed and then samples were exposed to AlexaFluor 594-conjugated donkey anti-rat 
IgG (1 0 ~g/ml, Invitrogen) and AlexaFluor 488-conjugated donkey anti-goat IgG 
(1 0 ~g/ml, Invitrogen) for 1 h. Rinsed sections were mounted with Vectashield 
containing DAPI and imaged. 
6.2.6 Photothermal Therapy of Intracranial Brain Tumors 
Photothermal therapy of intracranial glioma tumors was attempted using nanoshells but 
not gold-gold sulfide nanoparticles since nanoshells demonstrated higher intratumoral 
gold content according to ICP-MS. Mice received intravenous injections of 150 ~l 
nanoshells and after 24 h the near-infrared laser was applied for 3 min through the cranial 
window. Response to treatment was monitored with intravital microscopy and 
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bioluminescence imaging, and mice were euthanized by carbon dioxide asphyxiation 
when one of the following two criteria was reached: (1) ifmouse weight reduced by 20% 
from the day of tumor implantation; (2) if the animal was moribund, unable to eat or 
move, or showing other signs of neurologic deficits (such as limb paralysis, huddled 
posture, etc.). For the survival study, mice received 150 J..lI nanoshells at OD=100 
(2.9 x lOll particles/ml) and the laser fluence was 6 W/cm2 (power = 1 W, ~4.5 mm beam 
diameter). Three mice received PEG-NS, three mice received VEGF-NS, and three mice 
received saline. 
To quantify changes in vasculature induced by treatment, intravital microscopy 
images acquired on the day of laser application (Day 0) and three days later were 
analyzed for three mice that received VEGF-coated nanoshells and three mice that 
received saline. Mice that received PEG-coated nanoshells could not be included in the 
analysis since only 1 mouse survived to three days; it remains to be investigated in future 
studies why the mice that were treated with PEG-coated nanoshells did not survive 
longer. For the analysis, vessels within 1.5 mm from the tumor center were traced in 
ImageJ software (NIH), filled, and the image was binarized; this process is shown in 
Figure 6.3 for a sample image acquired on Day O. Vessel density was calculated as the 
area of positive pixels divided by the total area and the density on Day 3 was normalized 
to the density on Day 0 to quantify treatment effect. Lastly, treatment effect was also 
monitored with histology. A subset of mice was euthanized immediately following laser 
exposure and brain tissue was excised for hematoxylin and eosin (H&E) staining. These 
tissue samples were carefully evaluated to determine the effects of therapy on both the 
tumor and the normal brain. Additional sections from two of these mice were also 
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stained to detect CD31 as described above and imaged by fluorescence and darkfield 
microscopy to determine the proximity of nanoshells to tumor vessels. 
Figure 6.3: Preparing intravital microscopy images for vessel density analysis. 
(A) A region of interest (ROI) within 1.5 mm from the tumor center is encircled. (B) 
Vessels within the ROI are outlined. (C) Outlined vessels are filled and the image is 
binarized. The tumor signal is removed so all that remains is a trace of vessels. 
6.3 Results and Discussion 
6.3.1 N anoparticie Characterization 
Silver staining of PEG-VEGF protein samples separated by SDS-PAGE confirmed the 
conjugation ofVEGF to OPSS-PEG-NHS. As shown in Figure 6.4, addition ofOPSS-
PEG-NHS caused an increase in observed molecular weight, with several bands 
appearing based on the number PEG chains added. VEGF appears as a 19 kDa monomer 
due to the reducing conditions used to prepare the gel. 
For the biodistribution study, nanoparticles were characterized with the ELISA: 
GGS-NPs were coated with 62.7 ± 7.6 VEGF per nanoparticle and nanoshells were 
coated with 100.9 ± 14.3 VEGF per nanoparticle. For the survival study, only nanoshells 
were used and these were characterized even further with DLS, Zeta potential, and the 
ELISA, which indicated 332.1 ± 112.1 VEGF per nanoparticle. DLS and Zeta potential 
measurements showed increased hydrodynamic diameter and neutralized surface charge 
upon functionalization, respectively (Table 6.1). 
MW 
(kOa) 
50 -
37 -
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VEGF OPSS-PEG-VEGF 
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Figure 6.4: SDSIP AGE confirms OPSS-PEG-NHS conjugation to VEGF. Silver 
staining showed that molecular weight of the product increased upon conjugation of 
VEGF to OPSS-PEG-NHS (2000 Da), with separate bands appearing based on the 
number of PEG chains attached. The reaction included a 10: 1 PEG to VEGF molar ratio. 
Sample Type Hydrodynamic Diameter (nm) Zeta Potential (mV) 
Bare NS 162.4 ± 2.0 -57.9 ± 0.6 
PEG NS 188.0±1.2 -33.4 ± 0.4 
VEGF NS 196.8 ± 7.0 -32.7 ± 1.3 
Table 6.1: Characterization of VEGF -coated nanoshells. DLS and Zeta potential 
measurements demonstrated that hydrodynamic diameter increased and Zeta potential 
magnitude decreased upon functionalization with PEG or VEGF. 
6.3.2 VEGF -Coated Nanoparticles Bind Murine Endothelial Cells In Vitro to 
Facilitate Thermal Therapy 
The ability of VEGF -coated nanoparticles to bind murine endothelial cells that over-
express VEGFR-2 and facilitate thermal therapy was first tested in vitro. Darkfield 
microscopy confirmed the hypothesis that VEGF-coated GGS-NPs and NS could bind 
MS 1 cells, while PEG-coated nanoparticles could not bind the cells and were removed 
during the rinsing steps (Figure 6.5). GGS-NPs and NS appear red under darkfield 
microscopy due to their light-scattering properties. Upon NIR-irradiation, only MS 1 
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cells that had been exposed to targeted (VEGF -coated) nanopartic1es experienced loss in 
viability, indicated by red EthD-1 fluorescence (Figure 6.5). Comparatively, cells 
previously exposed to saline or PEG-coated nanopartic1es remained viable (green calcein 
AM fluorescence). These results suggested that VEGF -coated nanopartic1es are a 
promising agent for vascular-targeted therapy worthy of further in vivo assessment. 
Saline PEG-GGS VEGF-GGS PEG-NS VEGF-NS 
A 
B 
Figure 6.5: VEGF -coated nanoparticIes bind MSI cells in vitro to mediate thermal 
ablation. (A) Darkfield microscopy proves that VEGF -coated nanoparticles bind MS 1 
cells that express VEGFR-2, while PEG-coated nanopartic1es do not. Nanoparticles are 
red against the blue cell background. Scale bars = 50 J.1m. (B) Fluorescence microscopy 
reveals that only cells treated with VEGF -coated nanopartic1es experience loss in 
viability upon laser irradiation. Live cells fluoresce green (calcein AM) and dead cells 
fluoresce red (EthD-l). Scale bars = 400 J.1m. 
6.3.3 VEGF Receptor Expression in Orthotopic U373 Tumors 
Immunofluorescence confirmed presence of the target receptor (VEGFR-2) in the tumor 
vasculature (Figure 6.6). VEGFR-2 (red fluorescence) was present on endothelial cells, 
which also stained positively for CD31 (green fluorescence). Hence, based on the in 
vitro binding assessment, VEGF -coated nanopartic1es should be able to target tumor-
associated vessels in vivo. 
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Figure 6.6: Fluorescence microscopy confirms VEGFR-2 expression in intracranial 
U373 tumors. This tissue section was stained to show CD31 (green), VEGFR-2 (red), 
and nuclei (blue). The border between the tumor and the normal brain is shown in (A) 
and a higher magnification of a region in the tumor (orange outline) is shown in (B) to 
demonstrate that VEGFR-2 co-localizes with CD31 (indicated by white arrows). Scale 
bar = 200 Jlm in (A) and 50 Jlm in (B). 
6.3.4 VEGF-Coated and PEG-Coated Nanoparticles Accumulate in 
Intracranial Tumors 
Using inductively coupled plasma-mass spectrometry (lCP-MS), the mean and standard 
deviation of gold content in each organ was calculated from three mice per group after 
nanoparticles circulated for 6, 24, and 48 hours, and the distribution trends for PEG-
coated nanoparticles agreed with those observed in Chapter 5 (Figure 6.7). The organs 
analyzed included spleen, liver, kidney, blood, heart, tumor, and normal brain. Kidney 
and heart were added to the analysis since anti-vascular therapies such as Bevacizumab 
have been linked to proteinuria and hypertension (Zhu et al. 2007). Coating (PEG or 
VEGF) did not influence nanoparticle accumulation in the kidney, but more gold was 
found in the heart for both gold-gold sulfide nanoparticles and nanoshells when the 
particles were coated with VEGF. This finding underscores the need to carefully monitor 
the effects of VEGF -coated nanoparticles on the heart as this therapy is developed. 
Addition ofVEGF to nanoparticles reduced gold accumulation in the spleen and 
increased gold accumulation in the liver, likely because the liver is highly vascularized; 
this effect was more pronounced for NS than for GGS-NPs. Finally, nanoparticles with 
VEGF coatings were more rapidly removed from the blood than those with PEG 
coatings, perhaps because of increased adherence to vessel walls. 
Figure 6.8 shows expanded graphs for the tumor and normal brain samples. 
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Importantly, for both GGS-NPs and NS, more nanoparticles were found within the tumor 
than in the normal brain at all times. These differences were tested for significance using 
a student's t-test and samples with p<O.05 are marked. It is critical to apply the laser 
when the difference in nanoparticle content between the tumor and the normal brain is 
maximized so the potential for off-target effects is minimized. Based on this criterion, it 
was decided that the survival study would include only nanoshells since they showed a 
more consistent pattern of tumor accumulation than the GGS-NPs. In addition, 
nanoshells require much less VEGF to constitute an equal surface coverage on GGS-NPs, 
reducing the overall cost of the treatment. In the survival study, a higher dose of 
nanoshells was delivered through the tail vein (4.35 x 1010 nanoshells per mouse), with 
the prediction that more particles would accumulate in the tumor, and the NIR laser was 
applied 24 h post-intravenous injection. 
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Figure 6.7: Distribution of VEGF-coated and PEG-coated nanoparticles. The 
accumulation of nanoparticles in several organs was determined by Iep-MS. In the top 
chart VEGF-NS are red and PEG-NS are blue. Similarly, in the bottom chart VEGF-
GGS-NPs are orange and PEG-GGS-NPs are green. Color intensities are lighter for later 
times. Data depicts mean ± standard deviation for n=3 samples for all sets. 
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Figure 6.8: N anoparticle accumulation in intracranial tumors. This chart shows an 
expansion of the y-axis from Figure 6.7 to more clearly identify differences in 
nanoparticle accumulation between the tumor and the normal brain. Times at which gold 
found in the tumor was significantly increased from gold content in the normal brain for 
the same nanoparticle type are marked (*p<O.05, student's t-test). 
6.3.5 Intravital Microscopy Indicates that Thermal Therapy with VEGF-
Coated Nanoshells Disrupts Tumor Vasculature 
With intravital microscopy the superficial layer of the tumor appears as a bright central 
region due to the GFP signal emitting from the tumor cells and the tumor-associated 
vessels are observed as shadows. This allows changes in vasculature induced by therapy 
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to be monitored both qualitatively and quantitatively by calculating vessel density. 
Figure 6.9 shows intravital microscopy images acquired for a mouse that received saline 
and for a mouse that received VEGF nanoshells one day prior to laser treatment. The left 
column displays an image acquired immediately before the laser was applied and the 
right column displays the same region 6 days later. In the saline control mouse, the 
tumor signal continues to grow over time and the vessels appear to be maturing. In 
contrast, the vessels appear to be disrupted following treatment for the VEGF-NS treated 
mouse and the tumor signal remains stable over this timeframe. 
Day 0 Day 6 
Saline 
VEGF-NS 
Figure 6.9: Intravital microscopy reveals changes in tumor vasculature foUowing 
treatment. Changes in tumor size and vessel morphology were qualitatively evaluated 
by comparing intravital microscopy images acquired the day the laser was applied and six 
days later. The mouse treated with saline shows increasing tumor signal and signs of 
vessel maturation, while the mouse treated with VEGF-NS shows a stable tumor signal 
and signs of vessel disruption. Scale bars = 1 mm. 
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Changes in vasculature were quantified for the three mice that received saline and 
for the three mice that received VEGF-NS using intravital microscopy images acquired 
on Day 0 and Day 3. As shown below in Figure 6.10, vessel density increased by 18% 
for the saline group but decreased by 24% for the VEGF-NS treatment group over these 
three days; this difference was significant at the 95% confidence level by a student's t-
test. Data in the figure represent the mean and standard error for each group. 
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Figure 6.10: Quantification of vessel density highlights treatment effect. Mice that 
received saline exhibited a mean increase in vessel density of 18% over three days after 
laser treatment (blue bar) while mice that received VEGF-coated nanoshells experienced 
a 24% decrease in vessel density (red bar) (*p<O.05, student' s t-test). 
6.3.5 Histology Supports Intravital Microscopy Data and Indicates that 
VEGF-Coated Nanoshells Remain Proximal to Tumor Vessels 
A subset of mice was euthanized immediately following laser application to further 
investigate the effects of therapy on the vasculature within the tumor and the normal 
brain since the laser application area covered both regions after it passed through the 
cranial window. Figure 6.11 displays images ofH&E stained sections of the tumor and 
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the normal brain for mice exposed to saline, VEGF-NS, and PEG-NS. There appear to be 
no changes to vasculature within the normal brain for any of the groups, indicating that 
both the laser power and the particle concentration are low enough to prevent thermal 
damage. By contrast, there are very extreme changes in the tumor vasculature for both 
PEG-NS and VEGF-NS treated mice, but not for saline control mice. Signs of vessel 
congestion, dilation, and hemorrhaging observed in the treatment arms were confirmed 
by a trained pathologist. 
Saline VEGF-NS PEG-NS 
Tumor 
Brain 
Figure 6.11: Histological evaluation of vascular-targeted photothermal therapy. 
Mice that received saline, VEGF -coated nanoshells, or PEG-coated nanoshells were 
sacrificed immediately after laser exposure to evaluate the effects of vascular-targeted 
photothermal therapy on the tumor and the normal brain with H&E staining. Minimal 
vascular disruption was observed in the normal brain for all groups and in the tumor for 
mice exposed to saline. Comparatively, mice exposed to VEGF-NS and PEG-NS showed 
signs of vessel dilation and hemorrhaging within the tumor. Scale bars = 50 ~m. 
Tissue sections from the same PEG-NS and VEGF -NS treated mice shown in 
Figure 6.11 were also stained for CD31 and imaged by fluorescence and darkfield 
microscopy to assess nanoparticle proximity to tumor vessels. Results of this analysis are 
displayed in Figure 6.12, where nuclei appear blue (DAPI), CD31 appears green (AF488 
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antibody), and nanoshells appear red (pseudo-colored from a darkfield image with 
background subtracted and merged with the fluorescence image). Red blood cells may 
also be observed as faint red due to tissue autofluorescence. Generally, the VEGF -coated 
nanoshells remained proximal to or within tumor vessels; interestingly, while many PEG-
coated nanoshells are near vessels, many are also seen farther from the vessels. Thus, it 
appears that the VEGF coating is limiting the particle distribution to tumor vessels, as 
desired. It should be noted that a limitation of the analysis here is that it accounts for 
only one sample of each particle type; a more thorough study of multiple tissue samples 
needs to be performed to ensure this finding is not coincidental. Furthermore, it would be 
better to perform this analysis on tissue samples that have not been previously exposed to 
the laser since it is possible that the PEG-coated nanoparticles may have leaked out of the 
vessels after they were disrupted rather than extravasating out of the vessels while they 
remained intact. 
VEGF-NS PEG-NS 
Figure 6.12: Microscopy shows nanoparticles remain proximal to tumor vessels. 
Darkfield and fluorescence microscopy reveal that both VEGF -coated and PEG-coated 
nanoshells remain proximal to tumor vessels. Vessels appear green (anti-CD31 
antibody), nuclei appear blue (DAPI), and nanoparticles appear red. Scale bars = 50 /J-m. 
6.3.8 Discussion 
Since the concept that tumors are angiogenesis-dependent was introduced in the 1970s 
(Folkman 1971), there has been explosive growth in development of vascular-targeted 
cancer therapies. Anti-angiogenic therapy seems particularly well suited for high-grade 
gliomas because they are among the most densely vascularized tumors. Unfortunately, 
approaches that utilize antibodies or small molecule inhibitors to disrupt tumor 
vasculature have faced clinical setbacks, including both toxicities and the inability to 
prevent vascular endothelial cells from developing resistance mechanisms such as 
signaling through alternative pathways. To overcome these limitations, nanoparticle-
mediated therapies are now being investigated. Here, VEGF-coated nanoparticles were 
evaluated for the ability to target intracranial glioma tumors and to facilitate subsequent 
vascular-focused photothermal therapy since the VEGF-receptor pathway is critical in 
glioma angiogenesis. 
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Both in vitro and in vivo assessment of vascular-targeted photothermal therapy 
was performed. Gold-gold sulfide nanoparticles and nanoshells coated with VEGF 
bound to VEGFR-2 expressing endothelial cells in vitro, marking these cells for 
photothermal ablation. Based on these data, it was decided to study the treatment further 
in intracranial tumor experiments. In vivo, both PEG-coated and VEGF-coated 
nanoparticles accumulated at higher levels in intracranial tumors than in the normal brain, 
and this delineation is necessary for therapy to be both effective and safe. Studies of 
therapeutic effect with nanoshells indicated that this difference allowed vessel disruption 
to be achieved selectively in and around the tumor but not in the normal brain of mice 
treated with a single 3 min laser exposure. Interestingly, although both PEG-coated and 
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6.3.7 Animal Survival Time Increases Moderately Following Vascular-
Targeted Photothermal Therapy of Intracranial Glioma Tumors 
Animal survival time following treatment was monitored to evaluate therapeutic efficacy. 
Figure 6.13 is a Kaplan-Meier diagram showing the percentage of mice alive versus days 
following laser exposure for the saline control group (blue), the PEG-NS treatment group 
(green), and the VEGF-NS treatment group (red). Mice that received PEG-coated 
nanoshells did not display a survival benefit compared to mice that received saline, but 
mice that received VEGF -coated nanoshells had a moderate, though not statistically 
significant (p=O.15 with log-rank test) , improvement in survival. The median survival for 
mice exposed to saline was 5 days compared to 3 days for mice exposed to PEG-coated 
nanoshells and 11 days for mice exposed to VEGF -coated nanoshells. 
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Figure 6.13: Kaplan-Meier survival analysis of vascular-targeted photothermal 
therapy. The percentage of mice alive versus days following laser treatment is shown 
for the saline control group (blue line, n=3), the PEG-NS non-targeted therapy group 
(green line, n=3), and the VEGF-NS vascular-targeted therapy group (red line, n=3). 
Vascular-targeted therapy prolonged median survival 2.2-fold compared to the saline 
control group (11 days versus 5 days). 
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VEGF-coated nanoshells induced vascular changes, there was a moderate survival benefit 
only for the targeted nanoparticle group compared to mice that received laser exposure 
alone. Although the median survival time doubled, this improvement was not statistically 
significant. Considered together, these results suggest that with further development 
vascular-focused photothermal therapy could be an effective strategy for elimination of 
brain tumors. 
To improve vascular-targeted photothermal therapy of brain tumors, it may be 
necessary to use a more direct mode of light delivery such as a fiber-optic probe. The 
rationale in support of fiber-optic light delivery is two-fold: first, it would ensure more 
even distribution of light energy throughout the tumor and avoid energy loss that occurs 
with external delivery as light traverses the normal brain before reaching the tumor; 
second, it would prevent off-target heating of nanoparticles that may accumulate in the 
normal brain. The feasibility of fiber-optic light delivery has already been demonstrated 
in two studies of nanoparticle-mediated therapy of brain tumors (Reddy et al. 2006; 
Schwartz et al. 2009). In the first, a probe delivered light for vascular-targeted 
photodynamic therapy mediated by F3-conjugated polymeric nanoparticles containing 
Photofrin (Reddy et al. 2006). The F3-targeting peptide binds nucleolin, a shuttle protein 
specifically expressed on angiogenic endothelial cells within tumor vasculature. In this 
study, rats with 9L glioma were exposed to a 750 mW for 7.5 min and median survival 
for mice treated with the targeted nanoparticles increased to 33 days compared to just 
8.5 days for mice treated with only the laser. It should be noted that, to date, this is the 
most successful vascular-targeted nanoparticle-mediated therapy reported in the literature 
(Reddy et al. 2006). 
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The second study to demonstrate the utility of fiber-optic light delivery was 
reported more recently (Schwartz et al. 2009). In a canine brain tumor model, a fiber-
optic probe was used to deliver light for non-targeted nanoshell-mediated thermal 
therapy. Intracranial tumor temperatures of 65.8 ± 4.1 °C were achieved in the presence 
ofnanoshells compared to 53.1 °C for a tumor infused with vehicle. Within the normal 
brain, the maximum recorded temperature was 48.6 ± 1. 1°C, below the damage 
threshold. This paper did not include survival data, however, so it was impossible to 
gauge treatment response (Schwartz et al. 2009). The work reported in this chapter was 
thus the first attempt to assess survival benefit from nanoshell-mediated photothermal 
therapy of intracranial brain tumors. A similar approach to brain tumor therapy is 
magnetic fluid hyperthermia (MFH), which has been introduced in previous chapters. 
When non-targeted MFH with amino silane-coated iron-oxide nanoparticles was tested in 
rats bearing 3-4 mm tumors, the animals experienced 1.7-4.5-fold prolongation of 
survival, with higher temperatures achieved in the tumor yielding better response (Jordan 
et al. 2006). One complication of comparing the studies in this chapter to the MFH 
studies is that a 3-5 mm tumor in a mouse accounts for a larger total brain volume than a 
3-4 mm tumor in a rat. In addition, the nanoshells and GGS-NPs used in this thesis were 
intravenously delivered while the iron-oxide nanoparticles were directly injected into the 
tumor. Nevertheless, it is promising that vascular-targeted nanoshell therapy yielded a 
similar 2-fold increase in median survival following only a single dose of nanoparticles 
and laser exposure. 
Although the data reported here are exciting for an initial attempt at vascular-
focused hyperthermia, parameters of the photothermal therapy will need to be adjusted in 
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future studies since a clinically relevant improvement in survival has not yet been 
achieved. For example, possible changes could include increasing the nanoparticle 
dosage or using a different nanoparticle delivery method. Several groups have utilized 
either direct intratumoral delivery or convection-enhanced delivery of nanoparticles for 
brain tumor therapy (Jordan et al. 2006; Hadjipanayis et al. 2010). Similarly, as already 
mentioned, the light delivery technique should be improved since in the clinical setting a 
cranial window would not be feasible. Additionally, multiple doses of the laser could be 
applied to improve the treatment response. Here, the laser was applied from only one 
direction but it is likely that repeated application from multiple directions would improve 
outcome by capturing any outlying cells missed by the initial treatment. Since infiltrative 
glioma cells beyond the main tumor mass missed by conventional therapies are often 
responsible for patient relapse (DeAngelis 2001), it is critical to develop photothermal 
therapy with the goal of eliminating these evasive cells. Once these improvements have 
been incorporated, vascular-targeted photothermal therapy should be able to elicit a better 
therapeutic response. 
6.4 Conclusions 
Overall, the results of these studies indicate that VEGF -coated nanoshells have potential 
as a novel mediator of anti-angiogenic glioma therapy. Vascular-targeted nanoshells can 
bind vessels associated with intracranial tumors and subsequent application of a near-
infrared laser induces hyperthermia to disrupt the tumor vessels. In turn, this disruption 
slows tumor growth and improves survival compared to mice treated with non-targeted 
nanoshells or with saline. Importantly, the normal brain appears unaffected by treatment 
based on histological assessment. As this therapy is further developed it will be critical 
to continually evaluate the safety margin since brain tumor treatments are often plagued 
by long-term side effects. 
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Vascular-targeting confers several advantages to nanoparticles for photothermal 
therapy. First, because the receptor for the targeting agent is expressed on the luminal 
endothelium, nanoparticles do not need to extravasate out of blood vessels for therapy to 
be effective. Furthermore, the nanoparticles do not need to evade the blood-brain barrier, 
which is disrupted in high-grade glioma but may not be disrupted in early stage tumors. 
Second, although glioma was studied here, the surface markers expressed by endothelial 
cells involved in tumor angiogenesis are consistent across multiple tumor types. As a 
result, VEGF-coated nanoshells or GGS-NPs could be used for photothermal therapy of a 
wide-variety of tumors, increasing the applicability of this new therapy. A final 
advantage of vascular targeting that is specific to the VEGF ligand used in this work is 
based on the aforementioned discovery that the VEGF -signaling pathway regulates both 
paracrine and autocrine promotion of glioma tumorigenesis (Knizetova et aZ. 2008). 
Since VEGFR-2 is expressed on both endothelial cells and some brain tumor cells, 
VEGF -coated nanoshells or GGS-NPs could potentially inhibit tumor growth by enabling 
thermal ablation of both targets. 
To conclude, vascular-targeted nanoparticle-mediated photothermal therapy offers 
an intriguing alternative to conventional treatment for brain tumors. As mentioned 
earlier, vascular endothelial cells are highly resistant to chemotherapeutics, but it has 
already been shown in a breast tumor model that some drug-resistant cells are less 
resistant to nanoshell-mediated photothermal therapy (Carpin et aZ. 2011). Similarly, for 
brain tumors it is expected that vascular-targeted photothermal therapy should remain 
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effective even when chemotherapy fails, assuming the target receptor expression is 
maintained. Photothermal therapy offers the advantage over both chemotherapy and 
radiation therapy that it is relatively quick, and should prevent patients from enduring 
weeks or months of treatment. Finally, the procedures are much simpler to perform and 
therefore less risk is involved than with surgery. Even with the use of a fiber-optic probe 
to deliver light, it is likely that the normal brain will be affected to a much lesser extent, 
although the treatment margins around tumors following photothermal therapy remain to 
be defmed. In the future, vascular-targeted nanopartic1e-mediated photothermal therapy 
could be an excellent treatment not only for primary brain tumors, but also for a 
multitude of tumor types. 
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Chapter 7: Conclusions and Future Directions 
7.1 Introduction 
This thesis has attempted to advance the field of photothermal cancer therapy by 
developing silica-gold nanoshells and gold-gold sulfide nanoparticles as multifunctional 
agents for molecularly targeted imaging and treatment of cancer. Here, the significance 
of the results of this thesis will be summarized and then the impact of these results on the 
future of photothermal therapy will be discussed. 
7.2 Developing Molecularly-Targeted Gold-Based Nanoparticles for 
Cancer Imaging and Near-Infrared Photothermal Therapy 
Photothermal therapy incorporates nanoparticles as exogenous absorbers of near-infrared 
light to selectively delivery heat capable of inducing cell death to tumors. The benefits of 
photothermal therapy over surgical resection, chemotherapy, and radiation therapy are 
numerous; this approach is minimally invasive, simple to perform, has a low risk of side 
effects, and has the potential to treat embedded tumors in vital regions where surgical 
resection is not feasible. Additionally, the unique optical properties of nanoparticles 
allow them to act simultaneously as contrast agents for a variety of imaging modalities. 
Previously, PEG-coated nanoshells and gold-gold sulfide nanoparticles were used for 
photothermal cancer therapy in vivo using passive accumulation (O'Neal et al. 2004; 
Gobin et al. 2010); but, as increasing evidence showed that molecular alterations playa 
critical role in tumor development, approaches to combat the disease at this scale were 
developed. Specifically, nanoshells have been coated with antibodies (Loo et al. 2005; 
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Bernardi et al. 2008), proteins (Gobin et al. 2008), and peptides (Liu et al. 2010) to 
facilitate binding with tumor cell-specific antigens. While this advancement was met 
with great enthusiasm, it remained to be validated in vivo. Therefore, the overall goal of 
this thesis was to evaluate molecularly targeted cancer therapy in vivo. 
To begin, antibody-coated nanoshells were shown to have tumor cell-specific 
targeting in vitro using both mono culture and co-culture experiments. When nanoshells 
were coated with anti-HER2 antibodies, they specifically bound breast carcinoma cells 
that over-express the HER2 receptor even when these cells were adjacent to HER2-
negative endothelial cells. Furthermore, these functionalized nanoshells were able to 
bind ovarian tumor tissue ex vivo at levels that corresponded to the HER2 receptor status. 
This suggests that, in the future, biopsy specimens could be exposed to antibody-coated 
nanoshells to determine a patient's receptor level status and predict whether they would 
benefit from targeted photothermal therapy. 
In the following chapter, it was proven that the conjugation chemistry used to 
functionalize silica-gold nanoshells is also acceptable for gold-gold sulfide nanoparticles. 
This was the first demonstration that GGS-NPs can be molecularly addressed. It was also 
shown that the light-absorbing properties of GGS-NPs facilitate their use as dual imaging 
and therapeutic agents when used in conjunction with femtosecond-pulsed NIR lasers. 
At low laser intensities antibody-coated gold-gold sulfide nanoparticles can be used to 
image cancerous cells, and then at higher laser intensities the particles can mediate 
thermal ablation. This capability renders GGS-NPs a truly "theranostic" nanoparticle 
capable of targeting, imaging, and therapy all in a single platform. 
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Chapter 5 investigated, for the first time, the distribution profile of antibody-
coated and PEG-coated nanoshells and gold-gold sulfide nanopartic1es. For these studies, 
a subcutaneous high-grade glioma tumor model was used. These studies provided insight 
into how nanopartic1e size and surface coating dictate in vivo organ distribution. 
Contrary to predictions, coating these nanopartic1es with antibodies did not improve their 
overall uptake into the tumor. Since these studies have been completed, however, more 
publications have appeared with similar data that suggests molecular targeting of 
nanopartic1es does not increase their uptake into tumors, but rather improves their cellular 
internalization (Choi et al. 2010; Huang et al. 2010). Following the distribution study, 
PEG-coated nanoparticles were used to establish the sensitivity of these aggressive 
primary brain tumors to photothermal therapy. Intravenously delivered nanoshells 
accumulated in the tumor at levels sufficient to induce tumor regression when the laser 
was applied 24 h post-intravenous delivery; mice that received gold-gold sulfide 
nanoparticles displayed only a partial tumor response. This data established that primary 
brain tumors are sensitive to photothermal therapy and warranted further investigation 
using an intracranial tumor model. 
Since brain tumors are highly vascularized, for the intracranial tumor studies the 
nanoshells and gold-gold sulfide nanopartic1es were coated with vascular endothelial 
growth factor (VEGF). It was hypothesized that VEGF-coated nanoparticles would bind 
tumor vessels, which over-express VEGF receptor-2 (VEGFR-2), and that the tumor 
vessels could then be disrupted upon application ofthe NIR laser. Following disruption 
of tumor vasculature the level of oxygen and nutrients in the tumor should decrease, 
leading to tumor regression. First, the ability of VEGF -coated nanoparticles to bind 
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VEGFR-2 positive endothelial cells and facilitate thermal ablation of these cells was 
demonstrated in vitro. Then, a distribution study in mice bearing intracranial glioma 
tumors proved that VEGF -coated nanoparticles could accumulate in these tumors. In 
subsequent treatment studies, it was shown that VEGF -coated nanoshells could induce 
vascular damage within the tumor but not the normal brain, and that this vascular-
targeted therapy could prolong median survival by 2.2-fold versus mice that received 
only laser exposure. This was the first attempt to treat an orthotopically-implanted tumor 
using nanoshell-mediated photothermal therapy, an important advancement since tissue 
environment can playa critical role in tumor behavior. 
7.3 Future Directions 
Molecular targeting is anticipated to improve the future of cancer nanomedicine by 
enhancing specificity, prolonging nanoparticle retention in the tumor, and decreasing off-
target effects. As demonstrated by the results of this thesis research, there is still much 
work to be performed and knowledge to be gained before this potential will be fully 
realized. Several groups have tested targeting schemes in vitro, but in vivo validation is 
lacking. It is critical to evaluate these systems in animal models because, as shown with 
antibodies in this thesis, in a complex biological setting it is more difficult to reach the 
target site. In these studies, whole antibodies were used and it is believed that the Fc 
portion induced immune recognition and more rapid elimination of the nanoparticles 
from the body. Comparatively, recognition and rapid clearance did not appear to be a 
significant problem for the VEGF -coated nanoparticles. In the future, it would be 
interesting to evaluate targeting with antibody fragments that do not contain the Fc 
fragment. Alternatively, aptamers could be a good option because they have no toxicity 
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or irnmunogenicity but exhibit high affinity (Blank and Blind 2005). More recently, 
Ruoslahti and colleagues have developed "tissue-penetrating peptides" that display 
remarkable tumor uptake (Sugahara et al. 2009). While some groups have demonstrated 
the ability to encapsulate nanoshells within macrophages for cell-mediated delivery (Choi 
et al. 2007; Baek et al. 2011), this approach lacks the ability to provide functional 
information and would not therefore be suitable as a molecular targeting strategy. 
In addition to optimizing the targeting strategy used to bind nanoshells and GGS-
NPs to specific cells, photothermal therapy could be further improved by capitalizing on 
the ability of these nanoparticles to provide dual imaging and therapy. In Chapter 4, it 
was shown that two-photon microscopy could be used with nanoparticles to "see and 
treat" tumors in a single setting. Future work should continue to develop this approach 
for in vivo application. Systems that offer dual imaging and therapy will be critical to 
successful elimination of tumors, particularly high-grade brain tumors in which many of 
the cells are infiltrative and may be found several centimeters away from the main tumor 
mass. Often these cells are left behind during surgical resection, so it will be important to 
determine whether these cells can be (1) targeted by nanoshells or GGS-NPs delivered 
systemically, (2) identified using inherent nanoparticle contrast, and (3) safely eliminated 
with photothermal therapy without inducing damage to normal brain in the laser field. 
To further enhance the dual imaging and therapy capabilities ofnanoshells and 
gold-gold sulfide nanoparticles, it may be beneficial to add moieties to the nanoparticle 
surface that enable contrast with currently used clinical imaging systems. For example, 
since MRI is one of the most powerful imaging techniques available it would be valuable 
to add MRI contrast-enhancing capability to the nanoparticles; this has recently been 
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realized for silica-gold nanoshells. Bardhan et al. coated nanoshells with amine-
terminated iron-oxide nanopartic1es and surrounded them with a silica layer doped with 
the fluorophore indocyanine green (leG) (2009). After adding anti-HER2 antibodies to 
the surface, the complex was able to target cells in vitro, provide enhanced contrast for 
MR and fluorescence microscopy, and mediate photothermal therapy (Bardhan et al. 
2009). To improve this system, one might use gadolinium chelates instead of iron-oxide 
nanopartic1es. This offers the advantage that the overall system could be reduced in size, 
enabling better penetration into tumors via the EPR effect. Futhermore, gadolinium 
chelates are FDA approved and are the most commonly used contrast agent clinically; as 
such, it is likely that approval of systems that use gadolinium chelates would be more 
streamlined. It is important to note that gadolinium chelates provide positive MR 
contrast (brightened signal) while iron oxide nanopartic1es provide negative MR contrast 
(darkened signal), and so the choice of appropriate coating may depend partly upon the 
end application. 
Lastly, photothermal therapy could be improved by developing gold-gold sulfide 
nanopartic1es and nanoshells that release both silencing RNA and chemotherapeutic 
drugs upon heating with exposure to NIR light. It has previously been shown that 
cisplatin can be loaded onto gold-gold sulfide nanopartic1es and released on-demand with 
light exposure (Tan et al. 2009), and it is possible that combining drug delivery with gene 
therapy may enhance transfection efficiency or achieve a synergistic effect. While 
systems that combine gene therapy and drug delivery have been created (Zhang et al. 
2010), none have been able to elicit on-demand release. By utilizing NIR-absorbing 
nanopartic1es to provide this capability, drug and siRNA content within tumors could be 
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maximized and the tumor could be attacked by three mechanisms (photothermal therapy, 
drug delivery, and gene therapy) in one platform. In addition, the nanoparticles' optical 
properties could yield the ability to monitor delivery with two-photon microscopy, optical 
coherence tomography, or photoacoustic tomography, as desired. 
The overarching goal of cancer nanomedicine is to produce multifunctional 
materials capable of molecular targeting, imaging, and treatment, and this thesis has 
demonstrated that nanoshells and gold-gold sulfide nanoparticles have potential to meet 
this goal. These nanoparticles can be functionalized with targeting moieties through 
well-established chemistry, and their inherent optical properties render them suitable as 
optical contrast agents and mediators of photothermal therapy. Improvements could 
include (1) optimizing the targeting ligands to reduce immune recognition and improve 
tumor internalization, (2) endowing the nanoparticles with properties that enable contrast 
enhancement for multiple imaging modalities, and (3) incorporating on-demand release 
of chemotherapeutics and silencing RNA to provide a synergistic anti-tumor effect. In 
the future, nanoparticle-mediated photothermal therapy could offer a minimally invasive 
and highly effective alternative to imaging and treatment strategies used in conventional 
cancer management. 
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